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Helicobacter pylori infection of the stomach causes a chronic gastritis that is associated 
with the development of peptic ulcer disease and gastric cancer. Chronic in amma-
tion and malignancy are diseases that are accompanied by excessive degradation of 
the extracellular matrix. Matrix metalloproteinases are zinc-dependent proteinases 
that are involved in these processes because of their capability of digesting various 
structural components of the extracellular matrix. The list of their known substrates 
has expanded over the years to a broad range of extracellular proteins including other 
proteinases, proteinase inhibitors, receptors, clotting factors, cytokines, growth factors 
and chemotactic molecules. Enhanced matrix metalloproteinase levels and activities 
have been described in Helicobacter pylori-induced gastritis and in gastric cancer. 
In this thesis several studies are described that assessed the putative role of matrix 
metalloproteinases in chronic Helicobacter pylori-induced gastritis and gastric cancer. 
Extracellular proteolysis
Extracellular proteolysis plays an important role in cell-cell and cell-matrix interac-
tions of physiological processes like mammary gland involution, ovulation, blastocyst 
implantation, cellular migration and angiogenesis, but also in pathological conditions 
like in ammation as well as invasion and metastasis of malignant tumours [1-8]. 
Whereas in physiological conditions this proteolysis is controlled and self-limiting, in 
in ammation and metastasis there appears to be an excessive or unbalanced produc-
tion of proteolytic enzymes. These proteolytic enzymes play an important role in the 
remodelling and breakdown of the extracellular matrix (ECM). The ECM, consisting of 
basement membranes and interstitial stroma, is composed of a large number of com-
ponents that interact with each other and with the di erent cell types present. Col-
lagens are the most abundant ECM constituents besides adhesive glycoproteins like 
laminin,  bronectin, elastin and proteoglycans-glycosaminoglycans like hyaluronic 
acid and heparan sulphate [9-11]. Proteinases can be classi ed in four main groups: 
1) Cysteine proteinases (e.g., cathepsin-B, -H, -L and -N); 2) Aspartyl proteinases (e.g., 
cathepsin-D); 3) Serine proteinases (e.g., cathepsin-G and -E, elastase, kallikrein, 
thrombin, trypsin, plasmin, plasminogen activators); and 4) Metalloendopeptidases. 
These metalloendopeptidases include the thermolysins, insulinases and metzincins 
(zinc-dependent proteinases). Metzincins can subsequently be subdivided into 
matrix metalloproteinases (MMPs, matrixins), adamalysins (ADAMs; a disintegrin and 
metalloproteinases, and ADAMTSs; a disintegrin and metalloproteinases with throm-
bospondin motifs), astacins and serralysins [12-14].
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Matrix metalloproteinases
The matrix metalloproteinase (MMP) gene family consists of a group of proteolytic 
enzymes capable of degrading components of the ECM during physiological pro-
cesses like pregnancy, parturition [15], development, growth and wound-healing 
[16], as well as in pathological conditions like rheumatoid arthritis [17], pulmonary 
emphysema [18], osteoarthritis [19], skin disorders [20] and malignancy [21]. MMPs 
share the following functional properties: 1) they contain a zinc ion at their active site 
and can be inhibited by chelating agents; 2) they are almost all secreted in a latent 
zymogen form that needs activation by partial proteolytic cleavage to become active; 
3) they are inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs); and 4) 
they share common amino acid sequences and cleave at least one component of the 
ECM [22]. Depending on their structure and substrate preference, the MMP family is 
divided into collagenases (MMP-1, -8, -13 and -18), stromelysins (MMP-3, -10, -11 and 
-28), matrilysins (MMP-7 and -26), gelatinases (MMP-2 and -9), elastases (MMP-12, -19 
and -20) and membrane-type MT-MMPs (MMP-14, -15, -16, -17, -24 and -25). Some 
relevant characteristics of the speci c MMPs and TIMPs studied as described in this 
thesis are summarized in Table 1 and discussed below.
Collagenases. The collagenases can degrade structural type I to III collagens only. 
Neutrophil collagenase or collagenase-2 (MMP-8) is one of the collagenases regarded 
as being synthesized exclusively by polymorphonuclear neutrophils before emigration 
from the bone marrow. In polymorphonuclear leucocytes it is stored in and released 
from secretory granules and its expression is stimulated by tumour necrosis factor-α. 
In addition, MMP-8 mRNA has been detected in mononuclear  broblast-like cells in 
rheumatoid synovial  broblasts and endothelial cells. Doxycycline has been shown to 
down-regulate MMP-8 induction, at both the mRNA and protein levels [17].
Matrilysins. Matrilysin (MMP-7) or putative matrix metalloproteinase-1 (PUMP-1) 
lacks a speci c extracellular matrix-binding domain and is therefore the smallest of the 
MMP gene family, with a molecular weight in its inactive form of 28 kDa. The zymogen 
is activated by 4-aminophenylmercuric acetate, trypsin, plasmin and stromelysin-1 
(MMP-3), but not by tissue collagenase (MMP-1), gelatinase-A (MMP-2) nor gelatin-
ase-B (MMP-9). MMP-7 can activate pro-MMP-1 and pro-MMP-9 but not pro-MMP-2 
nor pro-MMP-3. It has strong stromelysin-like activity and degrades insoluble elastin, 
type IV collagen, laminin-1,  bronectin, proteoglycan and gelatins [27].
Gelatinases. Gelatinase-A (MMP-2) and gelatinase-B (MMP-9) are originally called 
gelatinases, enzymes which degrade denatured collagens (gelatin), although both 
gelatinases can degrade native collagens including type IV (basement membrane) 
and type V collagen and elastin as well. MMP-2 has been demonstrated in a variety 





























































































































































































































































































































































































































































































































































































































rophages, monocytes, keratinocytes, polymorphonuclear leucocytes and malignant 
cells [28, 29].
Tissue inhibitors of metalloproteinases
Tissue inhibitors of metalloproteinases (TIMPs) are ubiquitous and naturally occurring 
inhibitors of MMPs that inhibit the MMP proteolytic activity by forming noncovalent 
1:1 stoichiometric complexes resistant to heat denaturation and proteolytic degrada-
tion [for review see 25]. Up to now, four TIMPs have been described, TIMP-1, -2, -3 and 
-4, with molecular weights ranging from 21 to 28.5 kDa. TIMPs di er in solubility, inter-
action with proenzymes (pro-MMPs) and regulation of expression. Whereas TIMP-1, -2 
and -4 are present in soluble forms, TIMP-3 is tightly bound to the matrix. Apart from 
binding to MMPs, TIMPs are also able to form complexes with the pro-MMPs in uencing 
the MMP activation process. TIMP-2 is a constitutive protein, whereas TIMP-1 expres-
sion is in uenced by external stimuli including growth factors, serum, phorbol esters, 
cytokines and erythropoietin. It has become apparent that apart from regulation of 
MMP activity, TIMPs are also involved in various other biological processes including 
cell-growth, apoptosis and angiogenesis. For example, TIMP-1 and -2 have been 
shown to potentiate the e ect of erythropoietin on erythroid stem cell proliferation 
and di erentiation. Moreover, TIMP-1 and -2 are able to induce the growth of normal 
and malignant cells and are associated with resistance against apoptosis in malignant 
cells. In addition, TIMP-1 has been shown to potentiate steroidogenesis. Moreover, 
TIMPs are also able to inhibit angiogenesis, partly by MMP inhibition, and are involved 
in embryogenesis by controlling the MMP-mediated remodelling of the extracellular 
matrix during blastocyst implantation. In tumours of various origins, downregulation 
of both TIMP-1 and -2 has been associated with increased invasiveness, while overex-
pression was associated with reduced tumour growth and metastasis. 
Detection of matrix metalloproteinases 
MMPs can be detected by various techniques including zymography, in situ zymogra-
phy, enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, mRNA in 
situ hybridization and quantitative RT-PCR analysis, Western blotting and quantitative 
activity assays, including radiolabelled collagen substrate degradation assays and bio 
immuno assays (BIAs). Gelatin zymography allows quanti cation of the active and 
the pro-enzyme form but is primarily suitable for measurement of gelatinases [30] 
and does not provide information at the cellular level. This disadvantage has been 
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overcome with the introduction of in situ zymography, that enables visualisation of 
activity of the gelatinases MMP-2 and -9 [31-34] and of MMP-7 [35] on frozen tissue 
sections. MMPs and their TIMPs can be localized by immunohistochemistry and mRNA 
in situ hybridization analysis without possibilities for quanti cation and detection of 
enzyme activity [36, 37]. In general, most ELISAs measure the grand total of pro-en-
zyme, active- and inhibitor-complexed forms of the respective MMP [38]. Enzymatic 
activities of MMPs can also be measured in blood samples and tissue homogenates 
using speci c biochemical immunosorbent activity assays (BIA) [39, 40].
Regulation of matrix metalloproteinases
MMPs are tightly regulated at di erent levels, including gene expression, secretion, 
activity, and clearance [41].
1) Gene expression. The expression of most MMPs is regulated at the transcrip-
tional level, by growth factors (e.g., epidermal growth factor and transforming growth 
factor-β), cytokines (e.g., tumour necrosis factor-α and interleukin-1), hormones [42-
44], bacterial endotoxins, stress and oncogene activation [45, 46]. Apart from soluble 
factors, also cell-cell and cell-matrix interactions in uence the expression of MMPs. 
For example, extracellular matrix metalloproteinase inducer (EMMPRIN), formerly 
called tumour cell-derived collagenase stimulatory factor, is a glycoprotein located on 
the outer surface of human tumour cells which interacts with  broblasts to stimulate 
expression of several matrix metalloproteinases in  broblasts [47, 48]. Various single 
nucleotide polymorphisms (SNPs) in gene promoter regions of MMPs have been 
shown to in uence transcriptional activity resulting in altered protein levels. The 
-1306 C/T transition in the MMP-2 promoter sequence, for example, disrupts a Sp-1 
binding site resulting in remarkably decreased promoter activity [49]. The -1562 C/T 
transition in the promoter region of the MMP-9 gene, on the other hand, results in 
higher promoter activity. This is due to preferential binding of a putative transcription 
repressor protein to the C allelic promoter [50].
2) Secretion in the latent form. MMPs are secreted in a latent proenzyme form, 
with the exception of MMP-11, MMP-28, and the membrane bound MT-MMPs. The 
other MMPs need to be activated in order to interact with the extracellular matrix. 
Several proteolytic activators, including the plasminogen activator/plasmin system, 
kallikreins, neutrophil elastase and trypsin, are involved in the activation of MMPs 
[51]. Unlike other MMPs, pro-MMP-2 is constitutively expressed by many cell types 
and activation occurs at the cell surface [52]. This activation appears to involve an 
interaction with MT1-MMP and TIMP-2 to form a membrane-bound complex that 
regulates the activation of pro-MMP-2 [53]. Pro-MMP-9 is not constitutively expressed 
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and its production and secretion can be induced and modulated by various factors. 
For example, pro-MMP-9 is synthesized by di erentiating neutrophils in the bone 
marrow, stored in speci c granules of circulating neutrophils, and released following 
neutrophil activation by in ammatory cytokines [54, 55].
3) Regulation of activity. TIMPs, the primary inhibitors of MMPs, form inhibitory 
complexes with most active MMPs [56, 57]. TIMP-1 also binds to pro-MMP-9, whereas 
TIMP-2 forms complexes with pro-MMP-2 [58]. TIMPs inhibit MMPs locally whereas 
alpha-2-macroglobulin, an abundant plasma protein, acts as a general non-speci c 
endoproteinase inhibitor [59]. Recently, the transformation suppressor factor RECK, 
a membrane-anchored glycoprotein, was found to contain 3 protease inhibitor-like 
domains that negatively regulate MMP-2, -9 and MT1-MMP activity and inhibits tu-
mour invasion and metastasis. Furthermore, down-regulation of RECK by oncogenic 
signalling leads to the excessive activation of MMPs thereby promoting malignant 
behaviour of cancer cells. In several types of tumours, a positive correlation between 
RECK expression and survival of the patients has been described [60-62].
4) MMP catabolism and clearance. Although MMPs are found in urine, the degra-
dation and excretion pathways of MMPs and TIMPs in the body have not been fully 
elucidated [63]. Little is known about autoproteolysis of active MMPs, but certain 
cleavages clearly diminish MMP-activity [54]. Some MMPs are also found in associa-
tion with accessory proteins, like lipocalins, which could serve as protection against 
autolysis.
Human neutrophil lipocalin
Lipocalins are a group of small extracellular proteins with great diversity at the 
sequence level. The lipocalins are member of an overall structural superfamily: the 
calycins. The other groups are the fatty-acid-binding proteins, a group of metallopro-
tease inhibitors, triabin and the avidins [64]. Lipocalins bind to a spectrum of small hy-
drophobic molecules and to speci c cell-surface receptors and form complexes with 
soluble macromolecules. Lipocalins are supposed to function as transport proteins. 
They appear to be involved in biological processes like retinol transport, invertebrate 
cryptic coloration, olfaction, pheromone transport and prostaglandin synthesis. 
They also play a role in the regulation of cell homeostasis, the modulation of the 
immune response, and, as carrier proteins, act in the clearance of endogenous and 
exogenous substances [65]. Neutrophil gelatinase-associated lipocalin (NGAL), also 
named human neutrophil lipocalin (HNL), siderocalin or lipocalin-2 (lcn2), is a 25 kDa 
glycosylated protein constitutively expressed in myelocytes and stored in secondary 
granules of human neutrophils [66]. NGAL is present as a monomer, homodimer, or 
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as a heterodimer with neutrophil gelatinase [67]. It is highly induced in epithelial cells 
during in ammation or malignant conditions [68-74]. Because accumulation and in l-
tration by neutrophils is a prominent feature of the in ammatory process in ulcerative 
colitis, it has been suggested that NGAL may serve as a speci c marker of intestinal 
neutrophil activation in ulcerative colitis [75]. In neutrophils, NGAL colocalizes with 
lactoferrin, whereas the gelatinases are localized in speci c gelatinase granules [67, 
76]. Interaction of NGAL with activation and enzymatic activity of gelatinase could 
initially not be shown [77]. The expression of NGAL in epithelial cells is totally de-
pendent on NF-κB and also depends on a NF-κB-binding co-factor that is induced by 
interleukin-1β but not by tumour necrosis factor-α and is required for transcription of 
the NGAL gene [78]. It has been shown that NGAL can act as a bacteriostatic agent by 
sequestering siderophore bound iron and preventing its uptake by microorganisms 
[73, 79, 80]. Therefore, NGAL seems to play a role also in the innate immunity by reduc-
ing the availability of iron for microbial growth [78].
Helicobacter pylori infection and gastric neoplasia
Gastritis is in ammation of the stomach and is caused by infectious agents, drugs, and 
autoimmune and hypersensitivity reactions. Gastritis in childhood is very common in 
non-industrialized countries but uncommon in the Western world. The prevalence of 
gastritis increases with age, reaching a prevalence of approximately 60% in indus-
trialized to 100% in non-industrialized countries at the age of 60 [81-83]. The most 
frequent cause of (chronic) gastritis is Helicobacter pylori (H. pylori), a Gram-negative 
bacterial species that preferentially colonizes human gastric mucosa resulting in a 
chronic gastritis [84, 85]. After eradication of H. pylori, the gastric mucosa is restored 
to normal [85]. In the majority of patients with peptic ulcer disease H. pylori is the 
causative factor [86-88] and eradication of H. pylori prevents recurrence of peptic 
ulcers [89]. H. pylori has also been associated with gastric carcinoma [90], gastric 
mucosa associated lymphoid tissue (MALT), lymphoma [91] and Ménétrier’s disease 
[92]. H. pylori gastritis progresses gradually over the years from the non-atrophic form 
into the atrophic form. Atrophic gastritis and intestinal metaplasia are premalignant 
conditions for gastric cancer except for cancers of the gastrointestinal junction. Of 
gastric carcinomas, 80% are related to H. pylori gastritis. H. pylori infection is currently 
associated with an approximately two-fold increased risk of developing gastric cancer 
[93]. In addition to H. pylori gastritis, another 10% of gastric carcinomas are related to 
atrophic gastritis of the autoimmune type [94, 95]. A possible mechanism through 
which H. pylori infection could induce carcinogenesis is via the accompanying in am-
matory response, which gives rise to the production of mutagenic substances like 
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nitric oxide [96]. Although H. pylori appears to be the most frequent cause of (chronic) 
gastritis [84, 85], only a minority of people who harbour this organism ever develop 
cancer. This process of gastric carcinogenesis seems to be in uenced by di erences in 
in ammatory response due to genetic diversity of both H. pylori isolates as well as host 
genes [97]. Four di erent genetic loci have been identi ed in the H. pylori genome with 
the potential to interact with host molecules that induce epithelial responses with 
carcinogenic potential: CagA, VacA, BabA, and SabA. CagA, derived from the cytotoxin 
associated gene, is injected in the host cells by the bacterium. CagA+ strains enhance 
the risk for severe gastritis, atrophic gastritis, and distal gastric cancer compared with 
that incurred by cag- strains [98, 99]. One of the mechanisms involved is an enhanced 
NF-κB mediated interleukin-8 induction and in ammatory neutrophilic response in 
human gastric tissue by H. pylori cagA+ strains compared to cag- strains [100]. VacA
encodes a secreted bacterial cytotoxin that induces multiple structural and functional 
alterations in cells leading to gastric in ammation, haemorrhage, and ulcers [101, 
102]. H. pylori strains with a type s1/m1 vacA allele are associated with enhanced 
gastric epithelial cell injury [103] and gastric cancer risk compared with vacA s2/m2 
alleles [104]. BabA2 encodes for an adhesin that binds the Lewisb histo-blood-group 
antigen on gastric epithelial cells. The presence of babA2 is associated with cagA and 
vacA s1 and H. pylori strains with all three genes induce the highest risk for gastric 
cancer [105]. Sialyl-Lewisx antigen is a tumour antigen that is upregulated in gastric 
in ammation binding to gastric epithelial cells by the H. pylori adhesin sabA [106].
MMPs in gastrointestinal immunity, in ammation, infection and 
carcinogenesis
MMPs are tightly regulated and under normal conditions are involved in physiological 
tissue turnover and the host immune response. They play a role in matrix remodel-
ling, the recruitment of in ammatory cells into the intestinal wall and other organs, 
cytokine and chemokine processing and defensin activation. MMP-9, for example, 
is secreted during neutrophil migration across the basement membrane, whereas 
TIMP-1 is able to inhibit this process [107]. MMP-3 is involved in the cellular immune 
response against intraluminal colonic pathogenic bacteria by facilitating the migra-
tion of T-helper lymphocytes into the intestinal lamina propria [108]. The gelatinases 
are also necessary for migration of dendritic cells out of the skin and of T-cells across 
the basement membrane [109]. Several MMPs, including the gelatinases, can release 
active tumour necrosis factor-α from the membrane-anchored precursor [110] and 
can both activate pro-interleukin-1β or inactivate active interleukin-1β [111, 112]. 
Defensins are MMP-7 activated antibiotic peptides that kill bacteria by membrane dis-
General introduction 21
ruption. It has been shown that certain bacterial components can stimulate epithelial 
MMP-7 secretion, indicating its role in the early defence mechanism against infection 
[113]. 
Under pathological conditions, including gastrointestinal in ammation, infection 
and malignancy, enhanced levels and activities of MMPs have been described resulting 
in an imbalance in breakdown and remodelling of the extracellular matrix [114, 115]. 
In in ammatory bowel diseases, for example, enhanced expression of MMPs, either on 
the protein or mRNA level, or immunohistochemically, has been described to be asso-
ciated with the severity of in ammation [116-118]. Protein and mRNA levels of MMP-2 
and especially MMP-9 were markedly enhanced in in ammatory bowel tissues, with 
the highest concentrations in severely in amed tissues. Polymorphonuclear leuco-
cytes appeared to be the main source of MMP-9, whereas MMP-2 was predominantly 
located in the extracellular matrix [116]. Epithelial cells at the edge of gastrointestinal 
ulcers are strongly positive for matrilysin (MMP-7), probably because of their putative 
role in re-epithelization [119]. It has been demonstrated that activated lamina propria 
T-cells, for example elicited by luminal antigens, can cause a pathological chronic 
in ammatory response leading to intestinal damage by stimulating MMP secretion 
[120]. Enhanced MMP levels and activities have also been described in necrotising 
enterocolitis [121], celiac disease [122], collagenic colitis [123] and diverticulitis [124].
In infectious diseases, enhanced host MMP activity or decreased TIMP expression 
has been described in response to pathogens. In addition to inducing MMP secretion 
by host cells, it has been shown that bacterial pathogens are able to activate host 
pro-MMPs by secreting proteolytic enzymes themselves [125]. H. pylori, for example, 
produces several metalloproteases including one with MMP-3 like activity [126, 127]. 
In a number of human cancers enhanced expression of many MMPs, including 
MMP-1, -2, -3, -7, -9, -13 and -14, at the protein and mRNA levels or immunohis-
tochemically, in both primary tumours and/or metastases has been associated with 
tumour progression and poor prognosis [128]. For instance, enhanced immunohis-
tochemical expression of MMP-1, -7 and -13 has been associated with poor prognosis 
in colorectal cancer patients [129-131]. Enhanced expression of MMPs is found at the 
invasive front of tumours where malignant cells and stromal cells interact with each 
other and mutual induction of MMPs takes place. Several speci c cellular mechanisms 
have been described that facilitate activation of local pro-MMPs and containment of 
MMP activity to the invasive front. These mechanisms include: 1) the expression of 
membrane-bound metalloproteinases; 2) the binding of soluble MMPs to membrane-
bound docking factors; and 3) cell surface receptor-mediated activation of pro-MMPs. 
Pro-MMP-2, for example, can be activated at the cell membrane after forming a 
trimeric complex with TIMP-2 and MT1-MMP (MMP-14) [53].
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Chronic in ammation is associated with enhanced cancer risk and both chronic in-
 ammation and cancer are accompanied by enhanced MMP levels and activities [97]. 
Malignant cells, on their turn, secrete cytokines and MMPs, which stimulates in ux 
of in ammatory cells to the tumour site and induces (neo)angiogenesis [132]. It has 
been shown, for instance, that MMP-9 is involved in tumour-induced angiogenesis 
by releasing Vascular Endothelial Growth Factor (VEGF) [133] with tumour-related 
in ammatory cells being the main source of MMP-9 [134].
MMPs in H. pylori-induced gastritis
Immunohistochemical studies on human gastric tissue have shown that MMP-9 
immunoreactivity is predominantly expressed by in ammatory cells, including mac-
rophages and  broblasts [135, 136], by parietal cells [137], and to a lesser extent by 
epithelial cells with higher expression in H. pylori positive tissue compared to H. pylori 
negative tissue [135, 136]. Antral mucosa of H. pylori positive individuals showed ap-
proximately 20-fold higher MMP-9 activity compared to that of uninfected individu-
als, when measured by quantitative gelatin-zymography, probably by an increased 
number of macrophages containing a higher amount of MMP-9. Macrophages secrete 
MMP-9 in response to H. pylori [136, 138] and it has been demonstrated that H. pylori
can induce activation of NF-κB in gastric epithelial cell lines leading to MMP-9 gene 
transcription [135]. 
In histologically normal, H. pylori negative human gastric tissue MMP-2 immunore-
activity was observed in parietal cells and to a lesser extent in epithelial cells [137]. 
MMP-2 activity was elevated in H. pylori positive individuals compared to uninfected 
individuals, but at lower levels than MMP-9 [136].
H. pylori positive individuals expressed higher levels of MMP-7 at the protein and 
mRNA levels in their antrum and corpus when compared to uninfected individuals. 
MMP-7 immunoreactivity in epithelial cells of H. pylori positive individuals was more 
intense than in uninfected persons [138, 139]. MMP-7 expression was strongly related 
to the infestation of cag+ H. pylori strains since MMP-7 expression was demonstrated 
in gastric epithelial cells in 80% of cag+ colonized persons but in none of cag- or 
uninfected individuals. Cag+ H. pylori strains augment the risk for gastric cancer. In in 
vitro studies the increased levels of MMP-7 in in amed gastric mucosa appeared to 
be induced by cag+ H. pylori strains dependent on activation of extracellular signal-
regulated kinase (ERK) 1/2 mitogen–activated protein kinase [140]. H. pylori infection 
has also been reported to stimulate MMP-1, MMP-3, TIMP-3, and MMP-3/TIMP-3 
complex formation in gastric epithelial cells and in gastric mucosa [141, 142]. A strong 
interaction of interleukin-1β and H. pylori on MMP-3 secretion has been found [142]. 
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In H. pylori-induced ulcers higher concentrations of MMP-1 were found compared to 
NSAID (non-steroidal anti-in ammatory drug)-induced ulcers, possibly due to the 
anti-in ammatory e ect of the NSAIDs used [143].
Gastric carcinoma
Despite the sharp decrease in the incidence rate of gastric cancer over the last 50 
years [144, 145] gastric cancer is still the second most common cancer worldwide 
accounting for approximately 10% of all cancers and being responsible for approxi-
mately 12% of all cancer deaths [146-148]. In contrast to the decreased incidence 
rate of gastric cancer, the incidence rates of cancer of the distal oesophagus and of 
the cardia have increased signi cantly over the last decades [149]. In 1985, the age-
standardized incidence rate per 100,000 population varied from 8.8 and 4.2 in North 
America to 74.8 and 35.2 in Japan, in men and women, respectively. The incidence 
rate for Western Europe in 1985 was 18.0 and 9.4 in men and women, respectively 
[146, 150]. The incidence rate in the Netherlands from 1989 until 1992 was 15.4 and 
6.1 in men and women, respectively (World Standardized Rate) and in this period, 
10,116 new cases of gastric cancer were registered indicating approximately 2,500 
new cases annually [151]. In 1998, the incidence rate in the Netherlands ranged from 
18 in men (1,392 new cases) to 10 in women (768 new cases) according to the Dutch 
Cancer Registry (www.kankerregistratie.nl).
The 5-year cumulative survival rate ranges from 91% in stage 1 (intramucosal) to 5% 
in stage 4 (metastatic) gastric cancer [152]. The overall 5-year survival rate ranges from 
7.4% to 16.5% [153, 154]. In the southeast of the Netherlands, the relative 5-year sur-
vival rate of patients who underwent resection was 85% for stage I and 60% for stage 
II tumours [155]. Surgical resection remains the primary curative treatment option 
in gastric cancer with 5-year survival rates of 58%-78% and 34% reported for stage 
I and II disease, respectively [156]. Postoperative chemoradiotherapy, perioperative 
chemotherapy, and postoperative chemotherapy have been shown to decrease the 
risk for recurrence and to improve the outcome for patients  t to undergo these treat-
ments [157]. The aetiology of gastric cancer seems to be multifactorial with di erent 
relative in uence of causal factors in di erent geographical regions. Compared to 
U.S.-born individuals, immigrants had at least a 50% higher mortality from stomach 
cancer [158]. Epidemiological data suggest an increased risk for gastric carcinoma 
development in patients with H. pylori-associated gastritis [90, 159]. H. pylori infection 
was especially associated with non-cardiac carcinomas, and a stronger association 
was observed with di use rather than with intestinal-type tumours [160].
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MMPs in gastric carcinoma
Immunohistochemical and in situ hybridisation studies, as well as quantitative meth-
ods like gelatin-zymography and activity assays, have demonstrated that gastric car-
cinomas contain enhanced amounts of MMP-1, -2, -3, -9 and TIMP-1 [161, 162], MMP-7 
[163] and MT1-MMP [164]. Particularly MMP-1, MMP-7, MMP-9 and TIMP-2 were 
immunolocalized in carcinoma cells, whereas MMP-2 immunostaining was observed 
on advanced gastric carcinoma cells and correlated with vascular invasion by tumour 
cells [165, 166]. Pro-MMP-2 activation was present only on gastric carcinoma cells that 
expressed MT1-MMP, indicating MT1-MMP-assisted activation of pro-MMP-2 in human 
gastric carcinomas. The MMP-2 genotype appeared to in uence the susceptibility to 
develop gastric cardiac adenocarcinoma [166].
MMP-7 was reported to be produced by gastric carcinoma cells and signi cantly 
associated with aggressive pathological phenotypes of gastric cancer [167]. In gastric 
carcinomas, it has been shown that expression of E1AF/PEA3 (ETV4), an ets-family 
transcriptional factor, able to transactivate multiple MMP genes, correlates well with 
MMP-7 expression [168]. 
H. pylori infection of gastric carcinoma cells was reported to increase mRNA 
expression and protein levels of MMP-9 [169]. MT1-MMP [170] and MMP-1 [171] im-
munoreactivity in human gastric carcinomas were also found to be associated with 
worse prognosis, whereas increased TIMP-2 expression seems to be correlated with 
prolonged survival [172].
Outline of the studies described in this thesis
In this thesis, several studies are described on the putative role of the matrix metal-
loproteinases MMP-2, -7, -8 and -9, the tissue inhibitors of metalloproteinases TIMP-1 
and -2, and of the lipocalin neutrophil gelatinase-associated lipocalin NGAL in chronic 
H. pylori-induced gastritis and in gastric carcinoma. MMPs are the main degrading 
enzymes of extracellular matrix proteins and basement membranes and are therefore 
involved in tissue remodelling and repair as well as recruitment of in ammatory 
cells and angiogenesis in many physiological and pathological processes, including 
in ammation and malignancy. As introduction, a short overview is given in chapter 
1 on MMPs, TIMPs and lipocalins in general and their role in H. pylori-induced gastritis 
and gastric carcinoma in particular.
H. pylori gastritis is recognized as an important pathogenetic factor in peptic ulcer 
disease and gastric carcinogenesis. Chapter 2 reports on the in uence of H. pylori 
infection on gastric mucosal MMP-2 and -9 expression. In gastric mucosal biopsies 
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of individuals with or without H. pylori infection, the levels, isoforms and activity of 
MMP-2 and -9 were determined by quantitative gelatin-zymography, bioactivity assays 
(BIAs), enzyme-linked immunosorbent assays (ELISAs) and immunohistochemistry. In 
addition, the relation between gastric mucosal MMP-2 and -9 expression and severity 
of in ammation was assessed. 
The in uence of H. pylori eradication therapy on mucosal MMP-2 and MMP-9 levels 
is described in chapter 3. Gastric biopsies from patients with H. pylori-associated 
gastritis, that were treated with a combination regimen of acid inhibitory therapy and 
antibiotics in order to eradicate H. pylori and to reduce the risk for peptic ulcer disease, 
were evaluated for the levels, isoforms and activity of MMP-2 and MMP-9 by quantita-
tive gelatin-zymography, bioactivity assays (BIAs) and enzyme-linked immunosorbent 
assays (ELISAs).
In a number of human cancers, enhanced expression of MMPs has been described 
in primary tumours associated with tumour progression and poor prognosis. Chapter 
4 describes the initial study of levels, isoforms, and activities of MMP-2 and MMP-9 
in gastric carcinomas and corresponding normal mucosa, as assessed by quantita-
tive gelatin–zymography. These parameters were correlated with a number of 
clinicopathological parameters including TNM stage and histological classi cations 
according to Laurén and WHO. In addition, the prognostic signi cance of the MMP-2 
and MMP-9 levels for the overall survival of the patients was evaluated.
The results of a more comprehensive study that was carried out to endorse the 
 ndings as described in chapter 4 are presented in chapter 5. The MMP analyses in 
the same group of patients were extended and compared with those obtained with 
a new and more recent group of gastric cancer patients. Furthermore, instead of 
quantitative gelatin-zymography, bioactivity assays (BIAs) and enzyme-linked immu-
nosorbent assays (ELISAs) for MMP-2 and MMP-9 were used. Moreover, the prognostic 
value of MMP-2 and MMP-9 was compared with those of MMP-7 and MMP-8 and the 
study was expanded by determination of the inhibitors TIMP-1 and TIMP-2. In addi-
tion, because of the increasing age of the patients and the length of the follow-up, 
tumour-associated survival was evaluated. 
Neutrophil gelatinase-associated lipocalin (NGAL) is a lipocalin that has initially 
been discovered in speci c granules of human neutrophils and was later shown to be 
expressed also by certain epithelial cells, especially in in amed or malignant tissues. 
A part of the NGAL is present as a complex with MMP-9. In chapter 6, an analysis of 
the presence of MMP-9-NGAL complexes in tissue extracts from gastric cancers and 
their relation with survival is presented. In the same cohort of patients as used in the 
study described in chapter 5, MMP-9-NGAL complexes were measured by zymog-
raphy and by ELISA. The tumour levels of MMP-9-NGAL complex, MMP-9 and NGAL 
were evaluated for correlations with established clinicopathological parameters of 
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the gastric carcinoma patients and for their predictive value to patients’ outcome. In 
addition, immunohistochemical analysis of serial para  n-embedded tissue sections 
and immuno uorescence double staining were used to establish the cellular origin of 
MMP-9 and NGAL.
Single-nucleotide polymorphisms (SNPs) within MMP genes are thought to in u-
ence the expression of MMPs and/or even seem to be associated with the susceptibil-
ity for the development of malignancy. The clinical impact of MMP and TIMP gene 
polymorphisms in our cohort of gastric cancer patients is described in chapter 7. 
The genotype distribution and allele frequencies of SNPs of MMP-2, -7, -8 and -9 and 
TIMP-1 and -2 were studied. In order to get insight into the functional and clinical con-
tribution of these MMP-related gene polymorphisms, the relationship between the 
distribution of these SNPs and the respective protein levels in tumour and adjacent 
normal tissue, as well as the relation of the SNPs with established clinicopathological 
parameters and tumour-related survival was assessed.
The di erent studies are  nally compiled as a summarizing discussion in chapter 8, 
including a discussion on the potential role of MMP inhibition in gastric cancer.
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Summary
Colonization of the gastric mucosa with Helicobacter pylori (H. pylori) leads to an 
acute gastritis, which will develop into a chronic gastric in ammatory reaction in 
the majority of infected individuals. This long-term H. pylori-associated gastritis 
is recognized as an important pathogenic factor in peptic ulcer disease and 
gastric carcinogenesis, disorders where tissue remodelling through matrix met-
alloproteinases (MMPs) is known to occur. The present study was performed to 
investigate whether the gastric mucosal MMP-2 and MMP-9 levels are a ected by 
an H. pylori infection. The levels, isoform constitution and activity of MMP-2 and 
MMP-9 were determined by quantitative gelatin-zymography, bioactivity assay 
(BIA), Enzyme-Linked Immunosorbent Assay (ELISA) and immunohistochemistry 
in mucosal biopsies of the antrum and corpus originating from patients with an 
H. pylori- associated gastritis (n=45) and H. pylori negative control patients (n=27). 
H. pylori infection and gastritis was established by a combination of culture and/
or histological identi cation, and con rmed by speci c IgG H. pylori antibodies.
Patients with an H. pylori infection showed signi cantly elevated levels of 
all forms of MMP-9 (5- up to 70-fold, P≤0.005) in both antrum and corpus mu-
cosa when compared with H. pylori negative controls, whereas the MMP-2 levels 
were almost identical. The increase of MMP-9 in the corpus mucosa of patients 
with antral gastritis only was less impressive (3- to 6-fold) and intermediate 
(0.001≤P≤0.05) to that of H. pylori negative patients and pangastritis patients. A 
highly signi cant correlation between quantitative gelatin-zymography, BIA and 
ELISA was observed for MMP-9 (R>0.81, P<0.001), which was less coherent for 
MMP-2. Semi-quantitative histology scores con rmed that both active as well as 
chronic in ammation were signi cantly (P<0.001) increased in antrum as well as 
in corpus mucosa of H. pylori infected patients compared with H. pylori negative 
patients. The increase of MMP-9, primarily expressed in phagocytic in ammatory 
cells, correlated signi cantly (0.27≤R≤0.53) with the severity of both the active 
as well as chronic in ammation in antrum (P<0.05) and particularly in corpus 
mucosa (P<0.01).
In conclusion, H. pylori-associated gastritis is characterized by a signi cant 
increase in the MMP-9 levels in both antrum and corpus mucosa, which is par-
ticularly present in phagocytes and correlates with the severity of the mucosal 
in ammation. In contrast, MMP-2 levels are almost unaltered when compared 
with H. pylori negative patients. This MMP-9 pro le in the H. pylori-infected gastric 
mucosa is comparable to that seen in gastric ulceration and carcinomas.
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Introduction
Helicobacter pylori (H. pylori) is a curved or spiral-shaped Gram-negative bacterium that 
lives in the mucus layer of the gastric epithelium and in metaplastic gastric epithelium 
of the oesophagus and duodenum [1-3]. Infection with H. pylori is the most common 
cause of gastritis, preceeded by colonization of the gastric mucosa [4]. This infection 
leads to an acute gastritis that, over the course of several weeks, will develop into a 
chronic in ammatory reaction of the mucosa [5]. Patients with longstanding H. pylori-
associated chronic gastritis are predisposed for peptic ulcer disease as well as gastric 
carcinoma and lymphoma [6, 7]. In this sequence of events cells migrate through the 
gastric tissue that thereby undergoes constant remodelling. 
Matrix metalloproteinases (MMPs) are thought to be key enzymes in these kinds 
of in ammatory, ulcerative, and malignant processes [8-12]. The (patho)physiologic 
degradation of basement membrane components and the extracellular matrix is 
executed by these secreted or transmembrane endo-proteinases, which share a 
zinc-containing catalytic domain required for their proteolytic activity. Currently, at 
least 17 MMP family members have been identi ed which can be divided into 4 major 
subgroups, based on their substrate preferences: i.e. collagenases, stromelysins, ge-
latinases and membrane-type MMPs. Most of these enzymes are secreted in a latent 
form and require extracellular activation. Their activity is regulated by the interac-
tion with their antagonists, the tissue inhibitors of metalloproteinases (TIMPs), and 
through inhibition by α2-macroglobulin [8, 11, 12]. Previous studies have shown that 
gastric ulceration, both in animal models and in humans, is accompanied by enhanced 
expression and levels of several MMPs within the mucosa [13-16]. In addition, gastric 
cancer is also reported to be characterized by an increase of MMPs [17-22]. The aim 
of the present study was to assess whether the levels of the gelatinases MMP-2 and 
MMP-9 in the gastric mucosa are a ected already early in these pathophysiological 
processes, i.e. during an H. pylori infection, which has to our knowledge not been 
reported before.
Patients, materials and methods
Patients
Biopsy specimens at upper gastrointestinal endoscopy were obtained from 72 consec-
utive dyspeptic patients, between 21 and 80 years of age (mean age: 51.8±1.9 years), 
consisting of 42 males and 30 females. Patients who had recently used proton-pump 
inhibitors, corticosteroids, non-steroidal anti-in ammatory drugs (NSAIDs), bismuth 
compounds, sucralfate, or antibiotics were excluded. For histological examination, 2 
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biopsies were taken from the antrum, 3-5 cm proximal to the pylorus, and 2 from the 
corpus, 5 cm above the junction between antrum and corpus. These specimens were 
examined by an experienced pathologist according to the guidelines of the revised 
Sydney system, which provides a semi-quantitative grading of histological parameters 
(0 = normal, 1 = mild, 2 = moderate, 3 = marked) [23]. One biopsy was taken from the 
antrum for H. pylori culture and processed as described previously [24]. In 27 cases, 
the stomach was H. pylori negative, which is de ned as normal, while 31 patients had 
a pangastritis. In these cases both antrum and corpus showed histological signs of 
in ammation. In the other 14 cases, only the antrum was in amed. All cases of gastri-
tis were caused by H. pylori. The presence of these bacteria was assessed by a culture 
and/or histological identi cation, and con rmed by speci c IgG H. pylori antibodies. 
Two biopsies of antrum and corpus were used for the determination of MMP-2 and 
MMP-9.
Tissue extraction and protein concentration
Homogenates were made by adding 100 µl PBST (0.05% Tween®20 in phosphate 
bu ered saline) per mg biopsy material and homogenizing on ice in a Potter S (B. 
Braun). The protein concentration in the supernatant was determined by the Lowry 
method [25].
Gelatin-zymography
The presence of active and pro forms of the matrix metalloproteinases were assessed 
by gelatin-zymography, as previously described [18]. Ten per cent polyacrylamide 
gels were casted in a Mini-Protean® II Dual Slab Cell (Biorad). These gels contained 
1.5M Tris bu er (pH 8.8), 0.2% gelatin, 0.1% sodium dodecyl sulphate, 0.07% am-
monium persulphate and 0.07% tetramethylenediamine. First sample volumes were 
adjusted to obtain an equal protein content of 5 µg per sample. Two amounts (6.1 and 
12.2 µg protein) of an internal standard preparation, i.e. a homogenate of a colonic 
carcinoma containing both MMP-2 and MMP-9, were included on each gel for correc-
tion of intergel variation and as reference for the expression in arbitrary units. After 
electrophoresis the gels were incubated overnight at 37°C, stained with Amido Black 
(0.1% amido black, 30% methanol and 10% acetic acid), and destained in a solution 
containing 30% methanol and 10% acetic acid. Subsequently the gels were dried 
between sheets of cellophane. Finally the degree of gelatin digestion was quanti-
 ed by making a digital photo with a CCD Imaging System (Appligene), scanned in 
Aldus Photostyler 2.0 (Aldus Corporation) and analysed with Imagequant (Molecular 
Dynamics), using the peak nder-mode. The gelatin digestion was re ected as a peak 
and the MMP levels were calculated referring to the internal standard preparations, of 
which the peak-height correlated highly signi cant with the included concentration 
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(R=0.99, P< 0.001). The MMPs were analysed for the pro, active and total MMP levels, 
the latter de ned as the sum of the two isoforms, and expressed as Arbitrary Units per 
5 µg protein.
Bioactivity assay 
Latent (activatable) and active MMP were also measured using a newly developed 
immunocapture colorimetric activity assay (BIA) [26, 27]. Brie y, a polyclonal anti-
MMP-2 or monoclonal anti-MMP-9 antibody (TNO-PG) was used as catching antibody 
to capture MMP-2 or MMP-9 from appropriate dilutions of the tissue homogenates, 
respectively 1:4, and 1:20, by overnight incubation at 4°C. Active MMP was deter-
mined directly, whereas latent MMP was activated by incubation with 0.5 mM APMA 
(p-aminophenylmercuric acetate) for 0.5 and 2 hr at 37°C for MMP-2 and MMP-9, 
respectively. After washing MMP activity was assessed by adding 750 ng modi ed 
MMP-activatable pro-urokinase (Ukcol) and 0.6 mM of its chromogenic substrate 
S-2444 (pyro-Glu-Gly-Arg-p-nitroanilide; Chromogenix, Sweden) in assay bu er and 
incubating at 37°C. Reactions were performed in 96-well  at-bottomed microtitre 
plates, and a Titertek Multiskan photometer was used to follow the absorbance kinet-
ics at 405 nm. Results were expressed as MMP activity Units per mg protein, with Units 
de ned as (∆A405/hr
2)*10.
ELISAs
The total amount of MMP-2 and MMP-9 protein was determined by sandwich-ELISAs 
[27]. In brief, the same catching antibodies were used as for the immunocapture activ-
ity assays and appropriate dilutions of tissue homogenates, respectively 1:6.7 and 1:5, 
were incubated overnight at 4°C. Immunodetection of MMP-9 was performed with 
biotinylated rabbit anti-MMP-9 and for MMP-2 using rabbit anti-MMP-2 (TNO-PG) fol-
lowed by biotinylated goat anti-rabbit-IgG. After incubation with avidin/horseradish-
peroxidase the chromogenic substrate 3,3’,5,5’-tetramethyl benzidine and H2O2 were 
added and the reaction was stopped with H2SO4 and read at 405 nm. The amount of 
MMP was calculated from the parallel standard curves and expressed in ng MMP per 
mg protein. 
Immunohistochemistry
MMP-2 and MMP-9 were localized by routine indirect peroxidase-labelled antibody 
immunohistochemistry. Brie y, 4 µm para  n sections were sequentially treated with 
0.005% proteinase K (Boehringer Mannheim, Germany) in Tris-bu ered saline (TBS) 
to retrieve hidden antigens and with 0.3% H2O2 in methanol to block endogenous 
peroxidase activity. After permeabilization in 0.5% Triton X-100 in 0.1% sodium citrate 
the sections were rinsed in TBS and 5% normal goat serum was applied for 20 minutes 
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to block non-speci c binding. Excess serum was drained o , and sections were incu-
bated overnight at 4°C with rabbit anti-MMP-2 or anti-MMP-9 polyclonal antibodies, 
appropriately diluted in TBS containing 0.5% BSA. The sections were subsequently 
incubated with biotinylated goat anti-rabbit IgG and peroxidase-labelled streptavidin 
for 45 minutes each. Sections were stained by incubation in 0.1 M acetate bu er (pH 
5.2) containing 0.03% 3-amino-9-ethylcarbazole and 0.03% H2O2 for 10 minutes, 
resulting in a red staining product. Finally, sections were counterstained in Mayer’s 
haematoxylin and mounted in AquamountTM.
Statistical analysis
Group means are given as mean ± s.e.m. Di erences between groups were evaluated 
for signi cance using the Kruskal-Wallis and Mann-Whitney U tests or the Wilcoxon 
Signed-Ranks test. The correlations between zymography, immunocapture activity as-
say, and ELISA were assessed by the Pearson correlation procedure (SPSS for Windows 
7.0 statistical package, SPSS Inc., Chicago, Illinois, U.S.A.). Di erences were considered 
signi cant when P≤0.05.
Results
Patients with an H. pylori infection were found to have a signi cantly higher level of total 
MMP-9, as assessed by zymography, in both antrum [216±50 (n=45) vs. 4.8±1.5 (n=27), 
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Figure 1. Mean levels of pro (A) and active (B) MMP-9 ± s.e.m. in antrum and corpus mucosa 
originating from subjects with or without an H. pylori infection, as assessed by gelatin-
zymography. The number of patients is indicated. * P < 0.001
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with patients who where H. pylori negative. The same was true for both zymographic 
MMP-9 isoforms, i.e. pro and active MMP-9, which were also signi cantly increased in 
both antrum and corpus mucosa (Figure 1). These results were further substantiated 
by the BIA and ELISA for MMP-9. Latent MMP-9 as well as the total amount of MMP-9 
protein were also found to be approximately 6- to 30-fold enhanced in both antrum 
and corpus mucosa of H. pylori positive versus H. pylori negative patients (Figure 2). Ac-




















































16    25    
Antrum Corpus
Figure 2.
16    25    16    25    15   25   
Corpus Antrum
Figure 2. Mean levels of latent or activatable (A) and total amount protein (B) MMP-9 ± s.e.m. 
in antrum and corpus mucosa originating from subjects with or without an H. pylori infection, 
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Figure 3. Mean levels of pro (A) and active (B) MMP-2 ± s.e.m. in antrum and corpus mucosa 
originating from subjects with or without an H. pylori infection, as assessed by gelatin-
zymography. The number of patients is indicated. Di erences between H. pylori positive and 






[9.6±2.0 (n=25) vs. 1.1±0.4 (n=16), P<0.001] and corpus mucosa [8.0±2.2 (n=25) vs. 
0.6±0.2 (n=16), P<0.001] compared with patients who where H. pylori negative. Highly 
signi cant correlations between the di erent detection assays, i.e. zymography, BIA 
and ELISA, for MMP-9 were found in both tissue types (0.81<R<0.91, P<0.001). 
In contrast, the total MMP-2 levels in the zymographic analyses were found to be 
almost identical in the two patient-groups, in antrum [30±6.6 (n=45) vs. 29±6.3 (n=27), 
NS] as well as in corpus mucosa [19±1.9 (n=45) vs. 18±2.9 (n=27), NS]. The levels of the 
pro and active isoform of MMP-2 were also found to be highly similar in the gastric 
mucosa of H. pylori positive and negative patients (Figure 3). These results were con-
 rmed by the BIA and ELISA for MMP-2 in these tissues. Latent MMP-2 in the antrum 
[2.1±0.5 (n=23) vs. 2.8±0.7 (n=15), NS] and corpus mucosa [2.4±0.5 (n=25) vs. 2.8±0.5 
(n=15), NS] of patients with an H. pylori infection were almost identical to controls. The 
ELISA for MMP-2 also failed to show signi cant di erences between H. pylori positive 
and negative patients, i.e. 6.7±1.3 (n=25) vs. 7.7±2.1 (n=15) in antrum and 6.4±1.3 
(n=25) vs. 4.5±0.7 (n=17) in corpus mucosa. Active MMP-2 by the BIA was not assessed 
because of the absence of di erences in the other determinations. Overall, the di er-
Table 1 -  Mean values of MMP-2 and -9 in antrum and corpus mucosa, as assessed by 
gelatin-zymography and given in Arbitrary Units (AU) ± s.e.m. Total MMP 
is de ned as the sum of pro and active MMP. Normal mucosa is de ned as 
H. pylori negative.
Antrum Normal Mucosa (n=27) Antral Gastritis (n=14) Pangastritis (n=31)
MMP-2 Pro 23 ± 5.1 19 ± 3.4 27 ± 7.0
Active 5.5 ± 1.2 2.7 ± 0.7 7.0 ± 3.0
Total 29 ± 6.3 21 ± 3.5 34 ± 9.4
MMP-9 Pro 2.6 ± 0.7 108 ± 34 °1 224 ± 64 •1
Active 2.3 ± 0.8 20 ± 4.9 °1 31 ± 6.0 •1
Total 4.8 ± 1.5 127 ± 38 °1 256 ± 69 •1
Corpus Normal Mucosa (n=27) Antral Gastritis (n=14) Pangastritis (n=31)
MMP-2 Pro 14 ± 2.2 13 ± 1.9 17 ± 2.2
Active 3.5 ± 1.5 2.0 ± 0.9 3.5 ± 0.7
Total 18 ± 2.9 15 ± 2.0 20 ± 2.6
MMP-9 Pro 1.8 ± 0.5 12 ± 3.7 °2 119 ± 22 •1◊1
Active 2.4 ± 0.9 6.0 ± 2.7 18 ± 4.3 •1◊2
Total 4.2 ± 1.2 18 ± 5.7 °3 137 ± 26 •1◊1
The following signi cances are based on the di erences between the groups.
• = pangastritis compared with normal mucosa
° = antral gastritis compared with normal mucosa
◊ = pangastritis compared with antral gastritis
1 P ≤ 0.001, 2 P ≤ 0.01, 3 P ≤ 0.05
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ent detection assays for MMP-2 were found to be less coherent than for MMP-9, with 
the best correlation found between the BIA and the ELISA (0.46<R<0.67, P<0.005). 
Both H. pylori infected groups, i.e. patients with antral gastritis only or those with 
pangastritis, showed remarkably higher levels of MMP-9 in both antrum and corpus 
compared to control mucosa, exempli ed by the zymographic results (Table 1). 
Considering the H. pylori positives separately, the corpus mucosa of patients with pan-
gastritis showed signi cantly higher pro, active, and total MMP-9 levels than that of 
patients with antral gastritis only, whereas in the antrum mucosa a similar trend was 
observed, without reaching statistical signi cance. In addition, patients with an antral 
gastritis only were found to have signi cantly elevated levels of the MMP-9 isoforms 
(0.002<P<0.05) within the antrum mucosa when compared with their corresponding 
corpus mucosa. In the patients with pangastritis and the H. pylori negative patients 
the antrum only showed somewhat higher MMP-9 levels, although not statistically 
signi cant, when compared with their corpus mucosa.
The antrum of H. pylori-infected patients showed signi cantly more active in am-
mation [1.3±0.1 (n=44) vs. 0 (n=27), P<0.001] as well as chronic in ammation [1.5±0.1 
(n=44) vs. 0.6±0.1 (n=27), P<0.001] compared with the H. pylori negative patients. A 
similar e ect was seen in the corpus mucosa of H. pylori-infected patients for both 
active in ammation [0.7±0.1 (n=42) vs. 0 (n=26), P<0.001] and chronic in amma-
tion [1.2±0.1 (n=42) vs. 0.5±0.1 (n=26), P<0.001]. Compared with H. pylori negative 
patients, both H. pylori-infected groups showed signi cantly more active as well as 
chronic in ammation in the antrum (Table 2). A similar trend was found in the corpus 
mucosa for active in ammation, whereas chronic in ammation was only signi cantly 
Table 2 -  Mean values ± s.e.m. of active, i.e. presence of neutrophilic polymorphonuclear 
leukocytes, and chronic, i.e. cellular in ltrate consisting of lymphocytes, 
plasma cells, monocytes, mast cells and eosinophils, in ammation in antrum 
and corpus mucosa [23]. Normal mucosa is de ned as H. pylori negative.
In ammation Antrum Normal Mucosa (n=27) Antral Gastritis (n=14) Pangastritis (n=30)
Active 0 1.2 ± 0.1 °1 1.3 ± 0.1 •1
Chronic 0.6 ± 0.1 1.4 ± 0.1 °1 1.5 ± 0.1 •1
In ammation Corpus Normal Mucosa (n=26) Antral Gastritis (n=14) Pangastritis (n=28)
Active 0 0.1 ± 0.1 °3 1.0 ± 0.1 •1◊1
Chronic 0.5 ± 0.1 0.7 ± 0.2 1.4 ± 0.1 •1◊2
The following signi cances are based on the di erences between the groups.
• = pangastritis compared with normal mucosa
° = antral gastritis compared with normal mucosa
◊ = pangastritis compared with antral gastritis
1 P ≤ 0.001, 2 P ≤ 0.01, 3 P ≤ 0.05
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higher in patients with pangastritis. Regarding the two H. pylori-infected patient-
groups separately, the corpus of patients with pangastritis showed signi cantly more 
active as well as chronic in ammation than that of patients with antral gastritis only, 
in contrast to the corresponding antrum in which a similar intensity of active and 
chronic in ammation was found. As expected, the antrum of patients with antral 
gastritis only showed signi cantly higher scores of active (P<0.001) and chronic in-
 ammation (P<0.01) compared with their corresponding corpus mucosa. Within the 
H. pylori negatives only minimal chronic in ammation was detected in both antrum 
and corpus mucosa. 
Immunohistochemically MMP-9 was predominantly observed in in ammatory and 
stromal cells, i.e. neutrophilic granulocytes, macrophages, and (myo) broblasts, and 
in zymogen producing chief cells of corpus mucosa (data not shown). Faint MMP-2 
immunoreactivity was predominantly observed in in ammatory cells as well, but not 
in chief cells. 
In the overall patient-group, i.e. H. pylori positives and negatives together, a sig-
ni cant correlation was found between the zymographically determined total MMP-9 
levels and the active as well as chronic in ammation in both antrum [respectively, 
R=0.27, P<0.05 and R=0.33, P<0.01 (n=71)] and corpus mucosa [respectively, R=0.53 
and R=0.45, both P<0.001 (n=68)]. In the corpus mucosa of patients with an H. pylori
gastritis both the active and chronic in ammation correlated signi cantly with these 
MMP-9 levels [respectively, R=0.38 and R=0.36, both P<0.05 (n=42)], in contrast to the 
antrum where no correlation was found.
Discussion
Previous studies revealed an increased expression of MMPs during gastric ulceration 
[13-16] and in carcinomas of the stomach [17-22]. H. pylori-associated chronic gastritis 
is known to be able to evolve in peptic ulcer disease or gastric cancer in some 
patients. Therefore, we assessed the expression of the gelatinases MMP-2 and MMP-9 
in gastric mucosal biopsies from patients with a H. pylori gastritis. We found H. pylori 
positive patients to have signi cantly elevated levels of MMP-9 in antrum and corpus 
mucosa when compared with H. pylori negative patients, whereas the MMP-2 levels 
were highly similar. The increase in MMP-9 was very consistent and irrespective of the 
detection technique used, i.e. gelatin-zymography, BIA or ELISA. Moreover, not only 
the total mucosal MMP-9 protein level was enhanced due to the H. pylori infection, 
also the two isoforms latent (pro) and active MMP-9 were similarly increased. With 
regard to MMP-2 no changes were found neither in the total mucosal protein level nor 
in the isoform composition. 
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The signi cantly elevated levels of mucosal MMP-9 in patients with an H. pylori-
associated gastritis was found to be primarily localized in the in ltrating in ammatory 
cells such as macrophages, neutrophils and also in some (myo) broblasts. The pres-
ence and activation of these cells is most probably caused by the locally produced 
mucosal substances like cytokines, e.g. TNF-α and IL-8, which have been reported to 
be increased in H. pylori-induced chronic gastritis [28-31]. The  nding of a signi cant 
di erence in the corpus MMP-9 levels between H. pylori negative controls and patients 
with only an antral gastritis is remarkable. This might be due to both the presence 
of some minimal active in ammation and to proin ammatory alterations occurring 
in the corpus, induced by mediators such as cytokines and cytotoxins, originating 
from the infected and in amed adjacent antrum, thereby creating a kind of paracrine 
stimulation.
The antrum of patients with an antral gastritis only showed signi cantly higher 
levels of MMP-9 compared with their corresponding corpus. The antrum of H. pylori 
negative patients and that of patients with a pangastritis, however, contained similar 
MMP levels compared with their corpus mucosa. Therefore, one might conclude that 
there is at least no intrinsic di erence between antrum and corpus mucosa, regarding 
the MMP levels. The in ammatory reaction in the corpus mucosa of patients with 
an antral gastritis only was found to be less intense compared with the antrum 
mucosa as illustrated by the smaller amount of in ammatory cell in ltrate. This is 
probably related to the slow pyloro-cardial progression of gastritis as a consequence 
of a less dense H. pylori colonization of the corpus due to local acid production [32]. 
The di erences in MMP-9 levels found between the antrum and corpus mucosa 
of antral gastritis patients are thus most probably caused by the larger amount of 
MMP producing and secreting cells present within the antrum mucosa. In addition, 
within the antrum of all the patients a fairly good correlation was found between 
the MMP-9 level and the severity of both the active and chronic in ammation, which 
was even better in the corpus mucosa. This latter observation might be explained by 
the fact that the corpus mucosa of patients with an antral gastritis is intermediately 
in amed, when compared with H. pylori negatives and patients with a pangastritis, 
causing a more gradual increase of in ammation and accompanying MMP secreting 
in ammatory cells.
Gastric ulceration is known to be accompanied by an enhanced expression of sev-
eral metalloproteinases within the mucosal lesions, but gelatinases have only been 
assessed in animal models [13-16]. Interestingly also in the acetic acid-induced ulcers 
in rats only MMP-9 was found to be impressively increased whereas MMP-2 expression 
was hardly a ected [13, 15]. These  ndings are highly similar to our observations in 
H. pylori-associated gastritis. In contrast, studies in patients with gastric cancer, includ-
ing one by our group using similar techniques, consistently revealed that both MMP-2 
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and -9 levels are signi cantly elevated within the malignant tissue [18-20]. Apparently 
the premalignant in ammatory and ulcerative lesions are accompanied by the induc-
tion of only MMP-9, whereas the end-stage of the spectrum, i.e. gastric cancer, is 
characterized by a general upregulation of both gelatinases. Part of this di erence 
might be explained by the fact that MMP-9 is an inducible matrix metalloproteinase in 
contrast to MMP-2, which is expressed constitutively [8, 11]. Particularly with regard to 
the H. pylori infection it has been reported that the in ammation is associated with an 
increase of mucosal cytokines [28-31], which are able to enhance the MMP-9 produc-
tion. Furthermore, the divergence in MMP-2 and MMP-9 induction is probably also 
related to the di erences in predominant cellular origin of these gelatinases. MMP-2 
is expressed amongst others by stromal  broblasts and epithelial cells [11, 33, 34], 
whereas MMP-9 is particularly secreted by cells of the phagocytic lineage [11, 35-38], 
which  ts well with our immunohistochemical results in the H. pylori-infected gastric 
mucosa. Further prospective studies in patients with an H. pylori-associated chronic 
gastritis with a long follow-up might help to identify whether those patients with a 
relatively high MMP-2 level in the mucosa are the ones with the strongest predisposi-
tion for gastric carcinoma. 
Another aspect of the high MMP-9 levels in H. pylori gastritis might be the relation 
with wound healing. Acute wounds and impaired healing, i.e. chronic persistent 
wounds, have been shown to be accompanied by a high expression of MMP-9 [39-41]. 
Therefore, it is likely that the excessive MMP-9 expression as found in the H. pylori-
infected mucosa, may prevent spontaneous healing. Previous studies by our group in-
dicate that successful eradication of H. pylori leads to improvement and normalization 
of the active and chronic in ammatory reaction in the stomach, which is accompanied 
by a reversal of alterations in other mucosal parameters, e.g. plasminogen activators 
and superoxide dimutases [42, 43]. Similar studies will have to elucidate whether the 
MMP-9 levels will also be normalized by eradication of the H. pylori infection.
In conclusion, H. pylori-associated gastritis is characterized by a signi cant increase 
of MMP-9 in both antrum and corpus mucosa of the stomach, with no changes in 
MMP-2, compared with H. pylori negative patients. Moreover, the increase of the gas-
tric mucosal MMP-9 level is signi cantly correlated with the severity of both the active 
as well as the chronic in ammation. Future studies will elucidate the clinical relevance 
of these  ndings by evaluating the e ect of therapy and the association with gastric 
carcinogenesis. 
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Helicobacter pylori gastritis is recognized as an important pathogenetic factor in 
peptic ulcer disease and gastric carcinogenesis, and is accompanied by strongly 
enhanced gastric mucosal MMP-9 levels.
Aim 
This study was performed to investigate whether Helicobacter pylori-a ected 
gastric mucosal MMP-2 and MMP-9 levels are reversible by successful treatment 
of the infection.
Patients and methods 
Fifty-eight patients with H. pylori-associated gastritis were treated with a combi-
nation regimen of acid inhibitory therapy and antibiotics for 14 days. The levels 
and isoforms of MMP-2 and MMP-9 were measured by semi-quantitative gelatin-
zymography, bioactivity assay (BIA) and enzyme-linked immunosorbent assay 
(ELISA) in gastric mucosal biopsy homogenates.
Results
Latent, active and total MMP-9 levels decreased consistently and signi cantly by 
successful H. pylori eradication, in antrum as well as corpus mucosa, compared 
with those prior to treatment, irrespective of the therapy regimen used. The 
elevated levels remained unchanged, however, when treatment failed. MMP-2 
levels did not show major alterations after H. pylori therapy.
Conclusions
Elevated MMP-9 levels in H. pylori-infected gastric mucosa are reversible by eradi-
cation of the infection. No major changes in mucosal MMP-2 levels were observed 
by H. pylori eradication. 
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Introduction
Helicobacter pylori (H. pylori) is a curved or spiral-shaped Gram-negative bacterium 
that lives in the mucus layer of the gastric epithelium and also in metaplastic gastric 
epithelium of the esophagus or duodenum [1-3]. Infection with H. pylori is the most 
common cause of gastritis [4] and is preceded by colonization of the gastric mucosa. 
This infection leads to an acute gastritis that, over the course of several weeks, devel-
ops into a chronic in ammatory reaction of the mucosa [5]. Patients with long-term 
H. pylori-associated chronic gastritis are predisposed for peptic ulcer disease as well as 
gastric carcinoma and lymphoma [6, 7]. Matrix metalloproteinases (MMPs) are believed 
to play an important role in in ammation and carcinogenesis, amongst others, via 
the degradation and remodeling of extracellular matrix and basal membranes [8, 9]. 
MMPs are secreted or transmembrane endo-proteinases that share a zinc-containing 
catalytic domain, which is required for proteolytic activity. MMPs can degrade at least 
one component of the extracellular matrix. Currently, at least 25 family members have 
been identi ed which can be divided in four major subgroups, based on substrate 
speci city, amino acid similarity, and identi able sequence modules: collagenases, 
stromelysins, gelatinases, and membrane-type MMPs. The proteins are secreted in a 
latent form and require extracellular activation. When activated, the enzymes are sus-
ceptible to inhibition by α2-Macroglobulin and by their antagonists, the Tissue Inhibi-
tors of MetalloProteinases (TIMPs), by forming a complex with the (active) enzyme. 
This complex formation is believed to be a major regulatory mechanism [9, 10]. 
The gelatinases include MMP-2 or gelatinase-A, a 72 kDa proteinase, and MMP-9 
or gelatinase-B, a 92 kDa proteinase, which speci cally can degrade basement mem-
brane type IV collagen, as well as gelatin, collagen type I, V, VII , X, elastin, laminin 
and  bronectin [11, 12]. MMP-2, an ubiquitous enzyme in normal adult tissue, is pre-
dominantly produced by stromal cells, whereas MMP-9 is predominantly produced by 
in ammatory cells, especially the polymorphonuclear leucocytes [9, 11, 13, 14].
In gastric biopsies from H. pylori-infected individuals enhanced levels of MMP-2 and 
MMP-9 have been described, whereas TIMP-1 and TIMP-2 levels were unaltered [15]. 
We previously demonstrated increased MMP-9 levels in antrum and corpus mucosa 
of individuals with H. pylori-associated gastritis, with almost unchanged MMP-2 levels, 
compared to H. pylori negative patients [16]. Furthermore, we recently recon rmed 
our observation of enhanced MMP-2 and MMP-9 levels in gastric carcinoma tissues 
and found a consistent independent association between MMP-2 levels and patient 
survival [17]. As H. pylori gastritis is associated with gastric malignancy and H. pylori 
gastritis and gastric carcinomas are accompanied by alterations in the MMP levels we 
decided to investigate whether gastric mucosal MMP-2 and MMP-9 levels in H. pylori-
induced gastritis are a ected by successful eradication of the infection.
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Patients, materials and methods
Patients
Biopsy specimens were collected at upper gastrointestinal endoscopy from H. pylori 
positive patients between 22 and 75 years presenting with dyspeptic complaints, as 
described previously [18, 19]. Patients who had recently used proton-pump inhibitors, 
corticosteroids, non-steroidal anti-in ammatory drugs (NSAIDs), bismuth compounds, 
sucralfate, or antibiotics were excluded. Use of low dose H2-receptor antagonists was 
not considered to be a reason for exclusion. For histological examination, 2 biopsies 
were taken from the antrum, 3-5 cm proximal to the pylorus, and 2 from the corpus, 5 
cm above the junction between antrum and corpus. These specimens were examined 
by an experienced pathologist according to the guidelines of the revised Sydney sys-
tem, which provides semi-quantitative grading of histological parameters (0=normal, 
1=mild, 2=moderate, 3=marked) [20]. One biopsy was taken from the antrum for 
H. pylori culture and processed as described previously [21]. The presence of H. pylori
was assessed by a culture and/or histological identi cation, and con rmed by speci c 
IgG H. pylori antibodies. From 58 of the 63 patients included in the original study there 
was still biopsy material of antrum and/or corpus available for the present study to 
determine the MMP-2 and MMP-9 concentrations. 33 of these patients had an antral 
gastritis, 23 patients had a pangastritis, data of two patients were missing. 
All 58 patients were treated with a combination regimen of acid-suppression and 
antibiotics [omeprazole 20 mg bid in 26 patients, 16 male, 10 female, mean age 53 
(range 22-75) or ranitidine 150 mg bid or 300 mg qid in 32 patients, 26 male, 6 female, 
mean age 46 (range 22-74) with clarithromycin 500 mg tid and metronidazole 500 mg 
tid for 14 days, the latter only in 50% of the omeprazole patients]. These combinations 
are further referred to as omeprazole and ranitidine, respectively. Successful treat-
ment was de ned as negative culture and negative histology eight weeks after the 
end of therapy. Four patients treated with omeprazole (double) therapy kept gastric 
complaints and were allowed to continue omeprazole use. They were found to be still 
H. pylori positive after therapy [3 male, 1 female, mean age 39.5 (range 24-58)].
Tissue extraction and protein concentration
Homogenates were made by adding 100 µl PBST (0.05% Tween®20 in phosphate 
bu ered saline) per mg biopsy material and homogenizing on ice in a Potter S (B. 
Braun) [21]. The protein concentration in the supernatant was determined by the 
Lowry method [22]. 
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Gelatin-zymography
The presence of active and pro forms of the matrix metalloproteinases were assessed 
by gelatin-zymography, as previously described [23, 24]. Ten percent polyacrylamide 
gels were casted in a Mini-Protean® II Dual Slab Cell (Biorad). These gels contained 
1.5M Tris bu er (pH 8.8), 0.2% gelatin, 0.1% sodium dodecyl sulphate, 0.07% am-
monium persulphate and 0.07% tetramethylene-diamine. First sample volumes were 
adjusted to obtain an equal protein content of 5 µg per sample. Two amounts (6.1 and 
12.2 µg protein) of an internal standard preparation, i.e. a homogenate of a colonic 
carcinoma containing both MMP-2 and MMP-9, were included on each gel for correc-
tion of intergel variation and as reference for the expression in arbitrary units. After 
electrophoresis the gels were incubated overnight at 37°C, stained with Amido Black 
(0.1% amido black, 30% methanol and 10% acetic acid), and destained in a solution 
containing 30% methanol and 10% acetic acid. Subsequently the gels were dried 
between sheets of cellophane. Finally the degree of gelatin digestion was quanti-
 ed by making a digital photo with a CCD Imaging System (Appligene), scanned in 
Aldus Photostyler 2.0 (Aldus Corporation) and analysed with Imagequant (Molecular 
Dynamics), using the peak nder-mode. The gelatin digestion was re ected as a peak 
and the MMP levels were calculated referring to the internal standard preparations, of 
which the peak-height correlated highly signi cant with the included concentration 
(r=0.99, p< 0.001). The MMPs were analysed for the pro, active and total MMP levels, 
the latter de ned as the sum of the two isoforms, and expressed as Arbitrary Units per 
5 µg protein.
Bioactivity assay
Latent (activatable) and active MMP were also measured using a newly developed 
immunocapture colorimetric activity assay [17, 24]. Brie y, a polyclonal anti-MMP-2 
or monoclonal anti-MMP-9 antibody (TNO-QLBR) was used as catching antibody to 
capture MMP-2 or MMP-9 from appropriate dilutions of the tissue homogenates, 
respectively 1:4 and 1:20, by overnight incubation at 4°C. Active MMP was determined 
directly, whereas latent MMP was activated by incubation with 0.5 mM p-aminophen-
ylmercuric acetate for 0.5 and 2 hr at 37°C for MMP-2 and MMP-9, respectively. After 
washing MMP activity was assessed by adding 750 ng modi ed MMP-activatable 
pro-urokinase (Ukcol) and 0.6 mM of its chromogenic substrate S-2444 (pyro-Glu-
Gly-Arg-p-nitroanilide; Chromogenix, Sweden) in assay bu er and incubating at 37°C. 
Reactions were performed in 96-well  at-bottomed microtitre plates, and a multichan-
nel photometer was used to follow the absorbance kinetics at 405 nm. Results were 




MMP-2 and MMP-9 protein levels were measured by our highly speci c ELISAs, which 
detected the grand total of pro-enzyme, active- and inhibitor-complexed forms of 
the respective MMP, as previously described [17, 24]. In brief; the same catching 
antibodies were used as for the bio activity assays and appropriate dilutions of tissue 
homogenates, respectively 1:6.7 and 1:5, were incubated overnight at 4°C. Immu-
nodetection of MMP-9 was performed with biotinylated rabbit anti-MMP-9 and for 
MMP-2 using rabbit anti-MMP-2 (TNO-PG) followed by biotinylated goat anti-rabbit-
IgG. After incubation with avidin/horseradish-peroxidase the chromogenic substrate 
3,3’,5,5’-tetramethyl benzidine and H2O2 were added and the reaction was stopped 
with H2SO4 and read at 405 nm. The amount of MMP was calculated from the parallel 
standard curves and expressed in ng MMP per mg protein. 
Statistical analysis
The ELISA, zymography and BIA results are given as mean ± s.e.m. Di erences between 
groups were evaluated for signi cance using the Kruskal-Wallis and Mann-Whitney U
tests or the Wilcoxon Signed-Ranks test. The correlations between zymography, BIA 
and ELISA were assessed by the Pearson correlation procedure (SPSS for Windows 11.0 
statistical package, SPSS Inc., Chicago, Illinois, U.S.A.). Di erences were considered 
signi cant when P≤0.05.
Results
ELISA
Overall MMP-9 levels measured by ELISA showed a signi cant decrease after suc-
cessful therapy in both antral and corpus mucosa (Table 1). No relevant changes in 
MMP-9 levels were found in the four patients with persistent H. pylori infection, either 
in antrum or in corpus. The changes in the gastric MMP-9 levels were similar in the 
ranitidine and omeprazole treatment groups (data not shown). In addition, the levels 
Table 1 -  Overall MMP-2 and -9 levels in gastric mucosa biopsy specimens of H. pylori






Before After P-value Before After P-value
Antrum Successful, n = 49/53













Corpus Successful, n = 52/53













Levels are expressed in ng / mg protein; NA : not applicable; NS : not signi cant
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of MMP-9 in the gastric mucosa were found to be strongly related to the severity of 
the active in ammation. This was particularly noticeable in the corpus mucosa where 
the MMP-9 level in the patients with a pangastritis (7.37 ± 1.46 ng/mg protein, n=22) 
was signi cantly higher (P<0.02) compared to those with an antral gastritis (3.68 ± 
0.84, n=27). After eradication of H. pylori these levels were found to be signi cantly 
decreased (P<0.01) in both groups but no longer signi cantly di erent between both 
groups (respectively, 2.56 ± 0.87 and 0.73 ± 0.19). Furthermore, the MMP-9 levels in the 
antrum were also found to be signi cantly correlated with the severity of the in am-
mation, as illustrated by the stepwise decrease in the MMP-9 level in accordance with 
the in ammation score of the combined pre- and post-treatment biopsies (Figure 1). 
The MMP-2 levels showed a tendency to decrease in the antral mucosa, although 
the changes were relatively small, without meaningful di erences between the treat-
ment groups. MMP-2 levels were found to be una ected in the corpus mucosa by 





































Figure 1. Scatter plot of the MMP-9 levels in the antrum, as measured by ELISA, in relation to 
active in ammation, as scored by immunohistological evaluation, combined of biopsies from 
before (■) and after (□) treatment of the H. pylori infection. Means per in ammation score 
group, as indicated by the horizontal bar, were 22.9 ± 3.2 (score 2, n=11), 13.1 ± 1.9 (score 
1, n=39) and 2.3 ± 0.4 ng MMP-9/mg protein (score 0, n=49). Statistical signi cance of the 
association according to the Kruskall Wallis test P <0.0005.
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Gelatin zymography
In antral mucosa, active and latent MMP-9 levels decreased signi cantly after suc-
cessful H. pylori eradication, compared with before treatment (Table 2). In corpus 
mucosa latent MMP-9 levels decreased signi cantly as well, whereas active MMP-9 
levels showed a non-signi cant decrease. The three patients with persistent H. pylori 
infection also showed some decrease, though less impressive, in the active and latent 
MMP-9 levels after therapy. In contrast, the MMP-2 levels, active as well as latent, did 
not alter after therapy compared with those prior to therapy both in the H. pylori
eradicated and in the persistent H. pylori positive group (data not shown), similar to 
the levels as determined by ELISA.
Table 2 -  MMP-9 levels in gastric mucosa biopsy specimens of H. pylori positive patients 





Latent MMP-9 Active MMP-9
Before After P-value Before After P-value
Antrum Successful, n = 34













Corpus Successful, n = 34













Levels are expressed in AU / 5 μgr protein homogenate; NA : not applicable; NS : not signi cant
Bioactivity Assay (BIA)
Latent MMP-9 levels, as assessed by the BIA, also revealed that successful treatment 
resulted in a signi cant decrease in the gastric mucosa compared with those prior to 
treatment, whereas no major alterations were found in the patients in whom H. pylori
was not eradicated after therapy (Table 3). With regard to the active MMP-9 levels 
similar results were obtained [antrum 5.6 ± 0.8 vs. 0.2 ± 0.1 (P<0.001) and corpus 2.1 ± 
0.4 vs. 0.3 ± 0.1 (P<0.001), before and after successful treatment, respectively (n=53). 
The changes observed in the gastric mucosal MMP-9 levels, as determined by the 
BIA, of the successfully H. pylori eradicated patients again showed an identical pattern 
in the ranitidine and omeprazole treatment groups (data not shown). Latent MMP-2 
Table 3 -  Latent MMP-9 levels in gastric mucosa biopsy specimens of H. pylori positive 







Antrum Successful, n = 47/53







Corpus Successful, n = 49/53







Levels are expressed in AU / mg protein; NA : not applicable
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levels in the gastric mucosa were once more found to be hardly a ected by the H. py-
lori treatment regimens (data not shown). Active MMP-2 was not assessed by the BIA 
based on the observations in the zymography, which revealed them to be very low or 
absent in the gastric mucosa homogenates. 
Comparison of the three techniques used for MMP-9 measurement
Positive and signi cant correlations of the upregulated pre-treatment MMP-9 levels 
in gastric mucosa of H. pylori positive individuals were found between zymography, 
BIA and ELISA (Table 4). After successful eradication these correlations remained sig-
ni cant, although the MMP-9 levels were consistently decreased. Interestingly, before 
therapy all MMP-9 assessments revealed a signi cantly higher level in the antral mu-
cosa compared with the corpus mucosa that completely disappeared after treatment, 
already noticeable in Table 1. However, the correlations between the overall MMP-9 
levels measured by ELISA and the MMP-9 levels measured by the gelatin-zymography 
or the BIA after therapy are lower than before therapy, while correlations between 
gelatin-zymography and BIA remain high after therapy. This observation suggests 
alterations in the isoform composition of MMP-9 and/or in TIMP levels.
Table 4 -  Correlation of MMP-9 levels in gastric mucosa of H. pylori positive patients 
before and after treatment as determined by ELISA, BIA and zymograpy 
MMP-9






















* 32 ≤ n ≤57, #Pearson correlation coe  cient, P-value; NS : not signi cant
Discussion
H. pylori-associated chronic gastritis is recognized as a major risk factor for the 
development of gastric carcinoma [6, 7]. We previously showed alterations in the 
MMP-2 and/or MMP-9 levels in gastric tissues from patients with H. pylori-asso-
ciated gastritis and from patients with gastric cancer [16, 17, 23]. In the present, 
uncontrolled, study we evaluated the e ect of eradication therapy on these gastric 
MMP levels in patients with H. pylori gastritis. Latent, active and total MMP-9 levels 
decreased consistently and signi cantly after successful H. pylori eradication, in 
antrum as well as corpus mucosa, irrespective of the therapy regimen used. The 
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elevated levels remained unchanged, however, when treatment failed. The MMP-2 
levels and activities in H. pylori positive patients did not change signi cantly by 
successful treatment.
MMP-9 in gastric mucosa is predominantly expressed by polymorphonuclear leuko-
cytes, macrophages, (myo) broblasts, although in vitro studies also reported MMP-9 
in epithelial cells [15, 24-27]. MMP-2 immunoreactivity was predominantly observed 
in stromal cells, in ammatory cells and epithelial cells [15, 24, 25, 28]. The MMP-9 
levels in the antrum of our gastritis patients were found to be two- to four-fold higher 
compared with the corresponding corpus, dependent on whether it was a pan- or 
antral gastritis. This observation corresponds very well with our previously reported 
observation that the active in ammatory reaction, i.e., the number of in ltrated neu-
trophils, in the antrum is similarly more intense compared with the corpus mucosa 
[19]. The higher antrum in ammation is probably caused by a slow pyloro-cardial 
progression of gastritis as a consequence of a less dense H. pylori colonization of the 
corpus due to local acid production [29]. The presence and activation of these in am-
matory cells are caused by mucosal cytokines, e.g. TNF-α and IL-8, which are increased 
in H. pylori-induced gastritis and are also capable of inducing the production of MMP-9 
and less that of MMP-2 [30, 31]. This  nding can be explained by the fact that the 
MMP-2 encoding gene lacks an AP-1 binding site that prevents activation by TNF-α or 
IL-β. MMP-9, however, is an inducible matrix metalloproteinase, in contrast to MMP-2 
that is expressed more constitutively [9].
With successful H. pylori eradication, the antigen responsible for the immune reac-
tion is removed, leading to a slow but progressive decrease in both the active and 
chronic component of the gastric mucosal in ammation, including reduction of cy-
tokine production [32-34]. In our population of patients, both forms of in ammation 
also decreased signi cantly in both antrum and corpus after successful treatment of 
the H. pylori infection [18, 19]. This decrease in in ammation was accompanied with 
a considerable and signi cant decrease of latent, active and total MMP-9, particularly 
in the antrum. Our results are in line with a preliminary immunohistochemical study 
that showed a signi cant decrease of enhanced MMP-9 expression in epithelial cells 
and  broblasts - but not in macrophages - after H. pylori eradication and no alterations 
in MMP-9 expression where eradication failed [35]. Another immunohistochemical 
study, however, reported an increase in MMP-9 staining of surface mucous cells and 
pyloric glands of gastric antral biopsies from patients after H. pylori eradication [36]. 
The observations that the MMP-9 levels in the gastric mucosa of the unsuccessfully 
treated patients remain elevated suggest a direct relationship between H. pylori pres-
ence and MMP-9 level. Yet, in some of our assessments, e.g. zymography and BIA, some 
decrease in MMP-activity was noticeable in the H. pylori persistent patients. Probably, 
the acid-reducing drugs used might have an intrinsic inhibitory e ect on the MMPs, 
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as previously shown by the inhibitory e ect of H2-receptor antagonists on matrix 
metalloproteinases in rat gastric tissues with acetic acid-induced gastric ulcers [37, 
38]. On the other hand, alterations in the level or activity of TIMPs, the endogenous 
MMP inhibitors, cannot be excluded but were not assessed in the present study. 
Improvement and normalization of the chronic in ammatory reaction in the 
stomach after successful H. pylori eradication is accompanied by a reversal of many 
altered mucosal parameters that have been associated with gastric cancer and its 
prognosis, e.g. growth factors and cytokines [31-33], plasminogen activators [18, 39] 
and superoxide dismutases [19, 40]. Patients with H. pylori-associated chronic gastritis 
are predisposed for gastric carcinoma but its remains unclear whether eradication 
therapy also results in a reduction of gastric cancer incidence, since most of the H. py-
lori positive patients do not develop cancer, and in ammation and cancer diversity 
genes might play a more important role [41, 42]. Apparently also higher tissue levels 
of MMP-2, as in the tumors [17, 24], are required in combination with elevated MMP-9 
levels for the development of H. pylori gastritis to carcinoma. Our study is not conclu-
sive in that respect due to the absence of major alterations in the MMP-2 levels. Larger 
studies, including pathogenicity classi cation of the H. pylori strains, are needed to 
get a better insight into the relevance of changes in the MMP expression in the devel-
opment of gastric cancer. In addition, genetic susceptibility might also play a role, as 
illustrated by the MMP-7-181A>G gene polymorphisms which has recently been found to 
be associated with both gastric ulcerogenesis in H. pylori infection and gastric cancer, 
which provides a potential genetic link and implicates other MMPs in the association 
between both disorders [43, 44]. 
In conclusion, the H. pylori-associated increased MMP-9 levels in antrum and corpus 
mucosa decrease signi cantly by successful eradication of H. pylori. No major changes 
occurred in the MMP-2 levels and activities by eradication therapy and in the MMP-9 
levels when eradication failed.
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Summary
Proteinases are involved in tumour invasion and metastasis. Several matrix metal-
loproteinases (MMPs) have been shown to be increased in various human carci-
nomas. We assessed the levels of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) 
in 50 gastric carcinomas and corresponding mucosa using quantitative gelatin 
zymography. Both MMP levels were signi cantly enhanced in gastric carcinomas 
compared with adjacent mucosal tissue, showed a relatively poor intercorrelation 
and no relation was found with histopathological carcinoma classi cations ac-
cording to Laurén, WHO and tumour-node-metastasis (TNM). Cox’s multivariate 
proportional hazards analyses revealed that high carcinomatous MMP values are 
of prognostic signi cance for a poor overall survival of the patients, independent 
of the major clinicopathological parameters.
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Introduction
The process of carcinogenesis involves sequential breakdown of extracellular matrix 
by a variety of proteolytic enzymes [1]. Gelatinases, collagenases and stromelysins 
are metalloproteinases (MMP-2), which are able to solubilise collagens in basement 
membranes and extracellular stroma [2]. This local proteolysis enables tumour cells 
to penetrate normal surrounding tissue. Immunohistochemical and in situ hybridisa-
tion studies in human gastrointestinal neoplasias have shown that these carcinomas 
contain enhanced amounts of matrix metalloproteinases [3-5]. The enhanced prote-
olytic capacity of tumour tissues is con rmed by studying tissue homogenates, using 
quantitative methods like activity assays, and ELISAs [6-8]. Some in vitro and in vivo
experiments showed that matrix metalloproteinase levels were related to the invad-
ing and metastatic potential of colorectal cancer [7, 9]. Moreover, plasma levels of 
some MMP-2 were found to be enhanced in patients with colonic cancer [10].
In this study we used a relatively straightforward method, gelatin zymography, to 
evaluate the presence of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) in stomach 
carcinomas and adjacent mucosa from 50 patients, from whom clinical and histo-
pathological data concerning patients and carcinomas were available. Quantitative 
zymography has been shown previously to be an extremely reliable and sensitive 
technique for the detection of gelatinases [11, 12]. Moreover, this method of detec-
tion distinguishes proteinases in the proenzyme and the active form. The amounts of 
MMP-2 were related to several types of gastric tumour staging systems, including the 
classi cations of Laurén, WHO and TNM. The prognostic signi cance of the MMP-2 and 
MMP-9 levels for the survival of patients with a gastric carcinoma was evaluated using 
Cox’s proportional hazards method in univariate analysis, and also multivariately by 
addition to a broad selection of established clinicopathological variables.
Patients, materials and methods
Patients
Fresh tissue was obtained from 50 patients who underwent resection with curative 
intent for primary gastric cancer at the Department of Oncology Surgery, University 
Hospital Leiden, as previously described [13]. Representative samples of the carcinoma 
and macroscopically normal mucosa, taken 5 – 10 cm from the tumour, were frozen 
and stored at –70°C until extraction. Pathological and histological data of the tissues 
were re-evaluated by one pathologist (JvK). The patients entered the study at the date 
of surgery, did no receive adjuvant (chemo) therapy, and were clinically checked twice 
a year. Follow-up had to be at least 2 years and ended in the event of death or when 
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still alive the last follow-up date before the common closing date (follow-up range 0.5 
– 81 months).
Tissue extraction and protein concentration
Tissue specimens were homogenised in 0.1 M Tris-HCl, 0.1% (v/v) Tween 80 as de-
scribed extensively previously [13-15]. Protein concentrations of the supernatants 
were determined by the method of Lowry et al. [16].
Gelatin-zymography
Presence of active and latent forms of matrix metalloproteinases was analysed by 
zymography on 10% polyacrylamide gels containing 2% gelatin and overnight incu-
bation at 37°C, as described previously [17]. Sample volumes were adjusted to obtain 
a uniform protein content of 20 µg per sample. The gels were stained with Coomassie 
brilliant blue R-250, dried between sheets of cellophane, and the degree of gelatin 
digestion was quanti ed using an LKB Ultroscan XL enhanced laser densitometer (633 
nm). Two amounts (12 and 24 µg protein, S1 and S2 respectively) of an internal standard 
preparation, i.e. a homogenate of a colonic carcinoma containing both MMP-2 and 
MMP-9, were included on each gel for correction of intergel variation and as reference 
for the expression in arbitrary units (AU). This zymographic analysis was highly linear 
over an at least 20-fold range (i.e. 2 – 40 µg protein per sample and was validated for 
MMP-9 by an established ELISA [18] in 30 diverse gastrointestinal tissue homogenates 
yielding a good correlation between these assays (0.65 < r < 0.77, P < 0.0001).
Statistical analyses
Group means are given as mean ± s.e.m. Di erences between groups were tested for 
signi cance using paired Student’s t-test with separate variance estimate if the stan-
dard deviations were signi cantly di erent according to the ƒ-test. Optimal cut o  
analysis was performed by stepwise univariate Cox’s proportional hazards analyses. 
Univariate and multivariate survival analyses were performed using Cox’s proportional 
hazards method (EGRET statistical package, SERC Corp., Seattle, WA, USA) [19]. Overall 
survival curves were constructed according to the method of Kaplan and Meier [20]. 
Di erences were considered signi cant when P < 0.05.
Results
The characteristics of the 50 gastric cancer patients revealed that most of the pa-
tients were males (38 patients, i.e. 76%) and had died during follow-up (76%, 38/50), 
although the deceased patients were not signi cantly older [67.2 ± 1.8 years (n = 38) 
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Figure 1. Example of the gelatin zymograms used for the MMP-2 and MMP-9 quantitation by 
laser densitometry, as described in Materials and methods. Complete inhibition of the MMP 
activities was achieved by overnight incubation in the presence of 50 mM EDTA. Numbers 
indicate pairs of tissue from one patient. N, gastric mucosa; C, gastric carcinoma; S, standard 
(reference). MMPs: P, pro-enzyme; A, active enzyme.
Table I -  Univariate Cox’s proportional hazards proportional hazards analysis of 
clinicopathological parameters in relation to overall survival of patients with 
gastric cancer







male vs female 38-12 16.0-13.0 26.3-16.7 1.1 (NS)
Age (years)
<66.3 vs ≥66.3 (median) 25-25 18.4-10.1 20.0-28.0 1.2 (NS)
Laurén classi cation
Di use/mixed vs intestinal 18-31 27.0-11.3 33.3-16.1 1.6 (NS)
WHO di erentiation 
Well/moderately vs poorly 34-15 15.0-27.1 14.7-40.0 0.6 (NS)
TNM
Stage I+II vs stage III+IV 34-16 18.3-15.0 29.4-12.5 1.3 (NS)
Localisation
Antrum vs other 23-27 18.3-12.3 30.4-18.5 1.6 (NS)
Diameter
≤5 cm vs >5 cm 28-22 18.0-12.5 25.0-22.7 1.1 (NS)
Eosinophils
Many vs moderate/few 7-43 4.3-16.4 0.0-27.9 0.4 (0.02)
Intestinal metaplasia in 
mucosa
Absent vs present
18-32 11.5-18.0 11.1-31.3 0.5 (NS)
NS, not signi cant
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vs 66.0 ± 4.5 years (n = 12)]. All the clinicopathological parameters assessed were di-
chotomised as illustrated in Table I. Subdivision according to established histological 
tumour classi cation systems was found to have no major prognostic relevance in 
this group of patients, although overall survival decreased with increasing TNM stage 
[i.e. I, 43% (6/14); 20% (4/20); III, 17% (2/12); IV, 0% (0/4)]. Including all the other clini-
copathological parameters evaluated, only the presence of many eosinophilic cells in 
the carcinomas was signi cantly associated with a worse survival, exempli ed by a 
shorter median survival time and a low percentage survival of the patients (Table I).
The mean levels of matrix metalloproteinases MMP-2 and MMP-9, as determined by 
EDTA-inhibitable gelatin-zymography (Figure 1), were signi cantly higher in carcino-
mas than in histologically con rmed tumour-free adjacent mucosa of the stomach, 
irrespective of MMP type or activity state (Table II). Of the carcinomas, 82% (41/50) 
contained more total MMP-2 and 80% (40/50) contained more total MMP-9 than their 
corresponding mucosa, i.e. ratios higher than 1, as illustrated in Figure 2. The enhanced 
amounts of MMPs in the carcinomas were not signi cantly correlated to any of the 
histological gastric tumour classi cation systems, although the carcinomas that were 
super cially invasive showed the lowest total MMP levels (MMP-2, 1.28±0.34; MMP-9, 
2.49 ± 1.18; in AU, n = 4), and were similar to the mucosal levels. The total levels of 
MMP-2 and MMP-9 showed a relatively poor intercorrelation (mucosa r = 0.19, NS; car-
cinomas r = 0.34, P = 0.01). For each of the MMP parameters in mucosa and carcinoma 
tissues the optimum cut-o  values were determined using Cox’s proportional hazards 
analyses (Table III). In mucosa a signi cant cut-o  value was found only for the active 
form of MMP-9 and indicated that a high level was associated with a good prognosis. 
In contrast, for the carcinomas, the total and the pro-forms of MMP-2 and MMP-9, 
as well as the active form of MMP-2 showed signi cant cut-o  values revealing that 
Table II Levels of matrix metalloproteinases MMP-2 and MMP-9 in mucosa and carcinomas of 





Total 1.50 ± 0.11 2.63 ± 0.23 <0.001
Pro-form 1.24 ± 0.11 1.90 ± 0.16 <0.001
Active 0.26 ± 0.03 0.73 ± 0.10 <0.001
MMP- 9
Total 3.72 ± 0.23 5.92 ± 0.32 <0.001
Pro-form 3.18 ± 0.21 4.99 ± 0.25 <0.001
Active 0.54 ± 0.08 0.93 ± 0.09  0.001
Mean ± s.e. The MMPs were quanti ed using gelatin-zymography and subsequent laser densitometry. 
Values are expressed in arbitary units
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high levels indicated poor prognosis. Representative Kaplan-Meier curves for overall 
survival according to the cut-o  points for total MMP-2 and MMP-9 are shown in 
Figures 3 and 4. Table III shows the hazard ratios of all the signi cant MMP parameters 
according to Cox’s proportional hazards analyses. For the multivariate analyses the 
MMP parameters were separately evaluated by adjusting to all clinicopathological 
variables as listed in Table I. All the MMP parameters kept their prognostic signi cance 
in the multivariate analyses.
Figure 2. Individual data of the total MMP-2 and total MMP-9 ratio, carcinoma over mucosa, of 
the 50 gastric cancer patients. Dotted line indicates a ratio of 1, i.e. MMP level in carcinoma is 
identical to that of the gastric mucosa. 
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Table III -  Uni- and multivariate Cox’s proportional hazards analyses of MMP-2 and 
MMP-9 in gastric mucosa and gastric carcinomas related to overall survival of 
the patients












 <0.36 vs >0.36
25-25 8.4-27.4 16.0-32.0 0.4 (0.02) 0.3 (0.02)
Carcinoma
MMP-2 total
 <4.00 vs >4.00
42-8 18.2-10.0 28.6-0.0 2.6 (0.02) 2.5 (0.05)
MMP-2 pro-form
 <2.82 vs >2.82
42-8 18.2-10.0 28.6-0.0 2.6 (0.02) 2.9 (0.03)
MMP-2 active
 <0.55 vs >0.55
27-23 27.4-10.4 37.0-8.7 2.1 (0.03) 3.1 (0.02)
MMP-9 total
 <7.25 vs > 7.25
35-15 18.4-10.1 31.4-6.7 2.0 (0.04) 2.1 (0.05)
MMP-9 pro-form
 <5.75 vs >5.75
33-17 27.1-9.3 33.3-5.9 2.6 (0.006) 2.8 (0.01)
Multivariate analyses were performed by adjusting the separate MMP parameters to all 

































































































Figure 3. Kaplan-Meier overall survival curve for total MMP-2 levels in gastric carcinomas. 
MMP-2 values were evaluated using gelatin zymography and subsequent laser densitometry 
and are expressed in arbitrary units. High and low levels of MMP-2, cut-o  point 4.0, were 
determined by Cox’s univariate proportional hazards analysis. Values indicate the number of 
patients alive/deceased at the end of follow-up. 
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Discussion
Several proteolytic enzymes are involved in carcinogenesis. Various studies have 
shown, for instance, high concentrations of plasminogen activators, cathepsins and 
matrix metalloproteinases in di erent types of human carcinomas [1-10]. In the pres-
ent study we show that in a majority of gastric carcinomas the MMP-2 and MMP-9 
levels are signi cantly higher in the corresponding gastric mucosa, irrespective of 
the activity state of the enzymes. Moreover, our observation that the more deeply 
invasive carcinoma contain high levels of MMP’s, whereas the super cially invasive tu-
mours do not show more MMP than the corresponding mucosa, is in agreement with 
recent immunohistological data in which MMP-2 was found to be higher in advanced 
vs early gastric tumours [5]. The levels of MMP-2 and MMP-9 showed a relatively poor 
intercorrelation, both in gastric mucosa and in carcinomas, suggesting an indepen-
dent expression pattern for both proteinases, which is probably related to di erences 
in the cellular origin of these enzymes [2], but this was not assessed in the present 
study. Recently, the evaluation in carcinomatous tissue of some components of the 
plasminogen activation cascade, another important proteolytic system in carcino-
genesis, has been found to be of signi cant value for the prognosis of cancer patients 
[15, 21-26]. Although the number of patients in the present study is relatively low, the 
results clearly show that high levels of MMP-2 and MMP-9 in stomach carcinomas are 

































































































Figure 4. Kaplan-Meier overall survival curve for total MMP-9 levels in gastric carcinomas. 
MMP-9 values were evaluated using gelatin zymography and subsequent laser densitometry 
and are expressed in arbitrary units. High and low levels of MMP-9, cut-o  point 7.25, were 
determined by Cox’s univariate proportional hazards analysis. Values indicate the number of 
patients alive/deceased at the end of follow-up.
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distinction between total, active and pro-form of MMPs in our study, as one of the 
important advantages of the zymographic analysis, seems to be particularly useful 
for MMP-2. The interpretation of the prognostic signi cance of MMP-9 in mucosa 
from patients with a gastric carcinoma is di  cult. However, high levels of tissue-type 
plasminogen activator activity in normal colorectal and gastric mucosa were also 
found to be associated with a good prognosis in colorectal and gastric cancer patients 
[13, 24]. 
The results of this study could have important clinical implications. Firstly, the 
prognostic signi cance of both MMPs in carcinomatous tissue is striking, especially in 
comparison with the relatively disappointing performance of established parameters 
like TNM and Laurén classi cation or diameter of the carcinoma. Therefore these pro-
teolytic parameters may be suitable as prognosticators for the selection of patients 
for adjuvant therapy. Secondly, this study might give some rationale for therapeutic 
intervention with matrix metalloproteinase inhibitors, which has recently been dem-
onstrated to be e ective in patient-like orthotopic human tumour models in nude 
mice [27, 28].
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Abstract
In a pioneer study, we showed 10 years ago that enhanced tissue levels of the 
matrix metalloproteinases (MMPs) MMP-2 and MMP-9 in gastric cancers, as deter-
mined by zymography, were related with worse overall survival of the patients. To 
corroborate these observations, we now assessed MMP-2 and MMP-9 with new 
techniques in an expanded group of gastric cancer patients (n = 81) and included 
for comparison MMP-7, MMP-8 and the tissue inhibitors of MMPs, TIMP-1 and -2. 
All MMPs and TIMP-1 were signi cantly increased in tumour tissue compared 
to normal gastric mucosa. Matrix metalloproteinase-7, -8 and -9, and the TIMPs 
showed some correlations with the clinicopathologic parameters TNM, WHO and 
Laurén classi cation, but their levels were not related with survival. Regardless 
of the determination method used, that is, enzyme-linked immunosorbent assay 
or bioactivity assay, an enhanced tumour MMP-2 level did not show a signi cant 
correlation with any of the clinicopathological parameters, but was con rmed to 
be an independent prognostic factor in gastric cancer.
MMPs and TIMPs in gastric cancer 81
Introduction
A decade ago, we were the  rst to report that the levels of matrix metalloproteinase 
(MMP)-2 and MMP-9 in human gastric carcinoma tissues were enhanced and related 
to the survival of the patients, using a simple but laborious zymography technique 
in a relatively small group of patients (Sier et al, 1996). Matrix metalloproteinases are 
believed to play an important role in carcinogenesis via the degradation and remod-
elling of tumour surrounding extracellular matrix, which could explain the association 
with survival (Zucker et al, 2000; McCawley and Matrisian, 2001; Polette et al, 2004). We 
concluded that measuring MMPs could have clinical value as indicators for gastric car-
cinoma patients who needed adjuvant therapy and that inhibitors of MMPs might be 
useful for therapeutic intervention. Several accomplish ments have been made since. 
The prognostic value of MMPs for gastric carcinoma patients has been con rmed in 
several other studies (Allgayer et al, 1998; Zhang et al, 2003), and clinical trials testing 
the e ect of MMP inhibitors for patients with various types of cancer were performed, 
with variable success (Zucker et al, 2000; Bramhall et al, 2002).
In general, MMPs are secreted as inactive pro-enzymes, activated by proteolytic 
cleavage, and controlled in their activity by interaction with inhibitors. Disturbances 
in these processes are of eminent importance in tumour invasion and metastasis (Mc-
Cawley and Matrisian, 2001; Polette et al, 2004). In the present more comprehensive 
study, we extended our MMP analyses in the same group of patients and compared 
the results with those obtained with a new and more recent group of patients. Fur-
thermore, instead of zymography, which identi es isoforms, we now used recently 
established quantitative bioactivity assays (BIAs) and speci c antigen enzyme-linked 
immunosorbent assays (ELISAs) for MMP-2 and MMP-9. Moreover, we compared the 
prognostic value of MMP-2 and MMP-9 with those of MMP-7 and MMP-8 and expanded 
the study by determination of the inhibitors TIMP-1 and TIMP-2. In addition, because 
of the increasing age of the patients and the length of the follow-up, we now used 
tumour-associated survival. 
Patients, materials and methods 
Patients and study design
Fresh tissue specimens of 81 patients (21 female and 60 male subjects, mean age 65.9 
years, range 35.10 –91.33), who underwent resection for primary gastric adenocarci-
noma at the Department of Oncologic Surgery of the Leiden University Medical Cen-
tre, were collected prospectively. Immediately after resection, fresh samples from the 
mid-central, non-necrotic part of the carcinoma and/or from distant normal mucosa, 
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taken approximately 10 cm from the tumour, were snap frozen and stored at 70° C un-
til extraction, to be used for research purposes. Various clinicopathological data were 
evaluated or collected from patient  les. All carcinomas were classi ed according to 
the TNM classi cation (Hermanek and Sobin, 1992) and localisation and also diameter 
of the tumour, di erentiation grade, WHO, Borrman, and Laurén classi cation, as well 
as the presence of intestinal metaplasia in the normal gastric mucosa, as revised by a 
gastroenterologist (FK) and a pathologist (JvK). All patients entered the study at op-
eration date, and the patient’s time experience ended in the event of death or, when 
still alive, at the common closing date. The minimal follow-up was 33 months with a 
decreasing overall survival according to TNM stage, that is, from TNM I (52.2%, n = 23), 
to TNM II (26.9%, n = 26), to TNM III (28%, n = 25), and to TNM IV (0%, n = 7).
Tissue preparation and protein concentration 
Homogenisation of tissue specimens and determination of protein concentrations 
were performed as described previously (Sier et al, 1996). 
Metalloproteinase-2 and -9 activity assays 
Quantitative gelatin zymography and BIAs for MMP-2 and MMP-9 were carried out as 
described before (Sier et al, 1996; Hanemaaijer et al, 2000). Active and activatable (pro) 
MMP-2 and MMP-9 were determined with the BIA in 96-well plates, coated with mono-
speci c antibodies to the MMPs, sample/standard incubation overnight and detec-
tion by modi ed MMP-sensitive pro-urokinase in combination with peptide substrate 
S-2444 and measurement of absorbance change at 405 nm over time. Activation of 
pro-MMPs was achieved by incubation with p-aminophenyl-mercuric acetate. 
Enzyme-linked immunosorbent assay for MMP-2, MMP-7, MMP-8, MMP-9, 
TIMP-1 and TIMP-2 
Antigen levels of MMP-2 and MMP-9 were determined using previously described 
ELISAs (Hanemaaijer et al, 1998). In brief, the same catching antibodies were used 
as for the BIAs. Next, appropriate dilutions of tissue homogenates were incubated 
overnight at 4°C. Immunodetection of MMP-2 and MMP-9 was performed directly or 
indirectly with in-house anti-MMP-2 and -MMP-9 biotinylated-polyclonal antibodies. 
Avidin – horseradish peroxidase and 3,3’,5,5’ tetramethyl benzidine were used for the 
colouration reaction. The respective amounts of MMP-2 and MMP-9 were calculated 
from standard curves. The concentrations of MMP-7, TIMP-1 and TIMP-2 antigens were 
determined using commercial ELISAs according to the manufacturer’s instructions 
(R&D Systems Europe, Abingdon, UK). The amount of MMP-8 was measured using a 
previously described ELISA (Bergmann et al, 1989). 
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Statistical analysis 
Di erences between normal and tumour values for all parameters were calculated 
using the Wilcoxon signed rank test. For the survival analyses, the clinicopathological 
parameters were dichoto mised as described previously unless indicated elsewhere. 
Cuto  points for MMP data were optimised or medians were used. Univariate and 
multivariate survival analyses were performed with the Cox proportional hazards 
model, using the SPSS Windows Release 12.0.1. statistical package (2004, SPSS Inc., 
Chicago, IL, USA). Multivariate survival analyses were performed using the Cox pro-
portional hazards method by separately adding the signi cant MMP variables to the 
dichotomised clinicopathological parame ters. Overall and tumour-related survival 
curves were constructed using the method of Kaplan and Meier including the Log-
rank test. Di erences were considered signi cant when P≤0.05. 
Results
Although quantitative zymography is a reliable and sensitive technique to identify 
active and latent isoforms of MMP-2 and MMP-9, it is a laborious assay to perform. 
Therefore, we compared the previously obtained zymography data for MMP-2 and 
MMP-9 with the results from more practicable and sophisticated immunoassays, that 
is, BIAs and ELISAs. Table 1 shows an overview of the correlation coe  cients and P-
values for the di erent assays (samples n = 100). The total zymography data, which 
consist of the sum of active and pro-form bands, correlated signi cantly with the total 
BIA and ELISA levels for both MMP-2 (0.312 <ρ< 0.533, P≤0.003) and even better for 
MMP-9 (0.558<ρ<0.817, P<0.001). The latent pro-forms of MMP-2 and MMP-9, sepa-
rately detected by zymography and BIA, also correlated signi cantly. No correlation 
between both assays was found, however, for active MMP-2 or MMP-9, indicating that 
the active isoform as identi ed by the very sensitive zymography is not necessarily 
functionally active in the less-sensitive BIA, probably through interaction with inhibi-
tors.
The levels of MMP-2 and MMP-9 as detected with the BIAs and ELISAs in normal 
mucosa and tumour tissue in the expanded group of 81 gastric carcinoma patients are 
shown in Table 2. Carcinomas contained signi cantly higher MMP-2 and MMP-9 levels 
in antigen as well as activity than adjacent normal tissue. Particularly remarkable is 
the presence of more active MMP-2, but not of active MMP-9, in the tumour tissue 
homogenates. The most impressive enhancement (>20-fold) in carcinomas compared 
to normal tissue, however, was noted for MMP-7 (Table 2). Matrix metalloproteinase-8 
and TIMP-1 were also signi cantly increased, whereas tumour TIMP-2 levels were found 
not to be enhanced. Interestingly, a striking di erence was observed in the correlation 
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between the primary MMP – TIMP interactor antigen levels, that is, MMP-9 with TIMP-
1 (ρ=0.358, P<0.0005) and MMP-2 with TIMP-2 (ρ=0.085, NS). The levels of MMPs and 
TIMPs were also evaluated for correlation with all the clinicopathological parameters. 
Tumour levels of MMP-2, TIMP-1 and TIMP-2 did not show signi cant correlations 
with any of these parameters. The mean MMP-7 levels increased stepwise with TNM 
classi cation (Figure 1) and were signi cantly enhanced in Laurén’s intestinal-type 
carcinomas compared to di use or mixed types (56±16 vs 34±22, P<0.02). Matrix me-
talloproteinase-8 levels were enhanced in Laurén’s intestinal-type tumours (402±72 
vs 178±29 ng mg-1 protein, P<0.006) and di erentiated tumours (393±67 vs 163±29ng 
mg-1 protein, P<0.002) according to the WHO classi cation. Matrix metalloproteinase-
9 levels showed a similar enhancement for Laurén’s intestinal-type carcinomas (BIA 
total activity 140 vs 99 U mg-1 protein, P<0.02; ELISA 29 vs 17 ng mg-1 protein, P<0.01) 
and di erentiated tumours (BIA total activity 133±13 vs 104±16 U mg-1 protein, NS; 
Table 1 -  Spearman’s ρ for three di erent assays used for the detection of MMP-2 and 
MMP-9 in 50 normal/tumour pairs of tissue homogenates from gastric cancer 
patients



































































Zymo = zymography, BIA = bioactivity assay, ELISA = antigen; MMP = matrix metalloproteinase. The white 
values/boxes are the correlations between similar entities, for example, total-total, pro-pro, active-active 
with di erent techniques or total with ELISA.
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Table 2 -  Antigen levels (ng mg-1 protein) of MMP-2, MMP-7, MMP-8 and MMP-9 and of 




Antigen 4.7 ± 0.4 17.0 ± 2.0 ≤0.001
Total activitya 81.1 ± 23.6 185.7 ± 45.5 ≤0.001
Pro-forma 78.9 ± 23.6 181.1 ± 45.3 0.001
Activea 2.3 ± 0.5 4.7 ± 1.1 0.02
MMP-9
Antigen 9.0 ± 0.9 24.7 ± 2.3 ≤0.001
Total activitya 67.5 ± 6.0 128.8 ± 11.3 ≤0.001
Pro-forma 59.9 ± 5.6 117.1 ± 0.1 ≤0.001
Activea 7.6 ± 1.5 9.5 ± 2.1 NS
MMP-7 2.0 ± 0.5 47.1 ± 12.4 0.002
MMP-8 95 ± 12 319 ± 47 ≤0.001
TIMP-1 8.0 ± 0.8 16.9 ± 1.3 ≤0.001
TIMP-2 5.9 ± 0.2 6.3 ± 0.4 NS
Mean ± s.e.m. Bioactivity assay levels of MMP-2 and MMP-9 are expressed as units per mg protein. aAs 
determined by BIA. MMP = matrix metalloproteinase; BIA = bioactivity assay; TIMP = tissue inhibitors of 
MMP.
significantly enhanced in Laurén’s intestinal-type carcinomas
compared to diffuse or mixed types (56716 vs 34722, Po0.02).
Matrix metalloproteinase-8 levels were enhanced in Laurén’s
intestinal-type tumours (402772 vs 178729 ngmg�1 protein,
Po0.006) and differentiated tumours (393767 vs 163729 ngmg�1
protein, Po0.002) according to the WHO classification. Matrix
metalloproteinase-9 levels showed a similar enhancement for
Laurén’s intestinal-type carcinomas (BIA total activity 140 vs
99Umg�1 protein, Po0.02; ELISA 29 vs 17 ngmg�1 protein,
Po0.01) and differentiated tumours (BIA total activity 133713 vs
104716Umg�1 protein, NS; ELISA 2873 vs 1773 ngmg�1 pro-
tein, Po0.02). Matrix metalloproteinase-9 total activity showed a
stepwise decrease with TNM classification, which did not reach
significance (I, 145727; II 127718; III, 120720; IV, 1147
28Umg�1 protein).
For tumour-associated survival analyses, all MMP and TIMP
parameters in tumour homogenates were evaluated for optimal
cutoff points using the log rank test. Significant cutoffs were only
found for the MMP-2 levels by BIA and ELISA (Figures 2A and B).
No significant association for MMP-7, MMP-8, MMP-9, TIMP-1
and TIMP-2 with tumour-associated survival was found according
to stepwise univariate Cox analyses and thus the medians were
used (hazard ratio and 95% confidence interval ranges of the
median levels varied from 0.801 to 1.257 and from 0.445 to 2.307,
respectively). High MMP-2 levels determined by BIA as well as
ELISA were significantly associated with worse survival, but in
multivariate analyses with the clinicopathological parameters, only
the MMP-2 ELISA kept its independent prognostic value (Table 3).
The consistent prognostic relevance of MMP-2 is underlined by
Figure 2B, in which the old group of patients (n¼ 50) and the more
recent patients group (n¼ 31) are independently subdivided based
on a low or high MMP-2 antigen content of the carcinoma, using
the same cutoff value. Similar results were obtained with the BIA
data (not shown).
Table 2 Antigen levels (ngmg�1 protein) of MMP-2, MMP-7, MMP-8
and MMP-9 and of inhibitors TIMP-1 and TIMP-2 in normal mucosa and
carcinoma of 81 patients with gastric cancer
Mucosa Carcinoma P-value
MMP-2
Antigen 4.770.4 17.072.0 p0.001
Total activitya 81.1723.6 185.7745.5 p0.001
Pro-forma 78.9723.6 181.1745.3 0.001
Activea 2.370.5 4.771.1 0.02
MMP-9
Antigen 9.070.9 24.772.3 p0.001
Total activitya 67.576.0 128.8711.3 p0.001
Pro-forma 59.975.6 117.1710.1 p0.001
Activea 7.671.5 9.5 2.1 NS
MMP-7 2.070.5 47.1712.4 0.002
MMP-8 95712 319747 p0.001
TIMP-1 8.070.8 16.971.3 p0.001
TIMP-2 5.970.2 6.370.4 NS
Mean7s.e.m. Bioactivity assay levels of MMP-2 and MMP-9 are expressed as units
per mg protein. aAs determined by BIA. MMP¼matrix metalloproteinase;
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Figure 1 Relation between MMP-7 antigen levels and TNM classification
in gastric carcinomas. The mean and median for the subgroups are
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Figure 2 Kaplan–Meier tumour-related overall survival curves for (A)
MMP-2 BIA total activity, (B) MMP-2 ELISA old vs new gastric cancer
patient groups, with the cutoff levels from the Cox analyses.
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Figure 1. Relation between MMP-7 antigen levels and TNM classi cation in gastric 
carcinomas. The m an and median for the subgroups re indicated by bars on, respectively, 
the left- and right-hand side of each column.
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significantly enhanced in Laurén’s intestinal-type carcinomas
compared to diffuse or mixed types (56716 vs 34722, Po0.02).
Matrix metalloproteinase-8 levels were enhanced in Laurén’s
intestinal-type tumours (402772 vs 178729 ngmg�1 protein,
Po0.006) and differentiated tumours (393767 vs 163729 ngmg�1
protein, Po0.002) according to the WHO classification. Matrix
metalloproteinase-9 levels showed a similar enhancement for
Laurén’s intestinal-type carcinomas (BIA total activity 140 vs
99Umg�1 protein, Po0.02; ELISA 29 vs 17 ngmg�1 protein,
Po0.01) and differentiated tumours (BIA total activity 133713 vs
104716Umg�1 protein, NS; ELISA 2873 vs 1773 ngmg�1 pro-
tein, Po0.02). Matrix metalloproteinase-9 total activity showed a
stepwise decrease with TNM classification, which did not reach
significance (I, 145727; II 127718; III, 120720; IV, 1147
28Umg�1 protein).
For tumour-associated survival analyses, all MMP and TIMP
parameters in tumour homogenates were evaluated for optimal
cutoff points using the log rank test. Significant cutoffs were only
found for the MMP-2 levels by BIA and ELISA (Figures 2A and B).
No significant association for MMP-7, MMP-8, MMP-9, TIMP-1
and TIMP-2 with tumour-associated survival was found according
to stepwise univariate Cox analyses and thus the medians were
used (hazard ratio and 95% confidence interval ranges of the
median levels varied from 0.801 to 1.257 and from 0.445 to 2.307,
respectively). High MMP-2 levels determined by BIA as well as
ELISA were significantly associated with worse survival, but in
multivariate analyses with the clinicopathological parameters, only
the MMP-2 ELISA kept its independent prognostic value (Table 3).
The consistent prognostic relevance of MMP-2 is underlined by
Figure 2B, in which the old group of patients (n¼ 50) and the more
recent patients group (n¼ 31) are independently subdivided based
on a low or high MMP-2 antigen content of the carcinoma, using
the same cutoff value. Similar results were obtained with the BIA
data (not shown).
Table 2 Antigen levels (ngmg�1 protein) of MMP-2, MMP-7, MMP-8
and MMP-9 and of inhibitors TIMP-1 and TIMP-2 in normal mucosa and
carcinoma of 81 patients with gastric cancer
Mucosa Carcinoma P-value
MMP-2
Antigen 4.770.4 17.072.0 p0.001
Total activitya 81.1723.6 185.7745.5 p0.001
Pro-forma 78.9723.6 181.1745.3 0.001
Activea 2.370.5 4.771.1 0.02
MMP-9
Antigen 9.070.9 24.772.3 p0.001
Total activitya 67.576.0 128.8711.3 p0.001
Pro-forma 59.975.6 117.1710.1 p0.001
Activea 7.671.5 9.572.1 NS
MMP-7 2.070.5 47.1712.4 0.002
MMP-8 95712 319747 p0.001
TIMP-1 8.070.8 16.971.3 p0.001
TIMP-2 5.970.2 6.370.4 NS
Mean7s.e.m. Bioactivity assay levels of MMP-2 and MMP-9 are expressed as units
per mg protein. aAs determined by BIA. MMP¼matrix metalloproteinase;
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Fig r  2. Kaplan–Meier tumour-related overall survival curves for (A) MMP-2 BIA total activity, 
(B) MMP-2 ELISA old vs new gastric cancer patient groups, with the cuto  levels from the Cox 
analyses.
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ELISA 28±3 vs 17±3 ng mg-1 pro tein, P<0.02). Matrix metalloproteinase-9 total activity 
showed a stepwise decrease with TNM classi cation, which did not reach signi cance 
(I, 145±27; II 127±18; III, 120±20; IV, 114±28 U mg-1 protein). 
For tumour-associated survival analyses, all MMP and TIMP parameters in tumour 
homogenates were evaluated for optimal cuto  points using the log rank test. Signi -
cant cuto s were only found for the MMP-2 levels by BIA and ELISA (Figures 2A and B). 
Table 3 -  Uni-and multivariate Cox’s proportional hazards analyses of MMP-2, 
determined by ELISA and BIA, and clinicopathological parameters in relation to 
the overall tumour-related survival of 81 patients with gastric cancer
Univariate  Multivariate 
Parameter n HR CI 95% P HR CI 95% P 
Gender 
Male vs female 60/21 1.384 0.768 –2.494 NS 1.767 0.935– 3.342 NS 
Age 
Median (66 years) 40/41 1.313 0.764 –2.255 NS 1.467 0.775– 2.774 NS 
TNM 
I 23/81 1 — 1 — 
II 26/81 3.133 1.360 –7.222 0.007 4.001 1.510– 10.60 0.005 
III 25/81 3.021 1.305 –6.991 0.010 3.557 1.290– 9.813 0.014 
IV 7/81 7.387 2.495 –21.86 0.000 20.416 4.992– 83.49 0.000 
Laurén 
Di use/mixed vs intestinal 30/50 0.889 0.516 –1.531 NS 1.152 0.353– 3.756 NS 
WHO di erentiation 
Well vs poor 54/26 1.133 0.650 –1.975 NS 1.270 0.370– 4.363 NS 
Borrmann 
I+II vs III+IV 55/24 1.118 0.609 –2.053 NS 0.761 0.386– 1.502 NS 
Localisation 
Cardia vs rest 36/45 0.573 0.330 –0.993 0.034 0.330 0.159– 0.682 0.003 
Diameter tumour 
<5 vs >5 cm 47/34 1.048 0.608 –1.808 NS 0.622 0.337– 1.149 NS 
Eosinophils 
Few vs many 56/24 1.035 0.568 –1.886 NS 1.743 0.806– 3.766 NS 
Intestinal metaplasia 
Absent vs present 39/42 0.490 0.280 –0.858 0.013 0.706 0.379– 1.315 NS 
Carcinoma 
MMP-2 ELISA 
<13.4 vs >13.4 ng mg-1
protein 
45/31 2.611 1.455 –4.686 0.001 2.620 1.249– 5.494 0.011 
MMP-2 BIA 
<80 vs >80 U mg-1 protein 49/23 1.974 1.089 –3.577 0.025 1.493 0.655– 3.404 NS 
HR = hazard ratio; CI = con dence interval.
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No signi cant association for MMP-7, MMP-8, MMP-9, TIMP-1 and TIMP-2 with tumour-
associated survival was found according to stepwise univariate Cox analyses and 
thus the medians were used (hazard ratio and 95% con dence interval ranges of the 
median levels varied from 0.801 to 1.257 and from 0.445 to 2.307, respectively). High 
MMP-2 levels determined by BIA as well as ELISA were signi cantly associated with 
worse survival, but in multivariate analyses with the clinicopathological parameters, 
only the MMP-2 ELISA kept its independent prognostic value (Table 3). The consistent 
prognostic relevance of MMP-2 is underlined by Figure 2B, in which the old group 
of patients (n = 50) and the more recent patients group (n = 31) are independently 
subdivided based on a low or high MMP-2 antigen content of the carcinoma, using 
the same cuto  value. Similar results were obtained with the BIA data (not shown).
Discussion
The present study corroborates our previous  nding of increased MMP-2 in gastric 
cancer. The high MMP-2 antigen and activity levels were signi cantly associated with 
worse survival according to univariate Cox proportional hazards analysis. In the multi-
variate analysis, including a broad selection of clinical parameters, the MMP-2 antigen 
level kept its independent prognostic value, but the signi cance for the MMP-2 BIA 
activity level of the carcinomas was lost. The optimal cuto  point for MMP-2 antigen 
calculated for survival prognosis in the old group of patients was similarly predictive 
in the new group of patients, indicating the strength of MMP-2 as a prognostic indi-
cator for gastric carcinoma patients. The notion that MMP-2 is a valuable indicator 
of gastric cancer progression and prognosis is supported by immunohistochemical, 
zymography and mRNA studies showing that MMP-2 is associated with tumour in-
vasion, lymph node metastasis and survival (Allgayer et al, 1998; Mönig et al, 2001; 
Chuanzhong et al, 2002; Kabashima et al, 2002; Liu et al, 2002a; Elnemr et al, 2003; 
Yokoyama et al, 2004; Ji et al, 2005). The value of MMP-2 as an independent prognostic 
marker for gastric carcinomas is under scored by our observation that MMP-9, MMP-7, 
MMP-8, TIMP-1 and TIMP-2 have no prognostic relevance. 
Matrix metalloproteinase-9 levels were enhanced in some clinicopathological sub-
groups of gastric cancer, that is, according to the Laurén classi cation and for WHO 
di erentiation grade. The association between MMP-9 and early stages of gastric 
carcinoma, as shown before (Torii et al, 1998; Kabashima et al, 2000), was also present 
in our study. In contrast to our previous  ndings, high MMP-9 levels did not show 
a signi cant correlation with survival and also not for the ratio MMP-9/TIMP-1 (data 
not shown) as recently suggested (Zhang et al, 2003). One obvious explanation for 
the discrepancy with our previous data is the small number of patients in the study. 
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However, the relatively high MMP-9 levels in early gastric carcinomas also might af-
fect the relation between MMP-9 and prognosis, especially in our extended follow-up 
study using tumour-related survival. 
Matrix metalloproteinase-7, MMP-8, TIMP-1 and TIMP-2 were included in the pres-
ent study as comparisons to evaluate the prognostic strength of MMP-2 and MMP-9. 
Matrix metalloprotei nase-7 was selected because MMP-7 production in various types 
of carcinomas has predominantly been found in tumour cells and because MMP-7 
was recently suggested as potential marker for gastric carcinoma (Liu et al, 2002b). 
Although enhanced levels were found in the di erent carcinoma subgroups, for ex-
ample, TNM stage and Laurén’s intestinal type, there was no correlation between high 
MMP-7 levels and patients survival. This contrasts in part with several other studies 
reporting not only a clear asso ciation between MMP-7 expression and gastric cancer 
progression but also with survival (Liu et al, 2002b; Ajisaka et al, 2004). Essential dif-
ferences with our study are, however, that the latter studies were carried out using 
immunohistochemistry, focusing on MMP-7-expressing carcinoma cells at the inva-
sive front, whereas our ELISA antigen values were derived from representative overall 
parts of the tumours. Matrix metalloproteinase-8, like MMP-9, is mainly present in 
neutrophils in carcinomas. Therefore, the expected correlation in presence of MMP-8 
and MMP-9 was con rmed by the high correlation between both antigen levels (ρ 
0.810, P≤0.001, n = 158), and the similar distribution according to the di erent cancer 
subgroups. The lack of correlation with survival was, therefore, not surprising in this 
study, as described by others before (Yokoyama et al, 2004). 
The levels of TIMP-1 were signi cantly enhanced in cancer tissue, but the previously 
found association between TIMP-1 levels in sections or homogenates from gastric 
cancer tissue with survival (Joo et al, 2000; Yoshikawa et al, 2001) was not observed 
in our group of patients. However, our group contained relatively less patients with 
advanced TNM stages, which could account for the di erent results compared with 
these former studies. In contrast to what was expected from in vitro studies (Koyama, 
2004), we did not  nd di erences between TIMP-2 levels in normal and cancerous 
tissue. Also, the levels between di erent tumour subgroups did not vary, indicating 
a rather constitutive expression of this inhibitor. As TIMP-2 immunohistochemical 
staining combined with in situ hybridisation experiments detected the expression of 
TIMP-2 in gastric cancer tissue, primarily in peritumoral stromal cells rather than in 
malignant cells (Joo et al, 2000), we conclude that the localisation of TIMP-2 within the 
cancerous tissue might be of crucial importance but apparently not the total amount 
of the inhibitor. The recently suggested role for TIMP-2 in the activation of pro-MMP-2 
(Itoh et al, 2001), combined with the di erent cell types involved in the expression of 
MMP-2 and its main inhibitor TIMP-2 in gastric carcinoma, indicate the importance of 
local cell –cell and molecule –molecule interactions in the activation process. This is 
90 Chapter 5
particularly notice able from our  nding that there is no correlation between MMP-2 
and TIMP-2 levels in the tissue homogenates, where the increase in MMP-2 outbal-
ances that of TIMP-2, resulting in an increased net MMP-2 activity in the tumours, an 
observation which can only be made by using the BIA. This process was not observed 
with MMP- 9 and TIMP-1, where a more balanced increase was found in the tumours. 
Although many in vitro studies, animal models and clinical studies clearly showed 
that MMPs are indeed involved in a number of critical steps during tumour growth 
and invasion, most synthetic MMP inhibitors, designed as anticancer agents, failed 
to improve patients outcome in clinical trials (Zucker et al, 2000), showing that our 
understanding of the working mechanisms of MMPs in tumour biology is still poor. 
Coincidentally, gastric cancer appeared to be one of the few cancers for which a 
signi cant survival bene t from therapy with a matrix metallo proteinase inhibitor has 
been described (Bramhall et al, 2002). Recent studies indicate that proteolytic MMP 
activity is involved in the uncovering or release of speci c sites from macromolecules 
in the extracellular matrix (McCawley and Matrisian, 2001; Polette et al, 2004), which 
at least in vitro leads to various biological activities. Our study shows that an enhanced 
MMP-2 level is consistently and more strongly associated with prognosis of gastric 
cancer patients than other MMPs or TIMPs. This association might be caused by the 
noninvasion-related activities of MMPs, like cytokine release/activation, which makes 
MMP-2 in our opinion an important player in gastric cancer, deserving further investi-
gation. Finally, di erences in the association of the other MMPs and TIMPs with gastric 
cancer survival between our study and other reports, as mentioned above, might be 
related to di erences in genetic background, that is, Caucasian vs Asian, which is cur-
rently under study. 
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Abstract
Recently, complexes of matrix metalloproteinase MMP-9 with lipocalin-2 (neutro-
phil gelatinase-associated lipocalin) were found in the urine obtained from breast 
cancer patients, while these were completely absent in that obtained from healthy 
controls. In vitro data suggested a possible role for lipocalin-2 in the protection of 
MMP-9 against autolysis.
To establish this e ect in vivo, we determined the presence of MMP-9, lipocalin-2 
and their complex in tumour tissue from 81 gastric cancer patients. The e ect 
of the presence of the individual parameters, the complexes, and the inhibitors 
TIMP-1 and TIMP-2 on MMP-9 activity was evaluated with a bioactivity assay. Im-
munohistochemical (double) staining identi ed epithelial cells as the most likely 
cellular source. Finally, evaluation of all these parameters with clinicopathological 
scores revealed that tumour MMP-9/lipocalin-2 complexes were signi cantly 
related with the classi cations of Laurén and WHO, and highly associated with 
worse survival in Cox’s univariate (HR 2.087, P=0.006) and multivariate analysis 
(HR 2.095, P=0.025).
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Introduction
Lipocalin-2 (also known as neutrophil gelatinase-associated lipocalin) is a member of 
the highly heterogeneous family of lipocalins, sharing a common tertiary structure [1, 
2]. Lipocalin-2 has initially been discovered in speci c granules of human neutrophils 
[3] and was later shown to be expressed also by certain epithelial cells, in particular 
during in ammatory or cancerous circumstances [4-10]. There is little information 
about the physiological functions of lipocalins, but lipocalin-2 has been associated with 
cellular iron uptake, antibacterial activity, and epithelial cell di erentiation [2, 9]. 
Enhanced tissue, blood and urine levels of matrix metalloproteinase-9 (MMP-9) 
have been associated with the malignancy of various tumour types [11-14]. Using 
quantitative zymography and immunoassays we have previously shown that MMP-9 
as well as MMP-2 are enhanced in gastric cancer tissue and that high levels are as-
sociated with worse survival of the patients [15, 16]. Next to MMP-9 and MMP-2, the 
zymograms revealed extra bands, particularly between 125-135 kDa. These bands 
have been described before in the urine obtained from cancer patients, and are most 
likely complexes of MMP-9 with lipocalin [17, 18]. In vitro experiments suggested a 
role for lipocalin-2 in the protection of MMP-9 against autolysis [17].
To investigate the suggested relevance of MMP-9/lipocalin-2 complexes in vivo, we 
determined the levels of MMP-9, lipocalin-2 and their complex in tissue homogenates 
from 81 gastric carcinomas in comparison with adjacent normal mucosa from the 
same patients. We used immunohistochemical staining of para  n-embedded tis-
sue sections to establish the cellular origin of MMP-9 and lipocalin-2. To con rm the 
histological  ndings, the levels of MMP-9, lipocalin-2 and the MMP-9/lipocalin-2 com-
plexes in the homogenates were compared with markers for neutrophils, a known 
source of MMP-9 and lipocalin-2. The e ect of complex formation between MMP-9 
and lipocalin-2 on the MMP-9 activity state was evaluated using a speci c MMP-9 
bioactivity assay. Finally, the possible clinical consequence of the presence of MMP-9/
lipocalin-2 complexes in gastric tumours was evaluated by examining for correlations 
with established clinicopathological parameters of the carcinoma patients, including 
univariate and multivariate Cox proportional hazard survival analyses. 
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Materials & methods
Patients and study design
Fresh tissue specimens from 81 patients (21 females and 60 males, mean age 65.9 
years, range 35.1-91.3) who underwent resection for primary gastric adenocarcinoma 
between 1984 and 1996 at the department of Oncologic Surgery, Leiden University 
Medical Centre were collected prospectively. Samples from the mid-central non-ne-
crotic part of the carcinoma and from normal mucosa, taken approximately 10 cm 
from the tumour, were snap-frozen and stored at –70°C until extraction. All carcinomas 
were classi ed according to the TNM classi cation (UICC 1992), and localization as 
well as diameter of the tumour was registered. Microscopical histological parameters, 
including di erentiation-grade, WHO-, Borrmann-, and Laurén-classi cation, as well 
as the presence of intestinal metaplasia in the normal gastric mucosa, were revised 
by a gastroenterologist and a pathologist. All patients entered the study at operation 
date, and the patient’s time experience ended in the event of death or, when still alive, 
at the common closing date. The minimal follow-up was 33 months with a decreasing 
overall survival according to TNM stage, i.e. from TNM I (52.2%, n=23), to TNM II (26.9%, 
n=26), to TNM III (28%, n=25), and to TNM IV (0%, n=7). The study was performed 
according to the instructions and guidelines of the LUMC medical ethics committee.
Tissue preparation and protein concentration
Homogenisation of tissue specimens and determination of protein concentrations 
were performed as described previously [15].
MMP-9/lipocalin-2 complex zymography
Quantitative gelatin zymography for MMP-9/lipocalin-2 complexes was performed as 
described before [15], using an Ultroscan XL Laser Densitometer (LKB) for quanti ca-
tion. The MMP-9/lipocalin-2 complex levels in tissue homogenates were expressed in 
arbitrary units (AU) per mg protein.
ELISAs for MMP-9, lipocalin-2, MMP-9/lipocalin-2-complexes, MMP-8 and TIMPs 
Total antigen levels of MMP-9, lipocalin-2, and MMP-8 were determined using previ-
ously described ELISAs [19-22]. The concentrations of MMP-9/lipocalin-2 complexes, 
TIMP-1 and TIMP-2 were measured using commercial ELISAs according to the manu-
facturer instructions (R&D Systems Europe, Abingdon, UK). The MMP-9/lipocalin-2 
ELISA immobilizes complexes via anti-MMP-9 antibodies followed by detection using 
anti-lipocalin-2 antibodies and does not detect MMP-9 or lipocalin-2 in their free 
forms.
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MMP-9 activity assay
The bioactivity assay (BIAs) for MMP-9 was done as described previously [14, 19, 
22]. This assay detects active MMP-9 and total MMP-9 levels in parallel in 96-wells 
plates coated with MMP-9 speci c antibodies and using modi ed MMP-sensitive 
pro-urokinase as substrate. The fraction of the latent MMP-9 proform is calculated by 
subtraction of active from total MMP-9.
Myeloperoxidase (MPO) activity assay
MPO activity was measured as described previously [23]. In short, tissue homoge-
nates were incubated with 0.5% hexadecyl-trimethylammonium bromide in 50 mM 
potassium phosphate bu er (pH 5.5), plus 0.026% ortho-dianisidine dihydrochloride 
substrate and 0.018% H2O2. The reaction kinetics were followed for 30 min at 450 nm 
in 96-well plates. The speci city of the reaction was checked with sodium azide (0.1 
mM). All samples were analyzed in duplicate and standardized using a homogenate of 
pooled human neutrophils, and MPO activity was expressed in arbitrary units.
Immunohistochemistry and immuno uorescence double staining 
Para  n sections (5 µm) from the same tumours as used for the homogenates were 
depara  nized and stained for the localisation of MMP-9 and lipocalin-2. Antigen 
retrieval was performed through boiling in a 0.01 M citrate solution (pH 6.0) for 12 
minutes in a microwave oven. After being rinsed in PBS and incubated with 10 % 
of normal goat serum (Dako) for 30 minutes, the sections were incubated with the 
primary antibody polyclonal rabbit anti-lipocalin-2 (1:100, from Drs H. Tschesche and 
O. Hiller) or polyclonal rabbit anti-MMP-9 (1:400, TNO, Leiden, The Netherlands) over-
night at 4 degrees. After washing, the sections were incubated with biotinylated goat 
anti-rabbit 1:400 (Dako) for 30 minutes, followed by washing and incubation with 
Streptavidin/ABCcomplex/HRP (DakoCytomation) for 30 minutes. The brown colour 
was developed by 0.004 % H2O2 (Merck) and 0.05 % diaminobenzidine tetrahydrochlo-
ride (Sigma) in 0.01 M Tris-HCl pH 6.0 for 10 minutes. The slides were counterstained 
with Mayer’s haematoxylin (Merck). For speci c cell recognition, i.e. epithelial cells, 
(myo) broblasts, neutrophils and endothelial cells, sequential tissue sections were 
stained with mouse anti-pan-cytokeratin (1:1000, clone C11, Santa Cruz biotech-
nologies, Santa Cruz, USA), mouse anti-vimentin (1:400, clone V9 Santa Cruz), mouse 
anti-smooth muscle actin (1:1000, clone ASM-1, Progen Heidelberg, Germany), rabbit 
anti-myeloperoxidase (1:1000, Dako) and mouse anti-CD31 (1:400, clone JC70A, Dako) 
followed by appropriate second antibodies and staining procedures. Immuno uo-
rescence double staining was performed as described before [24]. In short, sections 
were incubated for 1 hr with rabbit polyclonal anti-lipocalin-2 and mouse monoclonal 
anti-MMP-9 (clone GE-213, 1:400, NeoMarkers, Fremont, CA) antibodies, appropriately 
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diluted in PBS with 1% BSA, washed, and incubated with respectively Alexa Fluor 488- 
and 546-conjugated anti-rabbit and anti-mouse antibodies (Molecular Probes, Leiden, 
The Netherlands) diluted in PBS-BSA. After incubation and washing, the sections were 
mounted in Mowiol. A Zeiss LSM 510 confocal microscope equipped with argon and 
He/Ne lasers and a 20x objective were used to obtain the images.  
Statistical analysis
Di erences between normal and tumour values for all parameters were calculated 
using the Wilcoxon signed ranks test and visualized by Box-Whisker graphs using 
lower and upper margins of 5%. Correlations between parameters were determined 
according to Spearman’s Rho test. For the survival analyses the clinicopathological 
parameters were dichotomized as described previously [15], unless indicated. Cut o  
values for MMPs and related factors were optimised. Survival analyses were performed 
with the Cox proportional hazards model using the SPSS Windows Release 12.0.1. Sta-
tistical Package (2004, SPSS Inc., Chicago, Illinois, USA). Multivariate survival analyses 
were performed using the Cox proportional hazards method by separately adding 
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Figure 1. Zymogram and immunoblot showing MMP-9, MMP-9/lipocalin-2 complexes and 
lipocalin-2 in a representative gastric cancer tissue homogenate (lane 2-4). MMP-9 activity is 
located in the zymograms (lane 2) between 70-92 kDa, representing active MMP-9 and pro-
MMP-9, and at 135 kDa corresponding with MMP-9/lipocalin-2 complex standard (lane 1). The 
immunoblots show corresponding complex bands for MMP-9 (lane 3) and lipocalin-2 (lane 4) 
with extra bands at approximately 25 and 50 kDA representing respectively the monomer and 
homodimer forms of lipocalin-2. Lane 1 contains 20 μl standard from the MMP-9/lipocalin-2 
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the signi cant MMP variables to the dichotomized clinicopathological parameters. 
Survival curves were constructed using the method of Kaplan and Meier including 

















225 from the zymograms, using laser densitometry (Fig. 2a). MMP-
226 9/lipocalin-2 complexes were significantly enhanced in can-
227 cer tissue compared with control mucosa (27.3 ± 2.0 versus
228 14.5 ± 1.4 AU/mg protein, P < 0.001, n = 81). The data from this
229 semi-quantitative assay were compared with the results ob-
230 tained with a commercial ELISA (Fig. 2b). The correlation be-
231 tween both assays was highly significant (rho = 0.488,
232 P < 0.0001, n = 75, i.e. 5 normal mucosa and 70 carcinoma
233 homogenates).
234 3.2. Levels of MMP-9 and lipocalin-2 in gastric
235 cancer tissue homogenates
236 The tissue levels of MMP-9 and lipocalin-2 are shown in Fig. 2c
237 and d. The gastric carcinomas contained significant higher
238 concentrations of MMP-9 (P < 0.001) and lipocalin-2
239 (P = 0.002) than adjacent normal tissues. In general, lipoca-
240 lin-2 was more abundantly present than MMP-9, in specific
241 cases even more than 100 times higher.
2423.3. Correlation between MMP-9 and MMP-9/lipocalin-2
243with MMP-9 activity state
244The correlation of MMP-9, lipocalin-2 and MMP-9/lipocalin-2-
245complex with MMP-9 activity in tissue homogenates of gastric
246cancer patients is shown in Table 1. Active MMP-9 levels cor-
247related significantly with the total antigen level of MMP-9, but
248more interestingly also with the MMP-9/lipocalin-2 concen-
249tration (P = 0.038), suggesting a protective role for lipocalin-
2502-complex formation in MMP-9 (auto)activation. The tissue
251concentration of TIMP-1, the most relevant tissue inhibitor
252of MMP-9, was equally correlated with the levels of MMP-9
253and lipocalin-2, but not with MMP-9 activity.
2543.4. Immunohistochemical staining for MMP-9
255and lipocalin-2
256To establish the cellular source of the MMP-9/lipocalin-2 com-

































































































Fig. 2 – Levels of (a) MMP-9/lipocalin-2 complex in AU/mg protein, (b) MMP-9/lipocalin-2 complex in ng/mg protein, (c) MMP-9
in ng/mg protein, and (d) lipocalin-2 in ng/mg protein in carcinoma tissue and adjacent normal mucosa from 81 gastric
cancer patients. n = 81 unless indicated.
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Figure 2. Levels of ) MMP-9/lipocalin-2 complex in AU/mg pr tein, b) MMP-9/lipocalin-2 
complex in ng/mg protein, c) MMP-9 in ng/mg protein, and d) lipocalin-2 in ng/ g protein in 







Quanti cation of MMP-9/lipocalin-2 complexes in gastric cancer tissue 
homogenates
The presence of MMP-9/lipocalin-2 complexes in tissue homogenates from gastric 
cancer patients was determined using zymography and ELISA. Figure 1 shows a 
typical gastric cancer homogenate with in the zymogram abundant MMP-9 mediated 
lysis and a smaller band at molecular weight 135 kDa, corresponding with standard 
MMP-9/lipocalin-2 complex. The nature of this band was further veri ed using immu-
noblots for respectively MMP-9 and lipocalin-2 under normal (Figure 1) and reduced 
conditions (not shown). The amount of the MMP-9/lipocalin-2 complexes was quanti-
 ed from the zymograms, using laser densitometry (Figure 2a). MMP-9/lipocalin-2 
complexes were signi cantly enhanced in cancer tissue compared with control 
mucosa (27.3±2.0 versus 14.5±1.4 AU/mg protein, P<0.001, n=81). The data from this 
semi-quantitative assay were compared with the results obtained with a commercial 
ELISA (Figure 2b). The correlation between both assays was highly signi cant (rho = 
0.488, P<0.0001, n=75, i.e. 5 normal mucosa and 70 carcinoma homogenates).
Levels of MMP-9 and lipocalin-2 in gastric cancer tissue homogenates
The tissue levels of MMP-9 and lipocalin-2 are shown in  gure 2c and d. The gastric 
carcinomas contained signi cant higher concentrations of MMP-9 (P<0.001) and 
Table 1 -  Correlation coe  cients (ρ plus P-values) for MMP-9, lipocalin-2 and MMP-9/
lipocalin-2 complexes in relation to myeloperoxidase (MPO), MMP-8 and TIMP-1 
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lipocalin-2 (P=0.002) than adjacent normal tissues. In general, lipocalin-2 was more 
abundantly present than MMP-9, in speci c cases even more than 100 times higher.
Correlation between MMP-9 and MMP-9/lipocalin-2 with MMP-9 activity state
The correlation of MMP-9, lipocalin-2, and MMP-9/lipocalin-2-complex with MMP-9 
activity in tissue homogenates of gastric cancer patients is shown in Table 1. Active 
MMP-9 levels correlated signi cantly with the total antigen level of MMP-9, but more 
interestingly also with the MMP-9/lipocalin-2 concentration (P=0.038), suggesting a 

















258 used for homogenates were stained for MMP-9 and lipocalin-
259 2. Normal mucosa showed barely any staining for MMP-9 nor
260 lipocalin-2 (not shown). In carcinoma tissues staining for
261 MMP-9 was found in neutrophils and a substantial part of
262 the epithelial cells, occasionally in endothelial cells, and inci-
263 dentally in muscle cells, macrophages and fibroblasts (Fig. 3a).
264 In neutrophils and epithelial cells lipocalin-2 was similarly
265 distributed compared with MMP-9, but lipocalin-2 was addi-
266 tionally present in tumour epithelial subgroups which lacked
267 MMP-9 staining (Fig. 3b). Endothelial cells and fibroblasts
268 showed little or no staining for lipocalin-2. Immunofluores-
269 cence double staining confirmed that particular epithelial
270cells stained for lipocalin-2 but not for MMP-9 (Fig. 3c, red ver-
271sus greend Q4). Furthermore, this staining revealed that only a
272fraction of MMP-9 and lipocalin-2 was actually in close prox-
273imity (Fig. 3c, yellow versus greend). Yellow staining was
274found in particular at the periphery of cells, suggesting that
275the majority of both proteins is uncomplexed and presumably
276still compartmentalised within the cells, as suggested by
277zymographic analysis.
Table 1 – Correlation coefficients (q plus P-values) for MMP-9, lipocalin-2 and MMP-9/lipocalin-2 complexes in relation to
myeloperoxidase (MPO), MMP-8 and TIMP-1 in 162 gastric cancer tissue homogenates (81 normal/81 cancer)
MMP-9 NGAL MMP-9/Lipocalin-2 complex MMP-9 active MMP-9 latent
MMP-9 (ng/mg protein) 0.438 (0.000) 0.641 (0.000) 0.240 (0.003) 0.817 (0.000)
Lipocalin-2 (ng/mg protein) 0.273 (0.001) )0.121 ns 0.443 (0.000)
MMP-9/Lipoc-2 (AU/mg protein) 0.166 (0.038) 0.586 (0.000)
MMP-9 active (U/mg protein) 0.263 (0.001)
MPO (AU/mg protein) 0.486 (0.000) 0.280 (0.000) 0.332 (0.000) 0.073 (ns) 0.462 (0.000)
MMP-8 (ng/mg protein) 0.810 (0.000) 0.482 (0.000) 0.578 (0.000) 0.128 ns 0.734 (0.000)
TIMP-1 (ng/mg protein) 0.358 (0.000) 0.363 (0.000) 0.315 (0.000) )0.097 (ns) 0.240 (0.004)
Fig. 3 – Typical immunohistochemical staining of a human gastric intestinal type carcinoma for: (a) MMP-9 (200·) and (b)
lipocalin-2 (200·). Black, red, green and yellow arrows indicate, respectively, epithelial cells, neutrophil-like cells,
(myo)fibroblast like cells and endothelial cells. Protein levels in corresponding homogenate for MMP-9, lipocalin-2 and
complex are, respectively, 29 ng/mg, 4928 ng/mg and 17 AU/mg protein. (c) Immunofluorescence double staining (400·) for
MMP-9 (red) and Lipocalin-2 (green). Yellow colour suggests complex formation. (For interpretation of the references to colour
in this figure legend, the reader is referred to the web version of this article.)Q6
d For interpretation of the references to colour in Fig. 3, the
reader is referred to the web version of this article.
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258 used for homogenates were stained for MMP-9 and lipocalin-
259 2. Normal mucosa showed barely any staining for MMP-9 nor
260 lipocalin-2 (not shown). In carcinoma tissues staining for
261 MMP-9 was found in neutrophils and a substantial part of
262 the epithelial cells, occasionally in endothelial cells, and inci-
263 dentally in muscle cells, macrophages and fibroblasts (Fig. 3a).
264 In neutrophils and epithelial cells lipocalin-2 was similarly
265 distributed compared with MMP-9, but lipocalin-2 was addi-
266 tionally present in tumour epithelial subgroups which lacked
267 MMP-9 staining (Fig. 3b). Endothelial cells and fibroblasts
268 showed little or no staining for lipocalin-2. Immunofluores-
269 cence double staining confirmed that particular epithelial
270cells stained for lipocalin-2 but not for MMP-9 (Fig. 3c, red ver-
271sus greend Q4). Furthermore, this staining revealed that only a
272fraction of MMP-9 and lipocalin-2 was actually in close prox-
273imity (Fig. 3c, yellow versus greend). Yellow staining was
274found in particular at the periphery of cells, suggesting that
275the majority of both proteins is uncomplexed and presumably
276still compartmentalised within the cells, as suggested by
277zymographic analysis.
Table 1 – Correlation coefficients (q plus P-values) for MMP-9, lipocalin-2 and MMP-9/lipocalin-2 complexes in relation to
myeloperoxidase (MPO), MMP-8 and TIMP-1 in 162 gastric cancer tissue homogenates (81 normal/81 cancer)
MMP-9 NGAL MMP-9/Lipocalin-2 complex MMP-9 active MMP-9 latent
MMP-9 (ng/mg protein) 0.438 (0.000) 0.641 (0.000) 0.240 (0.003) 0.817 (0.000)
Lipocalin-2 (ng/mg protein) 0.273 (0.001) )0.121 ns 0.443 (0.000)
MMP-9/Lipoc-2 (AU/mg protein) 0.166 (0.038) 0.586 (0.000)
MMP-9 active (U/mg protein) 0.263 (0.001)
MPO (AU/mg protein) 0.486 (0.000) 0.280 (0.000) 0.332 (0.000) 0.073 (ns) 0.462 (0.000)
MMP-8 (ng/mg protein) 0.810 (0.000) 0.482 (0.000) 0.578 (0.000) 0.128 ns 0.734 (0.000)
TIMP-1 (ng/mg protein) 0.358 (0.000) 0.363 (0.000) 0.315 (0.000) )0.097 (ns) 0.240 (0.004)
Fig. 3 – Typical immunohistochemical staining of a human gastric intestinal type carcinoma for: (a) MMP-9 (200·) and (b)
lipocalin-2 (200·). Black, red, green and yellow arrows indicate, respectively, epithelial cells, neutrophil-like cells,
(myo)fibroblast like cells and endothelial cells. Protein levels in corresponding homogenate for MMP-9, lipocalin-2 and
complex are, respectively, 29 ng/mg, 4928 ng/mg and 17 AU/mg protein. (c) Immunofluorescence double staining (400·) for
MMP-9 (red) and Lipocalin-2 (green). Yellow colour suggests complex formation. (For interpretation of the references to colour
in this figure legend, the reader is referred to the web version of this article.)Q6
d For interpretation of the references to colour in Fig. 3, the
reader is referred to the web version of this article.
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 broblast like cells and endothelial 
cells. Protein levels in corresponding homogenate for MMP-9, lipocalin-2 and complex ar  
respectively 29 ng/mg, 4928 ng/mg and 17 AU/mg protein. c) Immuno uorescence double 




sue concentration of TIMP-1, the most relevant tissue inhibitor of MMP-9, was equally 
correlated with the levels of MMP-9 and lipocalin-2, but not with MMP-9 activity.
Immunohistochemical staining for MMP-9 and lipocalin-2
To establish the cellular source of the MMP-9/lipocalin-2 complexes, sequential paraf-
 n sections adjacent to the tissue used for homogenates were stained for MMP-9 and 
lipocalin-2. Normal mucosa showed barely any staining for MMP-9 nor lipocalin-2 
(not shown). In carcinoma tissues staining for MMP-9 was found in neutrophils 
and a substantial part of the epithelial cells, occasionally in endothelial cells, and 
incidentally in muscle cells, macrophages, and  broblasts (Figure 3a). In neutrophils 
and epithelial cells lipocalin-2 was similarly distributed compared with MMP-9, but 
lipocalin-2 was additionally present in tumour epithelial subgroups which lacked 
MMP-9 staining (Figure 3b). Endothelial cells and  broblasts showed little or no stain-
ing for lipocalin-2. Immuno uorescence double staining con rmed that particular 
epithelial cells stained for lipocalin-2 but not for MMP-9 (Figure 3c red versus green). 
Furthermore this staining revealed that only a fraction of MMP-9 and lipocalin-2 was 
actually in close proximity (Figure 3c, yellow versus green). Yellow staining was found 
in particular at the perifery of cells, suggesting that the majority of both proteins is 
uncomplexed and presumably still compartmentalized within the cells, as suggested 
by zymographic analysis.
Correlations between MMP-9, lipocalin-2, MMP-9/lipocalin-2, MMP-8 and MPO
To con rm the similarities and the apparent di erence between MMP-9 and lipoc-
alin-2 in cellular origin, as found by immunohistochemistry, the concentrations of 
MMP-9, lipocalin-2 and MMP-9/lipocalin-2-complex in the tissue homogenates were 
evaluated for correlations with the levels of MPO and MMP-8 (Table 1). MPO, a com-
monly used cell marker for neutrophils, correlated strongly with MMP-8, a collagenase 
abundantly present in neutrophils (0.445, P<0.0005) as well as with MMP-9, but the 
correlation with lipocalin-2 was considerably less, suggesting a possible other source 
of lipocalin-2 than neutrophils only. 
Relation between MMP-9/lipocalin-2 complexes and clinicopathological 
parameters
The MMP-9/lipocalin-2 levels were signi cantly enhanced in di erentiated tumours 
according to the WHO classi cation (30.9±2.5 vs. 19.6±2.8 AU/mg protein, P≤0.006) 
and in tumours of the intestinal type (30.5±2.6 vs. 21.9±2.7 AU/mg protein, P≤0.04). 
MMP-9/lipocalin-2 levels showed a trend to increase with higher TNM stages. Dichoto-
mization of the patients, based on low (AU<36) or high (AU>36) MMP-9/lipocalin-2 
complex values in their tumour, showed a signi cant correlation with overall survival 
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Figure 4. Kaplan-Meier survival curve for a cohort of gastric cancer patients subdivided by 
low (≤36 AU/mg protein) or high (>36 AU/mg protein) levels of MMP-9/lipocalin-2 complex in 
their tumour tissue homogenate.
Table 2 -  Univariate and multivariate Cox proportional hazard overall survival analyses 
for low or high levels of MMP-9/lipocalin-2 in tissue homogenates of gastric 
cancer versus di erent clinicopathological parameters.
Univariate Multivariate
n HR CI 95% P HR CI 95% P
Gender F/M 21/60 1.247 0.730-2.131 NS 1.622 0.900-2.923 NS

































Laurén dif/mx vs inte 30/50 1.103 0.671-1.816 NS 1.125 0.402-3.137 NS
WHO di  vs undi 54/26 0.881 0.525-1.480 NS 0.874 0.289-2.609 NS
Borrmann fung. vs in ltr. 55/24 1.025 0.591-1.778 NS 0.846 0.457-1.567 NS
Localization cardia vs rest 36/45 0.603 0.368-0.989 0.045 0.419 0.223-0.764 0.005
Diameter ≤5 vs >5 cm 47/34 1.062 0.652-1.729 NS 0.695 0.403-1.195 NS
Eosinophils few vs many 56/24 1.220 0.725-2.053 NS 1.846 1.023-3.544 0.042
Intest. metaplasia not vs present 39/42 0.551 0.334-0.909 0.020 0.651 0.365-1.151 NS
MMP-9 antigen <median> 40/40 1.143 0.701-1.863 NS 1.336 0.756-2.363 NS
Lipocalin-2 <median> 40/39 1.029 0.632-1.674 NS 0.772 0.422-1.413 NS
MMP-9/lipocalin-2 ≤36 vs >36 AU 58/23 2.087 1.229-3.544 0.006 2.095 1.099-4.031 0.025
NS: non signi cant
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(Log Rank 8.04, P<0.005, n=81), as shown in  gure 4. Analysis of the MMP-9/lipocalin-2 
complex ELISA data showed a similar trend but did not reach statistical signi cance 
(Log Rank, 3.04, P=0.0815, n=70). 
Survival analyses
The relation of MMP-9/lipocalin-2 complexes with survival was further characterized 
with Cox’s uni- and multivariate analyses against the clinicopathological parameters 
(Table 2). The level of MMP-9/lipocalin-2 was signi cantly associated with worse 
survival and kept its signi cance in multivariate analyses, indicating its value as an 
independent prognostic factor.
Discussion
High levels of lipocalin-2 have been reported in various types of cancer [6-10]. Our 
study shows that lipocalin-2 levels are indeed signi cantly enhanced in gastric 
carcinomas compared to adjacent control tissue. Moreover and more interestingly, 
our data show that the complexes of lipocalin-2 with MMP-9 are also signi cantly 
enhanced in human gastric tumours.
In vitro experiments showed that lipocalin-2 is able to induce the expression of 
E-cadherin, to promote the formation of polarized epithelia, and to diminish the 
invasiveness and metastasis of Ras-transformed cells [25], suggesting a protective 
role against cancer. Other studies reported a positive correlation between lipocalin-2 
expression levels and the growth rate of lipocalin-2 transfected MCF-7 human breast 
carcinoma cells, which were subcutaneously implanted in immuno-de cient mice 
[18]. Immunohistochemical analyses of these xenografted tumours showed that the 
over-expression of lipocalin-2 was accompanied by enhanced levels of MMP-9, sug-
gesting the formation of complexes between MMP-9 and lipocalin-2. The formation 
of MMP-9/lipocalin-2 complexes has previously been shown to protect MMP-9 from 
auto-degradation in vitro [17, 18]. MMP-9/lipocalin-2 complex formation could result 
in increased extracellular, tumour-associated MMP-9, and hence in enhanced tumour 
growth as recently suggested by Fernández et al. [18]. We found that in gastric cancer 
tissue lipocalin-2 levels are in general 30 times higher than corresponding MMP-9 
levels, presumably leading to MMP-9/lipocalin-2 complex formation of a substantial 
part of the MMP-9 fraction after it has been released from the cells. These complexes 
were signi cantly correlated with the active, as well as the latent fraction of MMP-9. 
Therefore, our data support the hypothesis that enhanced production of lipocalin-2 in 
cancerous tissue stimulates the formation of a complex with MMP-9, playing a role in 
the maintenance of an extracellular pool of a latent form of this powerful proteinase, 
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by prevention from auto-degradation. This latent pool of secreted, lipocalin-2-bound 
MMP-9 has previously been shown to be important for the spatial control of VEGF 
release from the ECM and hence for enhanced angiogenesis [26]. Our study does not 
provide information about the presence and/or role of MMP-9/lipocalin-2/TIMP-1 
complexes. These ternary complexes have previously been isolated from phorbol 
myristate acetate stimulated neutrophils and showed low gelatinase activity, as 
expected [27]. In our study, total TIMP-1 levels correlated signi cantly with all the 
forms of MMP-9, except for the active form of MMP-9, suggesting that other factors 
are involved in regulating the activity of MMP-9, besides the ratio between MMP-9 
and TIMP-1. TIMP-2 levels were weakly inversely correlated with MMP-9 antigen levels, 
suggesting little or no mutual interaction (data not shown). 
The quantitative determination of MMP-9 and lipocalin-2 in tissue homogenates, 
as performed in this study, has several advantages compared to semi-quantitative 
immunohistological detection methods but obviously does not provide information 
about the localization of the proteins. Our immunohistochemical data revealed that 
lipocalin-2 as well as MMP-9 in gastric cancers are mainly present in neutrophils and 
epithelial cells, but that epithelial expression of MMP-9 is depending on the individual 
cancer and on the location within the tumour. MMP-9 was furthermore found in (myo)
 broblast-like cells and endothelial cells. These data are in accordance with what has 
been found previously in colonic cancer [6, 28]. Our  uorescent double-staining 
data suggest that, although MMP-9 and lipocalin-2 seem present in close proximity 
especially within the cells, overlap of green and red colours, presumably represent-
ing extra-cellular complex formation, is limited and mainly restricted to peri-cellular 
areas. Whether the enhancement of MMP-9/lipocalin-2 complexes in gastric cancer 
compared with adjacent normal mucosa was caused by the in ux of neutrophils or 
alternatively by upregulated expression in malignant epithelial cells, could not be 
established in this study. The  nding that high numbers of intra-tumoural neutrophils 
are associated with better survival of patients with gastric cancer [29], would suggest 
the latter.
From this study, the clinical relevance of MMP-9/lipocalin-2 complex formation ap-
pears most obvious from the correlation with overall survival of the patients. Enhanced 
levels of these complexes were highly prognostic for worse survival, whereas the levels 
of single MMP-9 and lipocalin-2 were not. The  nding that MMP-9/lipocalin-2 levels 
are increased in gastric cancer tissue and that enhancement might be associated with 
clinical outcome of the patients is supported by a recent study reporting that similar 
complexes were present in approximately 90% of the urines obtained from breast 
cancer patients, but not in those from healthy controls [18]. The prognostic value of 
MMP-9/lipocalin-2 complexes is in accordance with the presumed role of lipocalin-2 
in the protection of secreted MMP-9 against auto-degradation, which contributes to 
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an enhanced pool of potentially active MMP-9, a proteolytic enzyme associated with 
angiogenesis and tumour growth. High total MMP-9 levels were not associated with 
survival in the present study. This is not in agreement with what we have published 
previously [15], but those earlier data were based on a smaller group of patients and 
on detection of MMP-9 activity instead of total antigen level. The di erent outcome 
between both studies indicates the delicacy of the use of proteinase levels as prog-
nostic indicators, as discussed before [16, 30]. Apparently not just the enhanced 
presence, but more the (potential) activation state of the proteinase, i.e. the result of, 
respectively, production, release, activation, and the inactivation by inhibitors, seems 
to be crucial, similar to what has been described for other enzyms playing a role in 
gastric cancer like urokinase and MMP-2 [16, 31]. Additionally, our data indicate that 
prevention of auto-degradation of MMP-9 by lipocalin-2 might play an important role 
too. 
In conclusion, we have shown for the  rst time that complexes between MMP-9 
and lipocalin-2 are present in enhanced levels in gastric cancer tissue and that high 
levels are associated with worse survival of the patients. The potential clinical value 
of our  ndings should be con rmed in larger groups of cancer patients. Recently the 
enzymatic activity of MMP-9/lipocalin-2 complex has indeed been found to correlate 
signi cantly with the depth of tumour invasion in esophageal squamous cell carcino-
mas [32]. 
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Abstract
Gastric cancers express enhanced levels of matrix metalloproteinases (MMPs) and 
their tissue inhibitors (TIMPs). Single-nucleotide polymorphisms (SNPs) in MMP 
and TIMP genes may be associated with disease susceptibility and might also 
a ect their antigen expression. We studied the genotype distribution and allele 
frequencies of SNPs of MMP-2, -7, -8 and -9 and TIMP-1 and -2 in gastric cancer 
patients in relation to tumour progression, patient survival and tissue antigen ex-
pression. The genotype distribution and allele frequencies were similar in gastric 
cancer patients and controls, except for MMP-7-181A>G. In addition, the genotype 
distribution of MMP-7-181A>G was associated with Helicobacter pylori status (χ
2
7.8, P = 0.005) and tumour-related survival of the patients. Single-nucleotide 
polymorphism TIMP-2303C>T correlated signi cantly with the WHO classi cation (χ
2
5.9, P = 0.03) and also strongly with tumour-related survival (log rank 11.74, P = 
0.0006). Single-nucleotide polymorphisms of MMP-2, -8, -9 and TIMP-1 were not 
associated with tumour-related survival. Only the gene promoter MMP-2-1306C>T
polymorphism correlated signi cantly with the protein level within the tumours. 
First-order dendrogram cluster analysis combined with Cox analysis identi ed the 
MMP-7-181A>G and TIMP-2303C>T polymorphism combination to have a major impact 
on patients survival outcome. We conclude that MMP-related SNPs, especially 
MMP-7-181A>G and TIMP-2303C>T, may be helpful in identifying gastric cancer patients 
with a poor clinical outcome.
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Introduction
In the process of tumour dissemination and metastasis, matrix metalloproteinases 
(MMPs) and their tissue inhibitors (TIMPs) play an important role in the invasion of 
tissue, vascular and lymphatic basal membranes and the subsequent coordinated 
proteolytic breakdown and reconstitution of extracellular matrix (Kohn and Liotta, 
1995). Matrix metalloproteinases also modulate cell proliferation, apoptosis and host 
immune surveillance (Egeblad and Werb, 2002). Immunohistochemical and in situ
hybridisation studies as well as quantitative assays have demonstrated that gastric 
carcinomas contain enhanced amounts of MMPs (Nomura et al, 1995; Honda et al, 
1996; Mori et al, 1997). We previously reported signi cantly enhanced MMP and TIMP 
levels in gastric carcinomas, but only MMP-2 was independently associated with a 
poor overall survival of the patients (Kubben et al, 2006). Single-nucleotide polymor-
phisms (SNPs) within MMP genes are thought to in uence the expression of MMPs 
and/or even seem to be associated with the susceptibility for the development of 
malignancy. For instance, a functional SNP in the MMP-2 gene promoter (-1306C>T) 
was found to be associated with the risk of the development, but not the metastatic 
behaviour of gastric cardia adenocarcinoma, in an ethnic Chinese population (Miao 
et al, 2003). Furthermore, the frequency of a functional SNP of MMP-7 (-181A>G) was 
found to be signi cantly higher in gastric cardiac carcinoma patients compared to 
controls in another Chinese study (Zhang et al, 2005). Particularly, genotypes with the 
MMP-7-181G allele (A/G + G/G) showed a signi cantly increased susceptibility for gastric 
cardiac carcinoma with an odds ratio of 1.96 (Zhang et al, 2005). Finally, a signi cant 
association in Japanese gastric cancer patients was found between an SNP in the 
promoter of the MMP-9 gene (-1562C>T) and the degree of tumour invasion, clinical 
stage and lymphatic invasion (Matsumura et al, 2005). However, as indicated above, 
these studies on MMP-SNPs in gastric carcinoma patients describe ethnic Chinese and 
Japanese populations with a known high incidence of gastric cancer. 
In the present study, we determined the genotype distribution and allele frequen-
cies of SNPs of MMP-2, -7, -8 and -9, and of TIMP-1 and -2 in a cohort of 79 Caucasian 
gastric carcinoma patients, in which we previously assessed clinical relevance of 
the respective protein levels. In order to get insight into the functional and clinical 
contribution of these MMP-related gene polymorph isms, we assessed the relation 
between the distribution of these SNPs and the respective protein levels in tumour 
and adjacent normal tissue as well as the relation of the SNPs with established clinico-




Patients and study design 
Fresh histologically normal tissue specimens of 79 patients (21 females and 58 males, 
mean age 66 years, range 35 –91 years) who underwent resection for primary gastric 
adenocarcinoma at the department of Oncologic Surgery of the Leiden University 
Medical Centre were collected prospectively, as described before (Janssen et al, 2002). 
Various clinicopathological data were (re-)evaluated or collected from patient  les 
by one gastroenterologist and one pathologist (Janssen et al, 2002). All carcinomas 
were classi ed according to the TNM classi cation (Hermanek and Sobin, 1992) 
and localisation as well as diameters of the tumours were registered. Microscopical 
histological parameters, including di er entiation-grade, classi cation according to 
WHO, Borrmann and Laurén, as well as the presence of Helicobacter pylori (Hp) and 
intestinal metaplasia in the normal gastric mucosa were assessed. All patients entered 
the study at operation date and a patient’s time experience ended in the event of 
death or, when still alive, at the common closing date. The minimal follow-up was 
33 months with a decreasing overall survival according to TNM stage, that is, from 
TNM I (n = 23), to TNM II (n = 24), to TNM III (n = 25), and to TNM IV (n = 7). Genomic 
DNA was isolated using the salting out method (Miller et al, 1988). In addition, DNA 
was extracted from peripheral blood leucocytes of 169 healthy volunteers (38% male, 
median age 33 years (range 18 –73 years), >95% Caucasian) as described before (van 
der Veek et al, 2005).
Single-nucleotide polymorphism analyses
Genotypes were analysed by PCR-based techniques as described in Table 1.
Antigen determination and protein concentration 
From 50–100mg of wet tissue samples, homogenates were prepared. The samples 
were wet weighted, and 1 ml of 0.1 M Tris-HCl (pH 7.5) with 0.1% (v.v-1) Tween-80 
extraction bu er per 60 mg sample was added as described previously. The protein 
concentration was determined using the method of Lowry et al (1951). Speci c ELISAs 
for the MMP and TIMP antigen determination were performed as recently described 
(Kubben et al, 2006).
Statistical analysis 
Statistical analyses were performed using SPSS11.0 Statistical Package (2004, SPSS 
Inc., Chicago, IL, USA). Hardy –Weinberg analysis was performed using the chi-square 
(χ2) or Fisher’s exact test to examine di erences in the distribution of alleles and 
genotypes between patients and controls. Odds ratios and con dence intervals 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(95%) were calculated by logistic regression. For the tumour-related survival analysis, 
the clinicopatho logical parameters were dichotomised as described before (Sier et 
al, 1996). Univariate survival analyses were performed with the Cox proportional 
hazards model, using the clinico pathological parameters and MMP-SNPs, resulting in 
the identi cation of covariates that signi cantly correlated with the survival of the 
patients. Multivariate survival analysis was performed by separately adding the MMP-
SNPs variables to all the dichotomised clinicopathological parameters. Tumour-related 
survival curves were constructed using the method of Kaplan and Meier including the 
log rank test. Group means for antigen levels were compared using two-tailed Mann– 
Whitney U-tests. Di erences were considered signi cant when P≤0.05. 
Results
The genotype distribution and allele frequencies of the SNPs for MMP-2, -7, -8, -9, 
TIMP-1 and -2 for the 79 gastric cancer patients and 169 control subjects are sum-
marised in Table 2. Single-nucleotide polymorphisms 1306C>T and 1575G>A for 
MMP-2 were found to be in complete linkage disequilibrium and consequently, in the 
rest of the study only MMP-2-1306C>T will be described. None of the genotype distribu-
tions in the control group or in the cancer patients deviated from the Hardy–Wein-
berg equilibrium (data not shown). Matrix metalloproteinase-7-181A>G was the only 
polymorphism di erently distributed among gastric carcinoma patients compared 
with control subjects: AA 43.0%, AG 46.8%, and GG 10.1% in patients vs AA 27.2%, 
AG 62.7% and GG 10.1% in controls (P<0.04; Table 2). Comparison of the genotype 
distribution of our Caucasian control subjects with those published on other mainly 
Asiatic control groups (Wollmer et al, 2002; Ghilardi et al, 2003; Krex et al, 2003; Miao 
et al, 2003; Wang et al, 2004; Zhou et al, 2004; Matsumura et al, 2005; Zhang et al, 
2005) showed signi cant di erences for MMP-2-1306C>T, MMP 7-181A>G, TIMP-1372C>T and 
TIMP-2-418G>C (Table 3).
All the SNPs were evaluated for association with the clinico pathological parameters. 
Correlations were found for MMP 2-1306C>T with Borrmann’s classi cation (fungating 
vs in ltrating: CC 70% and CT/TT 30% vs CC 48% and CT/TT 52%; χ2 3.5, P = 0.06), 
MMP-7-181A>G with the presence of Hp (negative vs positive: AA 60% and AG/GG 40% vs
AA 21% and AG/GG 79%; χ2 7.8, P = 0.005) and TIMP-2303C>T with the WHO classi cation 
(di erentiated vs not di erentiated: CC 93% and CT/TT 7% vs CC 72 and CT/TT 28%; 
χ2 5.9, P = 0.03). 
The prognostic value for tumour-related survival of the respective SNPs was an-
alysed using Cox proportional hazards analyses (Table 4). In the univariate analyses, 
TIMP-2303C>T was signi cantly correlated with survival (Figure 1A), whereas MMP 7-181A>G










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































showed a trend (Figure 1B). From the clinico pathological parameters, only TNM clas-
si cation and the presence of intestinal metaplasia were signi cantly associated with 
survival, whereas the localisation showed a trend. In a multivariate analysis against 
all the clinical parameters TIMP-2303C>T kept its signi cance, indicating its potential 
value as an independent prognostic marker. A dendrogram showing a two-dimen-
sional unsupervised hierarchical cluster analysis for all 79 patients using all the SNPs 
determined in this study is presented in Figure 2. Interestingly, the  rst-order cluster 
(I) separated the eight patients with mutations in both the survival-associated SNPs, 
that is, MMP-7-181A>G and TIMP-2303C>T, from the rest of the patients. Further analyses of 
this SNP combination revealed a stepwise and statistically signi cant poorer tumour-
related survival for these mutations (0% (0 out of 11 patients) vs 32% (12 out of 37 
patients) vs 52% (16 out of 31 patients); χ2 9.7, P≤0.01). Cox analyses con rmed this 
prognostic signi cance of this MMP-7-181A>G– TIMP-2303C>T combination, as indicated in 
Table 4 and illustrated in Figure 3. 
The relation between the genotype distribution of the SNPs and the protein levels 
in normal and tumour tissue is shown in Table 5. As expected, the exon-located SNPs 
were not found to be accompanied by changes in the respective protein levels. The 
promoter-located SNPs showed some trends with the protein levels, but the only 
relevant signi cant di erence was found for MMP-2-1306C>T within tumour tissue. 
CC 70% and CT/TT 30% vs CC 48% and CT/TT 52%; w2 3.5,
P¼ 0.06), MMP-7�181A4G with the presence of Hp (negative vs
positive: AA 60% and AG/GG 40% vs AA 21% and AG/GG 79%; w2
7.8, P¼ 0.005) and TIMP-2303C4T with the WHO classification
(differentiated vs not differentiated: CC 93% and CT/TT 7% vs CC
72 and CT/TT 28%; w2 5.9, P¼ 0.03).
The prognostic value for tumour-related survival of the
respective SNPs was analysed using Cox proportional hazards
analyses (Table 4). In the univariate analyses, TIMP-2303C4T was
significantly correlated with survival (Figure 1A), whereas MMP-
7�181A4G showed a trend (Figure 1B). From the clinico-
pathological parameters, only TNM classification and the presence
of intestinal metaplasia were significantly associated with survival,
whereas the localisation showed a trend. In a multivariate analysis
against all the clinical parameters TIMP-2303C4T kept its
significance, indicating its potential value as an independent
prognostic marker. A dendrogram showing a two-dimensional
unsupervised hierarchical cluster analysis for all 79 patients using
all the SNPs determined in this study is presented in Figure 2.
Interestingly, the first-order cluster (I) separated the eight patients
with mutations in both the survival-associated SNPs, that is,
MMP-7�181A4G and TIMP-2303C4T, from the rest of the patients.
Further analyses of this SNP combination revealed a stepwise and
statistically significant poorer tumour-related survival for these
mutations (0% (0 out of 11 patients) vs 32% (12 out of 37 patients)
vs 52% (16 out of 31 patients); w2 9.7, Pp0.01). Cox analyses
Table 4 Univariate and multivariate Cox proportional hazard analysis for gastric cancer patients testing SNPs for MMP and TIMP vs clinico-pathological
parameters
Univariate Multivariate
Parameter n HR CI 95% P HR CI 95% P
Gender F vs M 21–58 0.706 0.390–1.278 NS 0.606 0.322–1.138 NS
Age omedian4 40–39 1.231 0.709–2.138 NS 1.422 0.749–2.701 NS
TNM 1 23 1 — — 1 — —
vs 2 24 3.041 1.302–7.102 0.01 4.282 1.629–11.257 0.003
vs 3 25 2.995 1.293–6.933 0.01 3.119 1.175– 8.280 0.022
vs 4 7 7.175 2.420–21.271 0.0005 19.661 5.096–75.855 0.0005
Laurén diffuse/mix vs intestinal 28–50 0.913 0.522–1.595 NS 1.281 0.344–4.774 NS
WHO differentiated vs undiff. 53–25 1.152 0.652–2.033 NS 1.846 0.470–7.251 NS
Borrmann fungating vs infiltrating 54–23 1.077 0.576–2.013 NS 0.677 0.338–1.356 NS
Localisation Rest vs cardia 45–34 1.715 0.980–3.001 0.059 2.878 1.410–5.874 0.004
Diameter p5 vs 45 cm 45–34 1.07 0.615–1.861 NS 0.612 0.324–1.158 NS
Intestinal metaplasia Not vs present 37–42 0.499 0.283–0.880 0.016 0.704 0.378–1.312 NS
SNP
MMP-2�1306C4T CC vs CT/TT 50–29 0.756 0.421–1.358 NS 1.158 0.578–2.321 NS
MMP-7�181A4G AA vs AG/GG 34–45 1.718 0.965–3.057 0.066 1.637 0.850–3.152 NS
MMP-7�153C4T CC vs CT 70–9 1.096 0.467–2.575 NS 1.137 0.396–3.269 NS
MMP-8�799C4T CC vs CT/TT 19–60 0.681 0.376–1.234 NS 0.607 0.302–1.222 NS
MMP-8+17C4G CC vs CG 68–11 1.349 0.656–2.775 NS 1.364 0.516–3.606 NS
MMP-9�1562C4T CC vs CT/TT 59–20 1.127 0.598–2.126 NS 1.006 0.482–2.101 NS
TIMP-1372C4T CC vs CT/TT 32–47 1.125 0.644–1.967 NS 0.739 0.387–1.411 NS
TIMP-2303C4T CC vs CT/TT 68–11 3.224 1.571–6.616 0.001 4.445 1.808–10.928 0.001
TIMP-2�418G4C GG vs GC 78–1 ND ND ND ND ND ND
MMP-7�181A4G and AA-CC 31 1 — — 1 — —
TIMP-2303C4T vs AG/GG-CC 37 1.896 1.011–3.558 0.046 1.911 0.947–3.856 0.071
vs AA or AG/GG-CT/TT 11 3.859 1.578–9.442 0.003 5.323 1.736–16322 0.003
CI¼ confidence interval; F¼ female; HR¼ hazard ratio; M¼male; MMP¼matrix metalloproteinase; ND¼ not defined; NS¼ not significant; SNP¼ single-nucleotide

















































Figure 1 Survival curves using tumour-related death for 79 gastric cancer patients subdivided by the presence of a SNP in (A) the TIMP-2 gene
(303C4T) and (B) the MMP-7 gene (�181A4G).
SNPs of MMPs and TIMPs in gastric carcinoma
FJGM Kubben et al
747
















Figure 1. Survival curves using tumour-related death for 79 gastric cancer patients subdivided 
by the presence of a SNP in (A) the TIMP-2 gene (303C>T) and (B) the MMP-7 gene (-181A>G).
SNPs of MMPs and TIMPs in gastric carcinoma 121
Figure 2. Dendrogram of a 
two-dimensional unsupervised 
hierarchical cluster analysis for 79 
gastric cancer patients using SNPs of 
MMP 2-1306C>T, MMP-7-181A>C(A), -153C>G(B), 
MMP-8-799C>T(C), +17C>G(D), MMP-9-
1562C>T, TIMP-1372C>T, and TIMP-2303C>T(E), 
-418G>C(F). For all the SNPs, 0 stands 
for the reference genotype and 1 
for the combined other genotypes 
as described in Table 2. Because of 
the distribution, for MMP-8-799C>T(C) 
a three-group subdivision was used: 
0 =CC, 1 =CT, 2 =TT. Status: 0 =alive 
or not tumour-related death, 1 = 
tumour-related death.
confirmed this prognostic significance of this MMP-7�181A4G –
TIMP-2303C4T combination, as indicated in Table 4 and illustrated
in Figure 3.
The relation between the genotype distribution of the SNPs and
the protein levels in normal and tumour tissue is shown in Table 5.
As expected, the exon-located SNPs were not found to be
accompanied by changes in the respective protein levels. The
promoter-located SNPs showed some trends with the protein
levels, but the only relevant significant difference was found for
MMP-2�1306C4T within tumour tissue.
DISCUSSION
Because some gene polymorphisms of MMPs and TIMPs have been
found to be related to disease susceptibility and changed gene
transcription in vitro, we investigated whether gastric cancer is
associated with SNPs of MMP-2, -7, -8 and -9, or their inhibitors
TIMP-1 and TIMP-2. The only SNP that was distributed
significantly differently among gastric carcinoma patients com-
pared to our control population was MMP-7�181A4G, with more
patients of the AA genotype than in controls. The latter was
not expected from previous studies on gastrointestinal cancer
(Ghilardi et al, 2003; Zhang et al, 2005) and is most likely caused
by ethnic differences (Asiatic vs Caucasian; Table 3), disease
localisation (gastric vs colon) and the relatively low number of
patients included in the studies. In our study, the gastric cancer
patients with the variant AG/GG genotype showed worse survival
data than the AA patients (Table 4 and Figure 1B), although the
difference did not fully reach statistical significance. The fact that
tumours of the AG/GG patients did not contain higher MMP-7
antigen levels in our study suggests that the presence of SNP MMP-
7�181A4G alone is not directly translated into an enhanced tumour
Figure 2 Dendrogram of a two-dimensional unsupervised hierarchical
cluster analysis for 79 ga tric cancer patients using SNPs of MMP-
2�1306C4T, MMP-7�181A4C (A), �153C4G (B), MMP-8�799C4T(C),
þ 17C4G(D), MMP-9�1562C4T, TIMP-1372C4T, and TIMP-2303C4T(E),
�418G4C(F). For all the SNPs, 0 stands for the reference genotype and 1
for the combined other genotypes as described in Table 2. Because of the
distribution, for MMP-8�799C4T(C) a three-group subdivision was used:



























Figure 3 Survival curves using tumour-related death for 79 gastric
cancer patients subdivided by the presence of combined polymorphisms in
the MMP-7 gene (�181A4G) and TIMP-2 gene (303C4T).
SNPs of MMPs and TIMPs in gastric carcinoma
FJGM Kubben et al
748

















Because some gene polymorphisms of MMPs and TIMPs have been found to be 
related to disease susceptibility and changed gene transcription in vitro, we inves-
tigated whether gastric cancer is associated with SNPs of MMP-2, -7, -8 and -9, or 
their inhibitors TIMP-1 and TIMP-2. The only SNP that was distributed signi cantly 
di erently among gastric carcinoma patients com pared to our control population 
was MMP-7-181A>G, with more patients of the AA genotype than in controls. The latter 
was not expected from previous studies on gastrointestinal cancer (Ghilardi et al, 
2003; Zhang et al, 2005) and is most likely caused by ethnic di erences (Asiatic vs
Caucasian; Table 3), disease localisation (gastric vs colon) and the relatively low num-
ber of patients included in the studies. In our study, the gastric cancer patients with 
the variant AG/GG genotype showed worse survival data than the AA patients (Table 
4 and Figure 1B), although the di erence did not fully reach statistical signi cance. 
The fact that tumours of the AG/GG patients did not contain higher MMP-7 antigen 
levels in our study suggests that the presence of SNP MMP 7-181A>G alone is not directly 
translated into an enhanced tumour MMP-7 antigen expression or activity. However, 
considering the previously shown localised presence of MMP-7 at the invasive front 
of tumours, immunohistochemical or in vitro studies might further elucidate this 
confirmed this prognostic significance of this MMP-7�181A4G –
TIMP-2303C4T combination, as indicated in Table 4 and illustrated
in Figure 3.
The relation between the genotype distribution of the SNPs and
the protein levels in normal and tumour tissue is shown in Table 5.
As expected, the exon-located SNPs were not found to be
accompanied by changes in the respective protein levels. The
promoter-located SNPs showed some trends with the protein
levels, but the only relevant significant difference was found for
MMP-2�1306C4T within tumour tissue.
DISCUSSION
Because some gene polymorphisms of MMPs and TIMPs have been
found to be related to disease susceptibility and changed gene
transcription in vitro, we investigated whether gastric cancer is
associated with SNPs of MMP-2, -7, -8 and -9, or their inhibitors
TIMP-1 and TIMP-2. The only SNP that was distributed
significantly differently among gastric carcinoma patients com-
pared to our control population was MMP-7�181A4G, with more
patients of the AA genotype than in controls. The latter was
not expected from previous studies on gastrointestinal cancer
(Ghilardi et al, 2003; Zhang et al, 2005) and is most likely caused
by ethnic differences (Asiatic vs Caucasian; Table 3), disease
localisation (gastric vs colon) and the relatively low number of
patients included in the studies. In our study, the gastric cancer
patients with the variant AG/GG genotype showed worse survival
data than the AA patients (Table 4 and Figure 1B), although the
difference did not fully reach statistical significance. The fact that
tumours of the AG/GG patients did not contain higher MMP-7
antigen levels in our study suggests that the presence of SNP MMP-
7�181A4G alone is not directly translated into an enhanced tumour
Figure 2 Dendrogram of a two-dimensional unsupervised hierarchical
cluster analysis for 79 gastric cancer patients using SNPs of MMP-
2�1306C4T, MMP-7�181A4C (A), �153C4G (B), MMP-8�799C4T(C),
þ 17C4G(D), MMP-9�1562C4T, TIMP-1372C4T, and TIMP-2303C4T(E),
�418G4C(F). For all the SNPs, 0 stands for the reference genotype and 1
for the combined other ge otypes as d scrib d in Table 2. Because of the
distribution, for MMP-8�799C4T(C) a three-group subdivision was used:



























Figure 3 Survival curves using tumour-related death for 79 gastric
cancer patients subdivided by the presence of combined polymorphisms in
the MMP-7 gene (�181A4G) and TIMP-2 gene (303C4T).
SNPs of MMPs and TIMPs in gastric carcinoma
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Figure 3. Survival curves using tumour-related death for 79 gastric cancer patients subdivided 
by the presence of combined polymorphisms in the MMP-7 gene (-181A>G) and TIMP-2 gene 
(303C>T).






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































functional relationship. The other striking correlation of MMP-7-181A>G in this study 
is with the presence of Hp. Gastric cancer patients with the AG/GG genotype were 
signi cantly more often Hp-positive, which might indicate an enhanced susceptibility 
for this bacterium. The presence of Hp is associated with the development of gastric 
cancer and stimulation of MMP-7 production by Hp in human gastric epithelial cells 
has previously been suggested as a possible mechanism predisposing towards gastric 
neoplasia (Wroblewski et al, 2003; Chen et al, 2004). 
Tissue inhibitor of metalloproteinase-2 is involved in the regulation of MMP-2 
activity (Howard et al, 1991; Wang et al, 2000). In addition, TIMP-2 has been shown to 
promote cell growth (Hayakawa et al, 1994). Enhanced amounts of TIMP-2 protein are 
found to be associated with prostate cancer malignancies (Ross et al, 2003), but for 
colon and gastric cancer the correlation with clinicopathological parameters has not 
been established (Ring et al, 1997; Joo et al, 2000). In our study, the CT/TT variant of 
TIMP-2303C4T was observed more frequently in undi erentiated gastric carcinomas 
(WHO classi cation) and it was associated with worse tumour-related survival of 
gastric cancer patients. Tissue inhibitor of metalloproteinase-2303C>T is located in exon 
3 with no e ect on the  nal amino-acid sequence of the protein (S101S) and no e ect 
on the total TIMP-2 expression between gastric normal and tumour tissue (Table 5). 
Therefore, the TIMP-2303C>T SNP behaves as a disease susceptibility gene polymorphism 
by a so far unde ned mechanism. The other SNP for TIMP-2 in this study (-418G>C), 
localised in the promoter of the gene, has been described to abolish the Sp1-binding 
site and therefore may downregulate TIMP-2 gene expression (Hirano et al, 2001). A 
previous study reported that the variant TIMP-2-418G>C genotype (GC or CC) was indeed 
associated with a moderately reduced risk of breast cancer in a Chinese population 
(Zhou et al, 2004). Because our group of Caucasian gastric cancer patients contained 
only one patient with the variant genotype (GC), we could not determine an associa-
tion with tumour staging, patient survival or antigen expression. 
The  rst-order cluster in a two-dimensional unsupervised hierarchical cluster 
analysis including all SNPs clearly separated the patients with mutations in both the 
survival-associated SNPs, that is, MMP-7-181A>G and TIMP-2303C>T from the rest of the 
patients. Cox analysis con rmed this SNP combination as a prognostic parameter 
for gastric cancer. Although results of cluster analysis of SNPs in gastric cancer have 
not been published before, hierarchical cluster analysis of patterns of chromosomal 
aberra tions in gastric cancer patients identi ed patients with worse prognosis as well 
(Weiss et al, 2003), con rming the validity of such an approach. 
The (-1306C>T) SNP in the promoter of the MMP-2 gene has also been found to 
diminish promoter activity by abolishing the Sp1-binding site (Price et al, 2001). 
Consequently, the variant genotypes (CT/TT) are expected to produce less MMP-2 
antigen, which consequently might be associated with decreased cancer risk or better 
SNPs of MMPs and TIMPs in gastric carcinoma 125
survival of the patients (Sier et al, 1996). Although we did not  nd a signi cant di er-
ence in distribution of MMP-2-1306C>T between gastric cancer patients and controls, the 
tumours from patients with the CT/TT genotypes contained signi cantly less MMP-2 
antigen than the CC genotype (Table 5). This relation was expected, but as far as we 
know, never shown before. The fact that the MMP-2-1306C>T status on its own was not 
correlated with survival might be explained by the complicated activation mechanism 
of MMP-2 in which several other proteins are involved. Changes in MMP-2 antigen 
levels are therefore not directly correlated with MMP-2 activity levels. The fact that 
we did not  nd a relation with survival in our group of patients supports the study of 
Miao et al (2003), describing that the CC genotype was not associated with higher risk 
of metastasis at the time of diagnosis. A weak but signi cant di erence in genotype 
distribution of MMP-2-1306C>T and gastric carcinomas, classi ed according to the Bor-
rmann classi cation, was observed with the highest percentage of the CC genotype 
in type 1/2 (fungating) preceding in ltrating tumours (type 3/4). This underscores the 
role of MMP-2 in breaking down the extracellular matrix in early gastric cancer which 
has been suggested before (Miao et al, 2003). 
The genotype distribution of MMP-9-1562C>T in our group of healthy controls was not 
di erent from other publications. We did not  nd di erences in genotype distribution 
for MMP-9-1562C>T between gastric cancer patients and controls either, which is in 
agreement with the study of Matsumura et al (2005) in Japanese patients. However, 
that study showed signi cant associations of the CT/TT genotype with depth of 
invasion, lymphatic invasion and TNM classi cation. In our study, MMP-9-1562C>T was 
not correlated with clinicopathological parameters or survival. More over, MMP-9 
antigen levels in normal as well as tumour tissue of gastric cancer patients with the 
MMP-9-1562C>T genotype were not enhanced, as was recently also found in plasma of 
healthy subjects (Demacq et al, 2006). Our results indicate that the presence of the T 
allele variant in the MMP-9 promoter (-1562C>T) is not associated with clinical outcome 
in our Caucasian group of gastric cancer patients. 
Neutrophils secrete both gelatinase B (MMP-9) and neutrophil collagenase (MMP-8) 
after stimulation. Matrix metalloproteinase-8 expression levels correlated with tumour 
stage and poor prognosis in ovarian cancer (Stadlmann et al, 2003). Levels of MMP-8 
and -9 correlated signi cantly with each other and with TIMP-1 levels, but were not 
related to tumour size or prognosis in human breast cancer (Du y et al, 1995). Noth-
ing has been published thus far about SNPs for MMP-8 and cancer, but three MMP-8 
promoter haplotypes (MMP-8–799C>T, MMP-8+17C>G and MMP-8-381A>G) have been found to 
be associated with preterm rupture of membranes in delivery, indicating a functional 
role on MMP-8 expression (Wang et al, 2004). Because MMP-8+17C>G and MMP 8-381A>G
were found to be in complete linkage disequilibrium, we decided to study the distri-
bution of MMP-8 –799C>T, MMP 8+17C>G in our group of gastric cancer patients. However, 
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we did not  nd any relation of both SNPs with protein levels, clinicopathological 
parameters, or survival in this study. 
TIMP-1 is a ubiquitous glycoprotein capable of inhibiting all activated collagenases 
(Gomez et al, 1997). Tissue inhibitor of metalloproteinases were previously found not 
to be correlated with tumour stage, histological type, lymph node status or survival in 
human gastric cancer (Murray et al, 1998). We did not  nd any relation of TIMP-1372C>T
with gastric carcinoma, protein level or survival of the patients. 
Taken together, our data indicate that MMP and TIMP gene polymorphisms contrib-
ute to gastric carcinogenesis. Determina tion of these gene polymorphisms, especially 
MMP-7-181A>G and TIMP-2303C>T both as single parameter and in combination as a cluster, 
might be helpful to identify gastric cancer patients with a poor clinical outcome and 
in need of (neo)-adjuvant treatment aiming at better outcome.
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The studies presented and discussed in this thesis focus on the clinical relevance of 
matrix metalloproteinases (MMPs) in gastric in ammation and cancer. Because Helico-
bacter pylori gastritis is associated with gastric cancer [1], studies on the involvement of 
the gelatinases MMP-2 and MMP-9 in H. pylori-induced gastritis are described, includ-
ing the in uence of eradication therapy. Next, studies regarding the clinical impact 
of MMPs, tissue inhibitors of metalloproteinases (TIMPs) and neutrophil-gelatinase 
associated lipocalin (NGAL) in gastric cancer are addressed. As single-nucleotide 
polymorphisms (SNPs) within MMP and TIMP genes may be associated with disease 
susceptibility and altered antigen expression, subsequently the genotype distribu-
tion of SNPs of MMPs and TIMPs in gastric cancer was studied, and their relation with 
established clinicopathological parameters including survival. Finally, the concept of 
MMP inhibition as a potential treatment modality for gastric in ammation and cancer 
is discussed.
Matrix metalloproteinases in gastrointestinal in ammation and 
carcinogenesis
A brief review about the role and function of MMPs, TIMPs and lipocalins in gastroin-
testinal in ammation and carcinogenesis is provided in chapter 1. MMPs are a family 
of zinc-dependent proteinases that play an important role in destruction and repair 
of the extracellular matrix and basement membranes in various physiological and 
pathological processes including gastrointestinal in ammation and carcinogenesis. 
Depending on their structure and substrate preference, the MMP family is divided 
into collagenases, stromelysins, matrilysins, gelatinases, elastases and membrane-
type MT-MMPs [2]. The studies in this thesis focus on MMP-2, MMP-7, MMP-8 and 
MMP-9 because of their presumed clinical relevance in gastric cancer. Gelatinase-A 
(MMP-2) and gelatinase-B (MMP-9) are gelatinases that can speci cally degrade base-
ment membrane type IV and gelatins. MMP-2 is predominantly produced by stromal 
cells, whereas MMP-9 is predominantly secreted by in ammatory cells, especially 
neutrophils [3]. Neutrophil collagenase (MMP-8) is one of the collagenases that is syn-
thesized exclusively by neutrophils before emigration from the bone marrow into the 
peripheral circulation. Matrilysin (MMP-7) is predominantly expressed by epithelial or 
tumour cells and can activate pro-MMP-9 [4, 5]. TIMPs are naturally occurring tissue 
inhibitors of metalloproteinases that can form inhibitory complexes with most MMPs. 
TIMP-1 predominantly binds to pro-MMP-9 and TIMP-2 to pro-MMP-2 [6]. Lipocalins 
are a group of small extracellular proteins that are involved in various biological pro-
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cesses including the regulation of cell homeostasis, the modulation of the immune 
response and, as carrier proteins, act in the clearance of endogenous and exogenous 
substances. Neutrophil gelatinase-associated lipocalin (NGAL, lipocalin-2) is stored 
in secondary granules of neutrophils and can form heterodimers with neutrophil 
gelatinase-B (MMP-9) [7].
The gelatinases MMP-2 and MMP-9 in Helicobacter pylori-induced 
gastritis
The results of an investigation whether gastric mucosal MMP-2 and MMP-9 levels 
were a ected by H. pylori infection in 45 patients with H. pylori-induced gastritis 
compared to 27 H. pylori negative control patients are presented in chapter 2. In 
patients with H. pylori-induced gastritis, signi cantly increased MMP-9 levels in both 
antrum and corpus mucosa were found, with a good correlation with the severity of 
the mucosal in ammation. The increase of MMP-9 in the corpus mucosa of patients 
with antral gastritis only was intermediate to that of H. pylori negative control patients 
and of patients with pangastritis. Immunohistochemically, MMP-9 was predominantly 
observed in in ammatory and stromal cells, and in zymogen-producing chief cells 
of corpus mucosa. In contrast, MMP-2 levels were almost unaltered when compared 
with H. pylori negative patients. 
As H. pylori-induced gastritis is associated with gastric malignancy and H. pylori-
induced gastritis and gastric carcinoma are accompanied by alterations in the MMP 
levels, subsequently a study was performed to investigate whether H. pylori-a ected 
gastric mucosal MMP-2 and MMP-9 levels were reversible after successful eradica-
tion therapy (chapter 3). Therefore, 58 patients with H. pylori-induced gastritis were 
treated for 14 days with a combination regimen of acid inhibitory therapy and anti-
biotics. Latent, active and total MMP-9 levels decreased consistently and signi cantly 
by successful H. pylori eradication, in antrum as well as corpus mucosa, compared with 
those prior to treatment, irrespective of the therapy regimen used. When treatment 
failed, however, the elevated levels remained unchanged. MMP-2 levels did not show 
major alterations after H. pylori eradication therapy. In the antrum of gastritis patients, 
approximately three-fold higher MMP-9 levels were found compared with the cor-
responding corpus. As MMP-9 is predominantly secreted by in ammatory cells, this 
 nding is consistent with the observation that the active in ammatory reaction, i.e. 
the number of in ltrating neutrophils and macrophages, in the antrum is similarly 
more intense compared with the corpus mucosa. The more severe antral in amma-
tion is probably caused by a slow pyloro-cardial progression of gastritis because of a 
less dense H. pylori colonization of the corpus due to local acid production. H. pylori-
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induced gastritis is accompanied by enhanced levels of mucosal cytokines, e.g. TNF-α 
and IL-8, that induce migration and activation of in ammatory cells and which are 
also capable of inducing the production of MMP-9 and, to a lesser extent, that of 
MMP-2 [8, 9]. Activation of the MMP-2 encoding gene by TNF-α and IL-8 is prevented, 
however, by the absence of an AP-1 binding site [2]. In summary, by successful H. pylori
eradication, active and chronic in ammation decreased signi cantly in both antrum 
and corpus, accompanied by a considerable and signi cant decrease of latent, active 
and total MMP-9, particularly in the antrum. 
The gelatinases MMP-2 and MMP-9 in gastric cancer
In chapter 4 and 5, two studies are presented regarding the presence of several 
MMPs and TIMPs in gastric cancer and their relationship with clinicopathological pa-
rameters, including survival. In the initial pioneer study, as reported in chapter 4, we 
assessed the levels of the gelatinases MMP-2 and MMP-9 in 50 gastric carcinomas and 
corresponding normal mucosa using quantitative gelatin zymography. In a majority 
of the gastric carcinomas the MMP-2 and MMP-9 levels were signi cantly enhanced 
compared with corresponding gastric mucosa, irrespective of the activity state of 
the enzymes. No relation was found with histopathological carcinoma classi cations 
according to Laurén, the WHO and the TNM system. According to Cox’s multivariate 
proportional hazards analyses, high MMP-2 and MMP-9 levels were of prognostic 
signi cance for a poor overall survival of the patients, independent of the major 
clinicopathological parameters.
MMPs and TIMPs in gastric cancer
In chapter 5, the results of a more comprehensive study are presented and dis-
cussed. The gelatinases MMP-2 and MMP-9 were assessed with new techniques in 
an expanded group of 81 gastric cancer patients, and MMP-7 and MMP-8 as well as 
TIMP-1 and TIMP-2 were included for comparison. Signi cantly enhanced levels of all 
MMPs measured and TIMP-1 were found in tumour tissue compared to normal gastric 
mucosa. Protein levels of MMP-7, MMP-8 and MMP-9 and the TIMPs showed some 
correlations with TNM stage, WHO and Laurén classi cation, but were not related with 
survival. An enhanced tumour MMP-2 level did not show a signi cant correlation with 
any of the clinicopathological parameters, but was con rmed to be an independent 
prognostic factor in gastric cancer. The consistent prognostic relevance of MMP-2 
was underlined by the fact that both the old group of patients (n =50), described in 
136 Chapter 8
chapter 4, and the more recent group of patients (n =31) were independently sub-
divided based on a low or high MMP-2 antigen content of the carcinoma, using the 
same cut o  value. Several immunohistochemical, zymographic and mRNA studies 
underscore the importance of MMP-2 as a prognostic indicator for gastric carcinoma 
patients [10-12]. In contrast to our initial study, high MMP-9 levels did not show a 
signi cant correlation with survival nor did the ratio MMP-9/TIMP-1, possibly related 
to the relatively small number of patients in the intial study and/or the relatively high 
MMP-9 levels in early gastric carcinomas. 
NGAL in gastric cancer
Next to MMP-2 and MMP-9, the zymograms analysed revealed extra bands that are 
most likely heterodimers of MMP-9 with neutrophil gelatinase-associated lipocalin 
(NGAL). The results of an additional analysis to the presence of MMP-9/NGAL complexes 
in gastric cancer tissue and their possible clinical relevance are described in chapter 
6. NGAL and MMP-9/NGAL complexes were determined in tissue homogenates from 
the same 81 gastric cancer patients analyzed in chapter 5 using speci c ELISAs and 
bioactivity assays (BIA). NGAL and MMP-9/NGAL levels were signi cantly enhanced in 
gastric carcinomas compared to corresponding normal gastric mucosa. High levels of 
MMP-9/NGAL complexes in gastric tumours were signi cantly associated with worse 
survival in Cox’s univariate and multivariate analysis, whereas the levels of NGAL and 
MMP-9 were not indicative for survival. Not just the enhanced presence, but more 
the activation state of the proteinase seems therefore crucial for prognosis. Immu-
nohistochemically, MMP-9 as well as NGAL in gastric cancers were mainly present in 
either the neutrophils or the epithelial cells, depending on the individual cancer and 
on the location within the tumour. Immuno uorescence double-staining indicated 
that, although MMP-9 and NGAL were in general present in close proximity, overlap of 
MMP-9 and NGAL immunoreactivity, presumably indicating complex formation, was 
limited and mainly restricted to extracellular areas. The prognostic value of MMP-9/
NGAL complexes is in accordance with the postulated role of NGAL in the protec-
tion of secreted MMP-9 against autolysis, hence contributing to an enhanced pool 
of potentially active MMP-9, a proteolytic enzyme associated with angiogenesis and 
tumour growth [5]. 
Summarizing discussion 137
MMP and TIMP gene polymorphisms in gastric cancer
A study regarding the genotype distribution and allele frequencies of SNPs of MMP-2, 
MMP-7, MMP-8 and MMP-9 and TIMP-1 and TIMP-2 in 79 Caucasian gastric cancer 
patients in relation to tumour progression, patient survival and tissue antigen expres-
sion, is reported in chapter 7. The genotype distribution and allele frequencies were 
similar in gastric cancer patients and controls, except for MMP-7-181A>G. In addition, 
the genotype distribution of MMP-7-181A>G was associated with H. pylori status and 
tumour-related survival of the patients. Single-nucleotide polymorphism TIMP-2303C>T
correlated signi cantly with the WHO classi cation and also strongly with tumour-
related survival. SNPs of MMP-2, MMP-8, MMP-9 and TIMP-1 were not associated with 
tumour-related survival. Only the gene promoter MMP-2-1306C>T polymorphism corre-
lated signi cantly with the protein level within the tumours. First-order dendrogram 
cluster analysis combined with Cox analysis identi ed the MMP-7-181A>G and TIMP-2303C>T
polymorphism combination to have a major impact on patients survival outcome. 
Therapeutic MMP inhibition
Because overexpression of MMPs in di erent in ammatory and malignant gastroin-
testinal diseases facilitates angiogenesis and carcinogenesis, the correction of unbal-
anced MMP levels would be a straightforward target of treatment. A simple approach 
to achieve this would be the elimination or inhibition of a causative agent responsible 
for chronic in ammation and unbalanced expression of MMPs, for example H. pylori
eradication in H. pylori-induced gastritis or altered intestinal  ora in pouchitis. After 
successful H. pylori eradication indeed an improvement and normalization of the 
chronic in ammatory tissue response in the stomach was observed that was ac-
companied by a signi cant decrease of MMP-9 levels and almost unchanged MMP-2 
levels. Many altered mucosal parameters that have been associated with gastric 
cancer and its prognosis, like growth factors and cytokines [13-15], plasminogen 
activators [16, 17] and superoxide dismutases [18, 19] show a reversal after successful 
H. pylori eradication. However, as only a minority of the patients with H. pylori gastritis 
develops gastric cancer on long-term, and since in ammation and genetic diversity 
might play an important role in cancer susceptibility [20, 21], the question remains 
whether eradication therapy will result in a decline of gastric cancer incidence. An-
other example is the decrease of enhanced MMP-1 and MMP-2 levels in patients with 
pouchitis that were treated with metronidazole [22].
If a causative agent cannot be removed, like in unsuccessful elimination of H. pylori, 
chronic in ammatory diseases and non-resectable cancer, inhibition of MMPs seems a 
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logical approach. Much e ort therefore has been invested in search and development 
of synthetic MMP inhibitors. The currently known MMP inhibitors are divided into four 
classes: 1) Tissue Inhibitors of MetalloProteinases (TIMPs); 2) Tetracyclin-derivatives; 
3) Peptide-based synthetic MMP inhibitors; and 4) Non-peptidic MMP inhibitors. 
Synthetic TIMPs are not suitable for oral administration due to their low molecular 
weight [23]. Tetracyclines have been shown to inhibit MMPs [24, 25] and especially 
minocycline appeared to be e ective in rheumatoid arthritis [26, 27]. Peptidic MMP 
inhibitors, like batimastat and marimastat, have been developed that mimicked part of 
the peptide sequence surrounding the point in the collagen molecule  rst cleaved by 
interstitial collagenase allowing the inhibitor to  t tightly within the active site of the 
MMP. The zinc atom in this active site is subsequently chelated through a zinc-binding 
group [28]. A number of non-peptidic inhibitors like prinomastat has been developed 
with some e  cacy in experimental cancer models [29]. The results of animal studies 
suggest a potential role for MMP inhibitors in chronic in ammatory diseases includ-
ing pulmonary emphysema, multiple sclerosis, bacterial meningitis, graft-versus-host 
disease and colitis [30]. For example, in experimental models of colitis several MMP 
inhibitors induced decreased MMP-9 levels accompanied by decreased in amma-
tory scores [31-33]. Unfortunately, MMP inhibitors have not been proven successful 
in clinical trials for use in most chronic in ammatory diseases or cancer [34-40]. The 
only example of a clinically available MMP inhibitor for use in chronic in ammation is 
periostat, which is FDA-approved for use in periodontitis [41]. The only MMP inhibitor 
with some clinical e  cacy in malignancy appeared to be marimastat, that showed 
a non-signi cant survival bene t in patients with non-resectable gastric cancer 
and a signi cant survival bene t in a sub-group of patients previously treated with 
chemotherapy (2-year survival of 5% in the placebo group and 18% in the treatment 
group, respectively)[40]. In higher dosages the use of marimastat was limited because 
of musculoskeletal side-e ects like arthralgia, tendinitis and myalgia [42]. 
Perspectives
The studies in this thesis describe the clinical impact of several MMPs and TIMPs in 
H. pylori-induced gastritis and gastric cancer. MMP-2, MMP-7, MMP-8 and MMP-9, 
NGAL, MMP-9/NGAL and TIMP-1 were signi cantly increased in tumour tissue of 
gastric cancer patients compared to normal gastric mucosa whereas only enhanced 
levels of MMP-2 and MMP-9/NGAL complexes were independently related to worse 
prognosis. Several studies support the  nding that MMP-2 is associated with tumour 
progression and prognosis in gastric cancer [10-12]. Overexpression of individual 
MMPs is frequently accompanied by a corresponding increased expression of TIMPs, 
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as has been shown for MMP-9 and TIMP-1 in lung cancer patients [43]. The question 
remains whether enhanced MMP and TIMP levels in gastric cancer result in more 
functional activity of the enzymes during cancer progression or are merely a sign of 
deregulated expression [for review see 5].
Preclinical studies have demonstrated that MMP-9 plays an important role in tumour-
induced angiogenesis with tumour-associated in ammatory and stromal cells to be 
the main source of the proteinase. MMP-9-mediated release of vascular endothelial 
growth factor (VEGF) and recruitment of pericytes to the angiogenic vasculature have 
been postulated as major processes involved in host MMP-9 stimulated angiogenesis. 
Paradoxically, MMP-9 as well as other MMPs, including MMP-2, MMP-3, MMP-7 and 
MMP-13, are able to inhibit angiogenesis by proteolytic generation of endogenous 
inhibitors derived from extracellular matrix (ECM) proteins and non-matrix derived 
extracellular proteins. These endogenous inhibitors include tumstatin derived from 
the NC1 domain of type IV collagen, endostatin derived from type XVIII collagen and 
angiostatin generated from plasminogen. Both pro- and anti-angiogenic properties 
of MMP-7 have been reported in preclinical studies, as well as the ability to modify the 
function of proteins that are involved in tumour proliferation, apoptosis and invasion, 
such as epidermal growth factor (EGF) and tumour-necrosis factor-alpha (TNF-α) [5].
The lack of correlation between MMP-8 and outcome might be due to the anti-
metastatic properties of MMP-8, as, for example, human breast carcinoma cells with 
metastatic potential had dramatically reduced expression of MMP-8 compared to 
non-metastatic cells [44].
The failure of broad-spectrum MMP inhibitors to improve survival in clinical cancer 
studies appears to be related to the more complex role of di erent MMPs in di erent 
stages of carcinogenesis than initially thought [45, 46] and has raised the necessity to 
select appropriate MMPs as drug targets [47]. Because of the enhanced expression in 
various human tumours, the association with invasiveness and the ability to degrade 
type IV collagen, MMP-2 is considered a potential target for inhibition. In experimen-
tal models it has been shown that MMP-2 is indeed associated with angiogenesis, 
tumour growth and metastasis [47]. Our results regarding the enhanced MMP-2 levels 
in gastric tumours, their independent correlation with prognosis and the correlation 
between the MMP-2-1306C>T polymorphism and tumour MMP-2 levels further support 
the view that MMP-2 is a potential drug target. Based on animal studies, MMP-7 has 
also been proposed as an anticancer drug target [47]. This is further substantiated by 
our  nding of enhanced gastric tumour levels of MMP-7, the correlation with tumour 
stage and the correlation of the MMP-7-181A>G polymorphism with prognosis. MMPs -3 
and -8 should not be inhibited because of their essential role in homeostasis and are 
therefore considered anti-targets. MMP-9 has pro-tumourigenic e ects early in the 
malignant process stimulating angiogenesis but has anti-tumourigenic properties 
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in advanced disease, which makes it a di  cult drug target. MMP-1, MMP-2, MMP-3, 
MMP-9, MMP-13 and MMP-14 are involved in cleavage and inactivation of CXCL12, 
a chemokine that attracts metastasizing cells, and inhibition of these MMPs might 
even stimulate metastasis [47, 48]. To understand the pleiotropic roles of MMPs in 
cancer in vivo and to select appropriate target MMPs, it is necessary to fully elucidate 
the MMP substrate degradome. This will facilitate the development of e ective MMP 
inhibitors directed against target MMPs and avoiding anti-target MMPs [49]. An ex-
ample of a selective MMP inhibitor is Ro-28-2653, an inhibitor with high selectivity for 
MMP-2, MMP-9 and membrane-type 1 (MT1)-MMP [50], that has recently been shown 
to decrease livermetastasis in an animal model of pancreatic cancer [51]. However, 
it remains a challenge to develop e ective MMP inhibitors due to redundancy and 
similarities in MMP active sites. The clinical trials performed until now, have been car-
ried out in advanced stages of aggressive cancers. A possible application is the use 
of MMP inhibitors earlier in the disease process in benign tumors and in secondary 
prevention of cancer, for example by chemoprevention of colorectal cancer in high-
risk groups [52]. In experimental models, MMP inhibitors were e ective in reducing 
metastatic cell growth and the metastasis-associated bone remodeling [53, 54]. One 
remaining therapeutic opportunity may therefore be the inhibition of matrix degra-
dation in advanced cancers in order to limit bone metastases. Other techniques under 
investigation are RNA silencing technology for downregulation of endogenous MMP 
expression [55] and liposomal drug targeting against MT-MMP [56]. 
Conclusion
MMPs have important functions in normal physiology as well as in in ammatory 
processes and carcinogenesis, with distinct patterns of expression at di erent times 
and sites of progression. MMPs are associated with prognosis and are independent 
prognostic factors in gastrointestinal malignancies including gastric cancer. The con-
cept that inhibition of matrix degradation could improve survival in gastrointestinal 
malignancy could not be substantiated until now, due to dose-limiting toxicity, the 
advanced stage of the cancer in the patients treated and the lack of evidence that 
inhibition of matrix degradation will result in inhibition of disease progression and 
improved survival. Assessment of MMP pro les at time of diagnosis by measurement 
of MMP protein levels and determination of selected SNPs of MMPs to select patients 
who would potentially bene t from (neo-)adjuvant therapy in gastrointestinal cancer 
has not been investigated until now, but deserves more attention [57]. The develop-
ment of semi-selective MMP inhibitors aimed at target MMPs without musculoskeletal 
side e ects in therapeutic dosages is another promising  eld of interest that is being 
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explored now. In addition, MMP inhibitors should be investigated for their use earlier 
in the malignant process and for use in combination with other therapeutic modali-
ties [58]. 
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Helicobacter pylori infectie van het maagslijmvlies veroorzaakt een chronische gastritis 
die de kans op benigne peptische ulcera en maagkanker vergroot. Ondanks de sterk 
gedaalde incidentie is maagkanker nog altijd de op één na meest voorkomende vorm 
van kanker wereldwijd, verantwoordelijk voor 10% van alle gevallen van kanker en 
12% van de totale kankersterfte. Gemiddeld genomen is de vij aarsoverleving slechts 
12% omdat de helft van de patiënten ten tijde van het stellen van de diagnose al 
metastasen heeft en er bij de andere helft slechts in 50% van de gevallen een in opzet 
curatieve resectie mogelijk is. Bij chronische ontstekingsprocessen en tumorgroei is 
er sprake van een ongecoördineerde afbraak en herstel van de extracellulaire matrix 
door proteasen, waaronder de matrix metalloproteïnasen (MMPs). In dit proefschrift 
staan enkele studies beschreven naar de klinische betekenis van de gelatinasen 
MMP-2 en MMP-9 bij chronische, door H. pylori veroorzaakte, gastritis alsmede het 
e ect van eradicatietherapie hierop. Vervolgens worden onderzoeken besproken 
naar de klinische betekenis van MMPs, en hun natuurlijke inhibitoren TIMPs, bij 
maagkanker, alsmede de invloed van functionele genpolymor smen van deze MMPs 
en TIMPs. Tenslotte worden de mogelijkheden en onmogelijkheden van remming van 
MMPs bij gastritis en maagkanker besproken.
Matrix metalloproteïnasen bij chronische gastritis en maagkanker
In een overzicht (hoofdstuk 1) staan de belangrijkste kenmerken en functies van MMPs, 
TIMPs en lipocalinen beschreven. In het kort samengevat, MMPs zijn proteolytische 
enzymen met een centraal zinkion, die in inactieve vorm uitgescheiden worden en 
geactiveerd dienen te worden door beperkte proteolyse voordat ze hun biologische 
functie kunnen uitoefenen. Ze worden geïnactiveerd door zogenaamde TIMPs: tissue 
inhibitors of metalloproteinases. TIMPs zijn natuurlijk voorkomende MMP remmers 
die complexen vormen met de meeste MMPs. Gebaseerd op overeenkomsten in eiwit-
structuur en substraatvoorkeur worden de MMPs verdeeld in subgroepen, te weten 
collagenasen, stromelysinen, matrilysinen, gelatinasen, elastasen en membraan-type 
MMPs. De studies in dit proefschrift zijn gericht op MMP-2, MMP-7, MMP-8 en MMP-9 
vanwege de veronderstelde klinische betekenis van deze MMPs bij gastritis en maag-
kanker. MMP-2 en MMP-9 zijn gelatinasen die speci ek basaalmembraan collageen 
type IV en gelatines afbreken. MMP-2 wordt vooral door stromacellen geproduceerd, 
terwijl MMP-9 met name uit ontstekingscellen zoals neutro ele granulocyten 
vrijkomt. Neutro el collagenase (MMP-8) wordt gesynthetiseerd in neutrophiele 
granulocyten voor het verlaten van het beenmerg. Matrilysine (MMP-7) wordt vooral 
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afgescheiden door epitheliale- en tumorcellen. De lipocalinen bestaan uit een groep 
kleine eiwitten met uiteenlopende biologische functies waaronder regulatie van 
de celhomeostase en transport van eiwitten. Eén van deze lipocalinen is neutro el 
gelatinase-geassocieerd lipocaline (NGAL, lipocaline-2), dat wordt opgeslagen in 
secundaire granulae van neutro ele granulocyten en dat heterodimeren kan vormen 
met neutrophil gelatinase-B (MMP-9).
De gelatinasen MMP-2 en MMP-9 bij door Helicobacter pylori
geïnduceerde gastritis
Een studie naar de klinische betekenis van de gelatinasen MMP-2 en MMP-9 bij 
chronische, door H. pylori veroorzaakte, gastritis staat beschreven in hoofdstuk 2. 
Bij 45 patiënten met en 27 patiënten zonder H. pylori gastritis werden de MMP-2 en 
MMP-9 niveaus in maagbiopten gemeten. Bij patiënten met H. pylori gastritis werden 
zowel in antrum- als in corpusbiopten signi cant verhoogde MMP-9 niveaus gevon-
den ten opzichte van H. pylori negatieve controles. Deze verhoogde MMP-9 niveaus 
vertoonden een goede correlatie met de ernst van de ontsteking. Bij patiënten met 
een pangastritis werden in het corpus hogere MMP-9 niveaus gevonden dan bij 
patiënten met een antrale gastritis. Immunohistochemisch was MMP-9 voornamelijk 
gelocaliseerd in ontstekings- en stromacellen en in pariëtale cellen in het corpus. 
MMP-2 niveaus in maagbiopten van H. pylori positieve en negatieve patiënten ver-
schilden nauwelijks van elkaar. Aangezien H. pylori gastritis geassocieerd is met het 
maagcarcinoom, en zowel bij H. pylori gastritis en het maagcarcinoom veranderde 
MMP-pro elen worden gevonden, hebben wij een studie uitgevoerd naar het e ect 
van H. pylori eradicatietherapie op deze MMP-pro elen, zoals in hoofdstuk 3 staat 
vermeld. Daartoe werden 58 patiënten met H. pylori gastritis behandeld met H. pylori
eradicatietherapie, bestaande uit een combinatie van zuurremmende medicatie en 
antibiotica, gedurende 14 dagen. Na succesvolle eradicatietherapie was er sprake 
van een signi cante daling van MMP-9 niveaus in antrum- en corpusbiopten, terwijl 
na persisterende H. pylori infestatie deze nauwelijks veranderden. MMP-2 niveaus 
veranderden niet na succesvolle eradicatie. 
De MMP-9 niveaus in het antrum bij patiënten met H. pylori gastritis liggen een fac-
tor drie hoger dan in het corpus. Aangezien MMP-9 voornamelijk gesecerneerd wordt 
door ontstekingscellen is dit verklaarbaar door de intensere ontstekingsreactie in het 
antrum vergeleken met die in het corpus. Dit hangt mogelijk samen met de langzame 
uitbreiding van antrum naar corpus van de gastritis als gevolg van een minder intense 
H. pylori infestatie van het corpus door locale zuurproduktie. Gastritis door H. pylori
gaat gepaard met verhoging van mucosale cytokines die migratie en activatie van 
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ontstekingscellen veroorzaken en die tevens het vrijkomen van MMP-9, en in mindere 
mate van MMP-2, stimuleren. Activatie van het gen dat codeert voor MMP-2 door 
cytokines wordt namelijk verhinderd door de afwezigheid van een zogenaamde AP-1 
bindingsplaats. Samenvattend neemt de actieve en chronische ontstekingscompo-
nent in maagslijmvlies af na succesvolle H. pylori eradicatie, hetgeen gepaard gaat 
met een signi cante afname van MMP-9 niveaus, met name in het antrum. 
De gelatinasen MMP-2 en MMP-9 bij maagkanker
De resultaten van een pionierstudie naar de klinische betekenis van de gelatinasen 
MMP-2 en MMP-9 bij het maagcarcinoom worden besproken in hoofdstuk 4. MMP-2 
en MMP-9 niveaus werden gemeten in 50 maagcarcinomen en corresponderende 
normale maagmucosa door middel van gelatine-zymographie. Bij de meeste maag-
carcinomen werd een verhoogd MMP-2 en MMP-9 niveau gemeten, zonder duidelijke 
relatie met type histologie of TNM-stadium. Als één van de eersten vonden we een 
verband tussen verhoogde MMP-2 en MMP-9 niveaus en slechtere overleving, onaf-
hankelijk van de belangrijkste klinische- en pathologische variabelen.
MMPs en TIMPs bij maagkanker 
De resultaten van een uitgebreidere vervolgstudie naar verschillende MMPs en TIMPs 
bij een grotere groep patiënten met een maagcarcinoom, onder gebruikmaking 
van modernere analysetechnieken, staan in hoofdstuk 5 van dit proefschrift. Bij 81 
patiënten werden naast MMP-2 en MMP-9 ook het MMP-7, MMP-8, TIMP-1 en TIMP-2 
niveau gemeten. De niveaus van alle gemeten MMPs en van TIMP-1 waren in tumor-
weefsel signi cant verhoogd in vergelijking met normaal maagslijmvlies. Ongeacht 
de bepalingsmethode vonden we nog steeds een signi cant verband tussen hogere 
MMP-2 waarden in tumorweefsel en slechtere overleving, onafhankelijk van di eren-
tiatiegraad van de tumor en tumorstadium. Geen verband met de overleving werd 
gevonden voor de andere MMPs en voor de TIMPs, ook niet (meer) voor MMP-9.
De consistente prognostische betekenis van MMP-2 wordt onderstreept door het 
feit dat zowel de initieel onderzochte groep van 50 patiënten als de later toegevoegde 
groep van 31 patiënten onafhankelijk van elkaar onderverdeeld konden worden op 
basis van dezelfde discriminerende waarde van MMP-2 met betrekking tot de prog-
nose. Inmiddels hebben verschillende immunohistochemische, zymographische en 
mRNA studies de klinische relevantie van MMP-2 als onafhankelijke prognostische 
factor bij het maagcarcinoom bevestigd. De relatie tussen een verhoogd MMP-9 
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niveau en overleving kon in deze uitgebreidere studie, met een grotere groep patiën-
ten, niet bevestigd worden.
NGAL bij maagkanker
Naast de gelatinasen MMP-2 en MMP-9 bevatten de onderzochte zymogram-
men van maagcarcinomen, extra banden veroorzaakt door heterodimeren van 
neutro el-gelatinase met lipocaline (NGAL of lipocaline-2). In hoofdstuk 6 wordt 
een aanvullende analyse naar de presentatie van deze MMP-9/NGAL complexen in 
maagcarcinomen en de mogelijke klinische betekenis hiervan besproken. NGAL en 
MMP-9/NGAL complexen werden door middel van ELISAs en bioactiviteit-assays be-
paald in weefselhomogenaten van dezelfde 81 patiënten als besproken in de studie 
van hoofdstuk 5. In maagcarcinomen werden signi cant verhoogde MMP-9, NGAL 
en MMP-9/NGAL niveaus gevonden vergeleken met normale maagmucosa. Hoge 
MMP-9/NGAL spiegels waren geassocieerd met slechtere overleving, terwijl NGAL en 
MMP-9 waarden niet geassocieerd waren met overleving. Deze bevindingen wijzen 
erop, dat niet zozeer de verhoogde presentatie van beide enzymen geassocieerd 
is met prognose, maar meer de mate van activiteit van MMP-9. MMP-9 en NGAL 
waren immunohistochemisch vooral gelocaliseerd in neutro ele granulocyten en 
maagcarcinoomcellen. Immuno uorescentie dubbelkleuringen wezen echter uit dat, 
hoewel MMP-9 en NGAL in elkaars nabijheid voorkwamen, er slechts een beperkte 
co-localisatie van beide kleuringen was als maat voor complexvorming tussen beide 
factoren. De bevinding dat MMP-9/NGAL complexen geassocieerd zijn met overleving 
is in overeenstemming met de veronderstelde remming van de autolyse van MMP-9 
door NGAL waardoor er een grotere hoeveelheid MMP-9 circuleert. MMP-9 stimuleert 
tumorangiogenese en tumorgroei. 
MMP en TIMP genpolymor smen bij maagkanker
Als laatste is er een studie gedaan naar het verband tussen genpolymor smen in de 
MMP -2, -7, -8, -9 en TIMP -1, -2 genen en klinische- en histologische variabelen, zoals 
tumorstadium en overleving, bij patiënten met een maagcarcinoom. Genpolymor-
 smen zijn veranderingen in een stukje DNA, waarbij een enkel nucleotide in het 
genoom vervangen is door een ander. Er zijn aanwijzingen dat genpolymor smen 
in MMP en TIMP genen de eiwitexpressie van MMPs en TIMPs kunnen beïnvloeden 
en vanuit Aziatische landen is beschreven dat zij de kans op het ontwikkelen van een 
maligniteit kunnen vergroten. Zoals in hoofdstuk 7 staat beschreven, vonden wij een 
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verschil in distributie van een genpolymor sme in het MMP-7 gen (MMP-7-181A>G) dat 
bovendien geassocieerd was met H. pylori status en overleving. Een genpolymor sme 
in het TIMP-2 gen (TIMP-2-303C>T) was naast overleving ook gecorreleerd met de di e-
rentiatiegraad van de maagcarcinomen. De aanwezigheid van beide genpolymor s-
men was -onafhankelijk van klinische en histologische variabelen- geassocieerd met 
een slechtere overleving en alle patiënten met beide genpolymor smen bleken bin-
nen korte tijd te zijn overleden. Er bestond geen verband tussen genpolymor smen 
van MMP-2, MMP-8, MMP-9 en TIMP-1 genen en overleving. Alleen het genpromoter 
MMP-2-1306C>T polymor sme was signi cant gecorreleerd met het MMP-2 eiwitniveau 
in de tumor.
Therapeutische remming van MMPs
Omdat overexpressie van MMPs bij gastrointestale ontstekingsprocessen en malig-
niteiten de angiogenese en carcinogenese bevordert, lijkt correctie van deze afwij-
kende MMP expressie een aantrekkelijke behandelingsoptie. De meest eenvoudige 
oplossing bestaat uit het daar waar mogelijk elimineren van onderliggende oorzaken, 
zoals bijvoorbeeld H. pylori eradicatie bij H. pylori gastritis en correctie van veranderde 
darm ora door behandeling met metronidazol bij pouchitis. Na succesvolle H. pylori 
eradicatie trad er inderdaad een afname van de chronische ontstekingsreactie in het 
weefsel op, met een parallele daling van verhoogde MMP-9 niveaus. Een dergelijke 
normalisatie werd ook waargenomen bij afwijkende expressie van mucosale para-
meters die geassocieerd worden met maagkanker en prognose, zoals groeifactoren, 
cytokines, plasminogeenactivatoren en superoxide dismutasen. Aangezien slechts 
een minderheid van de patiënten met een door H. pylori veroorzaakte gastritis een 
maagcarcinoom ontwikkelt en genetische diversiteit de gevoeligheid voor het 
ontwikkelen van maagcarcinoom beinvloedt, blijft de vraag in hoeverre H. pylori 
eradicatie leidt tot een daling van de incidentie van het maagcarcinoom. 
Veel onderzoek is verricht naar de ontwikkeling van MMP remmers. De MMP inhibi-
toren kunnen worden verdeeld in: 1. tissue inhibitors of metalloproteinases (TIMPs); 2. 
tetracyclinederivaten; 3. peptide-achtige MMP inhibitoren en 4. non-peptide-achtige 
MMP inhibitoren. Synthetische TIMPs zijn als gevolg van hun lage molecuulgewicht 
niet geschikt voor orale toediening. Tetracylines remmen MMPs en met name 
minocycline blijkt e ectief bij reumatoide arthritis. De werkzaamheid van diverse 
MMP inhibitoren bij chronische ontstekingsziekten, zoals longemfyseem, multiple 
sclerosis, bacteriële meningitis, afstotingsreacties en colitis en bij kanker is gebleken 
uit dierexperimentele studies. Helaas bleken MMP inhibitoren in klinische studies niet 
werkzaam. De enige geregistreerde MMP inhibitor voor gebruik bij chronische ontste-
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king is periostat voor gebruik bij periodontitis. De enige MMP inhibitor die in klinische 
studies bij maligniteiten enig e ect ressorteerde, was marimastat. Bij patiënten met 
een inoperabel maagcarcinoom was er in de marimastat behandelde groep sprake 
van een niet-signi cante verbetering van de overleving. In een subgroep van eerder 
met chemotherapie behandelde patiënten was er wel sprake van een signi cante 
verbetering van de overleving (tweejaars overleving in de placebogroep 5% versus 
18% in de behandelde groep). Het gebruik van marimastat werd echter beperkt door 
het optreden van spier- en gewrichtsklachten bij gebruik in hogere doseringen.
Toekomstige ontwikkelingen
De in dit proefschrift beschreven studies laten de klinische betekenis zien van 
verschillende MMPs, TIMPs en NGAL bij H. pylori gastritis en het maagcarcinoom. 
MMP-2, MMP-7, MMP-8, MMP-9, NGAL, MMP-9/NGAL complexen en TIMP-1 bleken 
signi cant verhoogd te zijn in tumorweefsel van patiënten met een maagcarcinoom 
in vergelijking met normale maagmucosa. Alleen verhoogde MMP-2 en MMP-9/NGAL 
niveaus bleken onafhankelijk van klinische en histologische variabelen geassocieerd 
met slechtere overleving. Ook uit andere studies blijkt de relatie van MMP-2 met 
prognose. Verhoogde expressie van individuele MMPs gaat vaak gepaard met een cor-
responderende verhoging van hun remmende TIMPs, zoals ondermeer beschreven is 
voor MMP-9 en TIMP-1 bij longkankerpatiënten. Het blijft de vraag of verhoogde MMP 
en TIMP expressie bij het maagcarcinoom resulteert in verhoogde activiteit van deze 
enzymen of anderszins slechts een uiting is van een verstoorde en gedereguleerde 
expressie. Uit preklinisch onderzoek is gebleken dat gelatinase-B (MMP-9) een belang-
rijke rol speelt bij tumorgeïnduceerde angiogenese en dat in de tumor gelocaliseerde 
ontstekings- en stromacellen de belangrijkste bron van MMP-9 zijn. Het onder invloed 
van MMP-9 vrijkomen van vasculaire endotheliale groeifactor (VEGF) wordt gezien 
als een van de belangrijkste processen bij door MMP-9 gestimuleerde angiogenese. 
Net als een aantal andere MMPs kan MMP-9 echter ook angiogenese remmen door 
proteolytische afsplitsing van endogene inhibitoren, waaronder tumstatine uit type 
IV collageen, endostatine uit type XVIII collageen en angiostatine uit plasminogeen. 
Het matrilysine MMP-7 heeft zowel pro- als anti-angiogene eigenschappen en kan de 
functie van eiwitten die betrokken zijn bij proliferatie, apoptose en invadering, zoals 
epidermale groeifactor (EGF) en tumor necrosis factor-α, beïnvloeden. 
Het ontbreken van een correlatie tussen neutro el collagenase (MMP-8) en over-
leving kan verband houden met de anti-metastatische eigenschappen van MMP-8, 
omdat bijvoorbeeld de expressie van MMP-8 in een agressieve borstkankercellijn 
sterk verlaagd was in vergelijking met een minder agressieve cellijn.
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Het gebrek aan e ectiviteit in klinische studies van MMP inhibitoren lijkt samen 
te hangen met een meer complexe rol van de verschillende MMPs in de verschil-
lende stadia van de carcinogenese dan aanvankelijk werd aangenomen en toont de 
noodzaak om MMPs te selecteren die in aanmerking komen voor selectieve remming. 
MMP-2 lijkt een geschikt doelwit voor remming vanwege de verhoogde expressie in 
tumoren, de correlatie met invasief gedrag van deze tumoren en het vermogen om 
gelatinase af te breken. In experimentele modellen blijkt MMP-2 inderdaad geasso-
cieerd te zijn met angiogenese, tumorgroei en metastasering. De verhoogde MMP-2 
niveaus in maagcarcinomen, de correlatie van het MMP-2-1306C>T genpolymor sme met 
MMP-2 niveaus in de tumor en de onafhankelijke correlatie van MMP-2 niveaus in de 
tumor met prognose en overleving ondersteunen verder de gedachte dat remming 
van MMP-2 een geschikte interventie lijkt bij het maagcarcinoom.
Vanwege het verhoogde MMP-7 niveau in maagcarcinomen, de relatie met tu-
morstadium en de relatie van het MMP-7-181A>G genpolymor sme met prognose, en 
op basis van gegevens uit dierexperimenteel onderzoek, lijkt ook MMP-7 een geschikt 
doelwit voor remming. MMP-3 en MMP-8 spelen een belangrijke rol in homeostase en 
dienen wellicht niet geremd te worden. MMP-9 stimuleert vroeg in het proces van ma-
ligne ontaarding de tumorgroei door toename van de angiogenese maar heeft later 
in het ziekteproces tumorremmende eigenschappen door vorming van angiostatine, 
tumstatine en endostatine. MMP-1, MMP-2, MMP-3, MMP-9, MMP-13 en MMP-14 zijn 
betrokken bij de splitsing en inactivatie van CXCL12, een chemokine dat metasta-
serende kankercellen aantrekt. Remming van deze MMPs zou zelfs metastasering 
kunnen bevorderen. Om de onderscheiden functies van MMPs te kunnen begrijpen, 
teneinde MMPs te kunnen selecteren die in aanmerking komen voor selectieve rem-
ming, is het belangrijk het volledige substraat van MMPs bij maligniteiten in vivo in 
kaart te brengen. Een voorbeeld van een veelbelovende selectieve MMP inhibitor is 
Rp-28-2653, die selectief MMP-2, MMP-9 en membraan-type 1 (MT1)-MMP remt en 
levermetastasen remt in een diermodel voor het pancreascarcinoom. De ontwikke-
ling van MMP inhibitoren blijft echter een uitdaging vanwege de overlap in actieve 
plaatsen van MMPs. De weinig succesvolle klinische studies die tot dusverre met MMP 
inhibitoren uitgevoerd zijn vonden alle plaats bij patiënten met voortgeschreden of 
uitbehandelde maligniteiten. Omdat MMP inhibitoren ingrijpen in de tumorangio-
genese, verdient het overweging MMP inhibitoren vooral in te zetten in een vroeg 
stadium van de ziekte, bij premaligne aandoeningen (bijvoorbeeld bij Familiaire Ade-
nomatosis Coli patiënten met dunne-darmadenomen), en als secundaire preventie 
van kanker bij risicogroepen. Aangezien uit experimenteel onderzoek gebleken is dat 
MMP inhibitoren de groei van metastaserende cellen en de metastase gerelateerde 
botombouw remden, is een andere mogelijke toepassing het gebruik bij patiënten 
met botmetastasen ter vertraging van de botafbraak. Andere technieken die onder-
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zocht worden zijn RNA silencing technologie ter downregulatie van endogene MMP 
expressie en liposomale drug targeting tegen MT-MMP.
Conclusies
MMPs hebben belangrijke functies bij fysiologische- en pathologische processen 
zoals chronische ontstekingen en maligniteiten. Het expressiepatroon van MMPs 
varieert tussen verschillende tumortypen en stadia in het ziekteproces en meerdere 
MMPs, onder meer MMP-2 bij het maagcarcinoom, zijn onafhankelijk van klinische of 
histologische factoren geassocieerd met prognose. Het concept van MMP inhibitie 
als werkzame behandeling bij maligniteiten kon tot op heden nog niet vastgesteld 
worden als gevolg van dosisremmende toxiciteit, het onderzoeken bij een te ver 
voortgeschreden ziekteproces, en een gebrek aan bewijs dat brede MMP inhibitie 
resulteert in vertraging van ziekteprogressie en verbetering van de overleving. 
Het verdient aanbeveling om te onderzoeken of bij het maagcarcinoom door mid-
del van een bepaling van het MMP-pro el ten tijde van het stellen van de diagnose 
(bijvoorbeeld door het bepalen van eiwitniveaus in biopten uit de tumor en het be-
palen van relevante genpolymor smen in DNA uit perifere leucocyten) subgroepen 
van patiënten geïdenti ceerd kunnen worden met een slechte prognose. Vervolgens 
dient dan beoordeeld te worden welke subgroepen van patiënten het meest pro jt 
hebben van neo-adjuvante chemotherapie en adjuvante chemoradiatietherapie. Bij 
klinisch onderzoek naar de e ectiviteit van de semi-selectieve MMP inhibitoren die 
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“Het is pas klaar als het af is.”
Het was vaak bijna klaar maar nog niet af. Daarmee heeft het schrijven van een 
proefschrift veel weg van het produceren van een speel lm. Een belangrijk verschil 
tussen een speel lm en een Leids proefschrift is dat in de aftiteling van een Leids 
proefschrift de naam van de regisseur ontbreekt. Desondanks zal blijken uit de aftite-
ling van deze speel lm dat velen voor en achter de camera een steentje eraan hebben 
bijgedragen.
Zonder de belangeloze medewerking van de patiënten en vrijwilligers zouden de 
studies niet mogelijk zijn geweest.
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 ceren van de maagcarcinomen.
I would like to thank Prof.dr. Harold Tschesche, Dr. Oliver Hiller, Mr. A. Oberpichler and 
Ms. Vera Süwer (Dept. of Biochemistry, University of Bielefeld, Germany) for kindly 
performing the MMP-8 and lipocalin-2 ELISAs.
Dr. Gerrit Gri  oen, Dr. Ruud van Hogezand, Prof.dr. Ad Masclee en Dr. Roeland Vee-
nendaal waren als klinische sta eden nauw betrokken bij de diverse studies.
Loes Niepoth heeft manuscripten uitgewerkt en onmisbare steun verleend bij de 
vervaardiging van dia’s. Voor Loes was in Harvard Graphics® niets onmogelijk.
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De toenmalige MDL-artsen in opleiding en promovendi waren nauw betrokken bij 
het verzamelen en analyseren van weefselmonsters. De ko  ekamer van de endo-
scopie-afdeling vormde het zenuwcentrum waar de toestand in de wereld en andere 
belangrijke zaken besproken werden.
Na een eerste kennismaking met de internisten van het toenmalige Zuiderziekenhuis 
was alles op typisch Rotterdamse wijze (“Geen woorden maar daden”) razendsnel in 
kannen en kruiken. Arie Berghout, Piet Batenburg, Jet Bakker, Anja van Houten, Koos 
Ligthart en Tjebbe Kok, ik ben jullie zeer erkentelijk voor de ondervonden steun en 
geboden gelegenheid om dit proefschrift af te ronden. De internisten, longartsen 
en MDL-artsen van de in 2002 opgerichte fusiemaatschap inwendige geneeskunde, 
longziekten en maag-, darm- en leverziekten Medisch Centrum Rijnmond-Zuid dank 
ik voor de collegiale samenwerking.
Vanaf de eerste werkdag in het Zuiderziekenhuis te Rotterdam op 1 november 1997 
word ik door Irene Planqué op secretarieel en organisatorisch terrein perfect bijge-
staan, onder meer bij het schrijven van dit proefschrift.
Sjam Ganesh en Raymond Smeets staan vandaag naast mij als paranimfen.
Beste Sjam, jouw promotie-onderzoek vormde de basis voor enkele studies in dit 
proefschrift. Net als in 1994 zijn we weer elkaars buurmannen in het ziekenhuis en nu 
ook maten, en ik vind dat heel bijzonder.
Beste Raymond, in 1996 had ik de eer bij jouw promotie paranimf te mogen zijn. Elf 
jaar later zijn de rollen omgedraaid en staan we eindelijk quitte.
Beste pap en mam, met vooruitziende blik hebben jullie in 1968, het jaar dat ik begon 
in de eerste klas van de Mariaschool, een baksteentje bijgedragen aan een hand-
tekeningenactie voor de vestiging van een medische faculteit in Maastricht. Soms 
verbaasd, maar altijd enthousiast, hebben jullie mijn keuzes ondersteund en daar ben 
ik jullie nog steeds heel dankbaar voor.
Lieve Thijs, bovenop de Etna heb jij de prachtige foto van gloeiende lava gemaakt, die 
symbool staat voor het onderwerp van dit proefschrift. Vlak nadat je de foto gemaakt 
had spetterde de lava naast ons neer. Je hebt daarmee niet het moeilijkste, maar wel 
het gevaarlijkste deel van het proefschrift voor je rekening genomen. 
Lieve Ellen, in het dankwoord van jouw proefschrift heb je me een bepaalde titel 
toegedicht. Daardoor kan ik bevestigen dat ook bij jouw proefschrift het dankwoord 
waarschijnlijk het meestgelezen deel van het boekje geweest is. “Op naar het volgende 
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boekje!” was je devies en daar heb je me op alle fronten bij geholpen. Ik dank je voor je 
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